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Abstract

DEVELOPMENT AND EVALUATION OF A MULTIPLEX SUSPENSION ARRAY
PROTOCOL FOR THE DETECTION OF ENTERIC PATHOGENS FROM CLINICAL
SPECIMENS
By Carol C. Walters, M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2011
Major Director: Denise M. Toney, Ph.D.,
Commonwealth of Virginia, Division of Consolidated Laboratory Services
Affiliate Faculty, Department of Microbiology and Immunology

Foodborne illnesses are a significant public health challenge in the United States, with an
estimated 9.4 million illnesses annually attributed to the consumption of contaminated food, of
which 59% are estimated to be caused by viruses, 39% by bacteria and 2% by parasites. Timely
detection and identification of the pathogens causing foodborne outbreaks is vital for the
implementation of outbreak control strategies, allowing public health officials to prevent
additional illnesses and maintain confidence in the food supply. Public health laboratories
employ a variety of traditional and molecular testing techniques to identify foodborne outbreak
etiologic agents. One technology is the Luminex XMap® microsphere system, which is also
marketed as the Bio-Plex™ 200. This platform has a multiplexing capability with the potential
to simultaneously detect up to 100 targets in one reaction. The studies described here show that

the combination of two Bio-Plex assays with real-time virus assays and one extraction method
provides a flexible foodborne outbreak screening algorithm that potentially identifies an
outbreak-associated pathogen on the first day of specimen submission and aids in focusing
confirmatory laboratory testing. In these studies, two microsphere-based assays were designed
for use on the Bio-Plex 200 system as screening assays for the detection of four enteric protozoa
(Giardia intestinalis, Cyclospora cayetanensis, Cryptosporidium parvum, Entamoeba
histolytica) and six virulence determinants of shiga toxin-producing Escherichia coli (STEC),
enterotoxigenic Escherichia coli (ETEC), enteroinvasive Escherichia coli (EIEC) and Shigella
spp. Precision and limits of detections were established for both assays. The sensitivity and
specificity of the protozoan assay as compared to reference methods ranged from 81.25% to
100% for most targets, while sensitivity for the E. histolytica target was 42.86%. Sensitivity and
specificity for the bacterial assay was 100% as compared to reference methods. However, crossreactivity of the protozoan assay E. histolytica target with E. dispar and of the bacterial assay
uidA target with enteropathogenic E. coli strains was noted. Additionally, real-time detection of
norovirus and rotavirus nucleic acids extracted with the QIAamp DNA Stool Mini Kit was
statistically comparable to detection when extracted with the Ambion® MagMAX™-96 Viral
RNA Isolation Kit combined with the KingFisher® Magnetic Particle Processor.

CHAPTER ONE INTRODUCTION

Overview of Infectious Gastroenteritis in the United States. It is estimated by scientists at the
Centers for Disease Control and Prevention (CDC) that annually in the United States (U.S.),
there are 36.4 million domestically-acquired cases of gastrointestinal illness caused by 31
pathogens, with 9.4 million of these cases resulting directly from contaminated food ingestion
(100). In addition, over 55,000 hospitalizations and 1,300 deaths are thought to occur due to
contamination of food by enteric pathogens (100). The enteric pathogens that cause
gastroenteritis include bacteria, viruses, and protozoa, and of the 9.4 million annual foodborne
illness cases in the U.S., 59% are estimated to be caused by viruses, 39% by bacteria and 2% by
parasites (100). Transmission routes are not limited to contaminated food, as pathogens may
also be transferred via waterborne routes or person-to-person via contaminated feces.
Understanding the incidence of foodborne disease, trends associated with foodborne
infection and physical characteristics of acute gastroenteritis-causing pathogens, as well as the
clinical symptoms of infections caused by these organisms, is vital to the management of
outbreak investigations and long-term programs to prevent future foodborne outbreaks. To
acquire this type of epidemiologic data, the U.S. utilizes a variety of surveillance systems to
detect and prevent foodborne disease. Examples of surveillance systems include, but are not
limited to, the national requirement to report ―notifiable diseases‖, an active sentinel laboratory
system called FoodNet, a molecular subtyping network called PulseNet, the National
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Antimicrobial Resistance Monitoring System (NARMS), and the electronic Foodborne Outbreak
Reporting System (eFORS) (32). Epidemiologic data from these surveillance systems are used
by public health laboratories for a variety of purposes. For example, prevalence and trend
information may lead laboratories to implement new testing assays to detect and/or conduct
surveillance for emerging infectious disease strains, or conversely suspend testing due to the low
incidence of a particular pathogen. In outbreak investigations, information such as symptoms,
incubation periods, geographic locations, and potential modes of transmission are immediately
useful in determining what assays or types of testing must be completed first, to facilitate as
rapid an identification of the etiologic agent as possible. Discussed below are characteristics,
prevalence and trends of enteric pathogens commonly associated with foodborne illnesses and
outbreaks, with emphasis on the etiologic agents targeted by the detection assays that are the
focus of the project described in this dissertation.
Epidemiology of food- and waterborne intestinal protozoan gastroenteritis. Intestinal protozoa
are more commonly associated with prolonged symptoms, particularly in travelers, as opposed to
the acute gastroenteritis symptoms seen in bacterial and viral cases (84). Nonetheless, parasites
also cause significant acute disease worldwide, especially Giardia intestinalis, Cryptosporidium
spp., and Entamoeba histolytica (91). Although only 2% of domestic foodborne illnesses are
estimated to be caused by parasites, the prevalence of Cryptosporidium spp., G. intestinalis, and
Cyclospora cayetanensis are significant enough for their inclusion on the CDC’s Nationally
Notifiable Infectious Conditions list (100).
Infection by enteric protozoa occurs due to the ingestion of oocysts or cysts contaminating
food or water sources, and in the cases of Cryptosporidium spp. and Giardia, as few as 10
oocysts or cysts are required to cause disease (17, 19, 50). Transmission of Entamoeba,
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Cryptosporidium, and Giardia also occurs readily person-to-person, as the organisms are
infectious immediately upon excretion. In contrast, Cyclospora oocysts must mature in the
environment before becoming infectious and therefore person-to-person transmission typically
does not occur (24). In the U.S., Giardia and Cryptosporidium are associated with both
waterborne and foodborne outbreaks. These two pathogens alone were linked to over 29,000
cases of illness in 2008, and recently published models estimate that they are responsible for
approximately 134,000 cases of foodborne illness in the U.S. annually (17, 19, 100).
The sources of Cyclospora spp. infections are variable, ranging from international travel, to
foodborne outbreaks, to sporadic cases with no confirmed source (21). Prominent foodborne
outbreaks have occurred involving imported foods such as raspberries, basil and snow peas (86).
One data source that is used to follow food-related infection trends is the CDC’s Foodborne
Diseases Active Surveillance Network, or FoodNet, a network that tracks laboratory-confirmed
foodborne illness cases across ten states. According to 2009 FoodNet data, the incidence of
infection with Cyclospora is low in the U.S., with an incidence of 0.07 cases/100,000 population
(20). Although only 1,110 laboratory cases were reported during 1997-2008, more recent
estimates by the CDC suggest that there is on average over 11,000 domestically-acquired
foodborne Cyclospora infections annually (21, 100). The low reported numbers versus estimates
is most probably attributed to the fact that many laboratories do not test for Cyclospora without a
specific testing order, and the organism is not readily detected in a routine ova and parasite
microscopic examination (21).
Reports of U.S. food- and waterborne infections or outbreaks due to E. histolytica are not as
abundant in the literature as for other protozoa. However, E. histolytica has been implicated in a
number of waterborne outbreaks in the U.S. since the 1950s (62). Although infections by E.
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histolytica are not nationally notifiable, surveillance for E. histolytica cases is conducted in the
Commonwealth of Virginia, and as of 2009, the five-year average for Virginia cases was 41.4
per year (115). These cases typically represented infections acquired outside the U.S., rather
than outbreak-related infections.
Epidemiology of food- and waterborne bacterial gastroenteritis. Based on estimates recently
published by the CDC, bacteria are the second-leading cause of foodborne illnesses (39% of
annual episodes), with 20 disease-causing strains predominating (100). According to published
estimates, the top five bacterial agents implicated in domestically-acquired foodborne illnesses in
the U.S. are nontyphoidal Salmonella spp., Clostridium perfringens, Campylobacter spp.,
Staphylococcus aureus, and Shigella spp. (100). In addition, nontyphoidal Salmonella spp.,
Campylobacter spp. and L. monocytogenes are significant causes of foodborne hospitalizations
and/or deaths (100).
The most recent FoodNet report indicates that there were 17,468 laboratory-confirmed
cases of foodborne illness due to strains of Salmonella, Campylobacter, Shiga toxin-producing
Escherichia coli (STEC) of both O157 and non-O157 serotypes, Yersinia, Listeria, and Vibrio
reported in 2009 (20). On a positive note, continued declines in cases are occurring for
Campylobacter, Listeria, Salmonella, and Yersinia. Significant declines as compared to 20062008 levels were exhibited for Shigella and shiga toxin-producing E. coli (STEC) O157.
Unfortunately, cases of illness caused by Vibrio spp continue to increase (20).
In addition to food, contaminated recreational and drinking water are also sources of
bacterial pathogens that cause acute gastroenteritis, although the case numbers are not as high.
According to data from the CDC’s Waterborne Disease and Outbreak Surveillance System, 41
gastroenteritis illnesses caused by Shigella sonnei, 10 cases of E. coli O157:H7 illness and 6
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cases of Campylobacter jejuni illness resulting from activity in recreational waters were reported
in 2005-2006. Lakes and kiddie pools were the sources primarily implicated (14). In 2005,
water ingested from a river was the source for an outbreak involving at least 60 individuals and
yielded a mix of E. coli O157:H7, C. jejuni, and E. coli O145 (13). Campylobacter was
additionally implicated in 38 illnesses in 2006 due to contaminated well water (13).
Although not estimated to be one of the top five bacterial agents associated with
foodborne illness, E. coli strains are of significant public health interest, and are the focus of the
Bio-Plex bacterial assay described and evaluated in this paper. E. coli organisms have acquired
many virulence factors that allow them to expand beyond being commensal intestinal organisms
and ultimately lead to infection and disease. These ―diarrheagenic‖ E. coli can be characterized
based on virulence and pathogenesis into the categories of enterohemorrhagic E. coli (EHEC),
enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC),
enteroaggregative E. coli (EAEC), and diffusely adherent E. coli (DAEC) (61). Shiga toxinproducing E. coli (STEC) that also contain the invasion gene, intimin, are members of the EHEC
grouping.
While STEC O157:H7 is a prominent cause of foodborne infections in the US, several
other diarrheagenic E. coli strains have been implicated as etiologic agents in outbreaks
occurring in the U.S. In a retrospective study of 159 outbreaks occurring from 1971 to 1995,
Dalton et al. (33) described an increasing incidence of enterotoxigenic (ETEC) strains causing
foodborne outbreaks. During 1975-1989, ETEC was the causative agent of 6% of outbreaks, and
between 1990 and1995, the incidence rose to 39%. A similar increase was observed for cruise
ship outbreaks, increasing from 6% during 1975-1989 to 36% during 1990-1995. For most
outbreak cases, a food item was the implicated source of illness, with seafood being the most
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commonly implicated vehicle (33). Based on this study, Dalton recommended that ETEC should
be considered as a potential cause of acute gastroenteritis outbreaks exhibiting a 24-48 hour
incubation period with a diarrhea to vomiting ratio of greater than or equal to 2.5 and duration of
symptoms lasting longer than 60 hours (33). Further investigation into ETEC outbreaks during
1996-2003 revealed that the ETEC serotype O169:H41 had become increasingly prominent (4).
Although reports of foodborne outbreaks due to EIEC and EPEC are not as frequent in
the literature, both are considered to be potential causes of foodborne disease (38). In the past
several decades, EIEC strains have been attributed to outbreaks due to contaminated French
cheese and potato salad (38). EPEC strains are more commonly seen in developing countries,
particularly in children. Domestically, food and water may be contaminated by both pathogens
and cause illness, although there is a paucity of outbreak reports in the scientific literature, most
likely due to the fact that identification of these strains is not routinely included as part of
standard foodborne outbreak investigations. The low incidence of EPEC infections was
illustrated in a prospective study of diarrheal illnesses in Maryland and Connecticut in which 823
specimens tested with molecular techniques yielded only two EPEC strains (80).
Epidemiology of food- and waterborne viral gastroenteritis. As mentioned previously, viral
pathogens are the leading cause of foodborne illness in the U.S, with noroviruses being the most
prevalent viral infectious agent (100). Noroviruses are estimated to cause 58% of domesticallyacquired gastrointestinal illnesses, equating to an estimated 5.5 million illnesses annually. Of
those, 26% are estimated to be due to contaminated food sources (100). Rotaviruses,
astroviruses and sapoviruses are estimated to collectively cause slightly over 15,000 illnesses
annually, with 1% of those being foodborne (100). In the Commonwealth of Virginia,
surveillance is conducted for both noroviruses and rotaviruses, resulting in the detection of
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norovirus in over 2,000 specimens and rotavirus in 38 specimens between 2001 and 2009 (45).
The initial viral assay design discussed in this paper was intended to detect both noroviruses and
rotaviruses.
In addition to the recent CDC estimates, historical data further support the prevalence of
norovirus in the U.S. In one study, norovirus was attributed to 93% of non-bacterial outbreaks
investigated by the CDC during 1997-2000 (41). In 2006, a significant increase in norovirus
cases, including those in foodborne outbreaks, was reported by the CDC (12). The increase was
attributed to the emergence of two new co-circulating strains. The rising trend of norovirus cases
was experienced across the nation, with food-related venues being the second-most prevalent
source of infection in Virginia (45).
Rotavirus has been implicated in 32% of pediatric acute gasteroenteritis (AGE) cases and
is the primary pathogen causing AGE in children <5 years old (37, 88). Though mostly
associated with infections in children and adults in long-term care facilities, rotavirus has also
been linked to consumption of contaminated food and water sources. In 2000, an outbreak
among college students was attributed to rotavirus, with deli sandwiches being implicated as the
source (11). This outbreak was reported as being unusual since the population was assumed to be
naturally immune, and because the suspected source was food. In 1981, rotavirus was the
etiologic agent causing a Colorado outbreak due a contaminated community water source (54).
The Role of Pathogen Identification in Outbreak Investigations. Timely detection and
identification of the enteric pathogens causing gastrointestinal outbreaks is vital for public health
officials to implement strategies for outbreak control and case management, particularly in
outbreaks that involve food service workers. Prompt, informed outbreak management allows
public health officials in the short-term to stop the outbreak and prevent additional illnesses, thus
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maintaining the public’s confidence in the food supply (32). For example, rapid identification of
the environmentally-hardy norovirus in institutional settings allows swift infection control
measures to be instituted, such as staff restrictions, patient isolation, and use of bleach versus
quaternary ammonium compounds (22, 65). In addition, the use of pulsed-field gel
electrophoresis (PFGE) molecular subtyping by the CDC's PulseNet laboratories has facilitated
prompt Listeria spp., Salmonella spp. and STEC outbreak identifications and food product
recalls (118). To illustrate, PFGE was central to alerting public health officials about a unique
cluster of Salmonella serotype Typhimurium in 2008, linked to peanut butter products
manufactured in a single facility. Control measures culminated in the recall of over 400
commercially-distributed products and the subsequent closure of the manufacturing facility (15).
Pathogen identification also enables the long-term development of prevention strategies
and infection control guidelines. For example, establishing the epidemiology of rotavirus
infections assisted in the development and subsequent FDA clearance of two rotavirus oral
vaccines in the U.S. Continued characterization of this virus is necessary to detect shifts in
antigenicity that may compromise or reduce vaccine efficacy (25). Characterizing outbreaks also
allows public health officials to identify new pathogens, food vectors, and/or gaps in the food
safety system (32). FoodNet surveillance provides a strategic benefit by facilitating an
understanding of the foodborne illness burden and an understanding of food practices that may
potentially be outbreak-associated (118). For example, a Listeria monocytogenes outbreak
attributed to turkey deli meat resulted in 54 identified illnesses and the recall of over 30 million
pounds of meat products. This outbreak led to intensified USDA regulations for L.
monocytogenes control, resulting in a 25% reduction in the number of specimens testing positive
within one year (48).
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Established Methods of Pathogen Identification. Public health laboratories employ a variety
of traditional and molecular-based testing techniques to identify etiologic agents responsible for
gastroenteritis outbreaks.
Identification of foodborne enteric protozoa. Traditional ―gold standard‖ ova and parasite
(O&P) microscopic examinations are typically used to identify the presence of enteric protozoa
in clinical stool specimens. However, a known limitation of microscopy is the inability to
morphologically distinguish certain strains such as pathogenic E. histolytica from nonpathogenic E. dispar. Cryptosporidium may also be identified using O&P examination, although
this organism is usually missed unless a specific request for identification is submitted (55).
Identification of Cryptosporidium may be facilitated using a modified acid-fast stain for
microscopic examination. Cyclospora oocysts can also be identified during O&P examination,
however, they are quite small. Hot safranin stain may facilitate identification, and presence can
also be confirmed by looking for autofluorescence with the use of an excitation filter (86).
Several commercial kits are also available for identification of G. intestinalis and C. parvum,
including a lateral-flow immunoassay, a direct fluorescent-antibody (DFA) assay, and microplate
enzyme immunoassays. One study compared several of these methods and determined that the
DFA method was most effective in detecting both Giardia and Cryptopsoridium (58). In
addition to these techniques, a growing number of singleplex and multiplex molecular assays
have been described in the literature for detection and speciation of intestinal parasites, including
assays differentiating E. histolytica from E. dispar. However, these have not yet been widely
implemented in public health laboratories for surveillance or outbreak detection purposes.
Identification of foodborne bacterial pathogens. Traditional ―gold standard‖ microbiological
methods used for the identification of enteric bacterial pathogens include staining, culture using
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selective and differential media, and biochemical testing using manual methods such as the API
20 E® strip (bioMérieux SA, l’Etoile, France) or automated biochemical systems such as the
bioMérieux Vitek® and the Seimens MicroScan® instruments. Commercial immunoassay kits
have been developed for the detection of shiga toxins produced by E. coli in stool and/or culture,
although some do not differentiate between Shiga toxin types 1 and 2. In addition, E. coli strains
may be further characterized using latex agglutination to confirm the O157:H7 serotype.
Serological testing of Salmonella spp. using antisera specific for somatic and flagellar antigens is
conducted in many public health laboratories in order to support national surveillance programs.
Due to the increasing availability of genome sequences and simplicity of molecular techniques,
information on enteric bacterial virulence factors and their corresponding gene targets is widely
available in the scientific literature. This has facilitated an ever-increasing number of singleplex
and multiplex PCR assays in the scientific literature for epidemiological use.
Identification of foodborne viruses. Culture methods for enteric viruses are of limited use in
public health laboratories. Noroviruses are currently unculturable, and although methods are
described in the literature, rotaviruses and astroviruses are not easily cultured (69, 83, 93, 101).
Electron microscopy has been considered as the gold standard for virus identification, but this
capability is not readily available in most clinical or public health laboratories due to its cost and
training requirements. To facilitate rapid identification, commercial enzyme immunoassay (EIA)
and latex particle agglutination kits have been developed for norovirus and rotavirus detection,
although norovirus diagnostic kits are of limited availability in the U.S. Recently an FDAcleared norovirus EIA kit became available in the U.S.; however, its use is intended for
preliminary screening purposes only with all negative results requiring further confirmation with
molecular-based methods (22). According to the World Health Organization and the CDC, the
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sensitivity and specificity of several EIA assays for the detection of rotavirus are adequate for
surveillance, and these are used in some public health laboratories (16, 117).
As is the case for protozoa and bacteria, many molecular assays for the detection and
classification of enteric viruses are described in the literature. Molecular methods are the
primary method of detection of noroviruses by laboratories in support of outbreak investigations
(22). Use of molecular methods for the detection of rotavirus occurs mainly in research settings
and is particularly useful in genotyping virus strains (16).
Investigation of Gastroenteritis Outbreak Cases at DCLS. A primary interest of the
Division of Consolidated Laboratory Services (DCLS) and other state public health laboratories
is the detection and characterization of common enteric pathogens typically associated with
infectious disease outbreaks. DCLS receives clinical specimens for the detection and
characterization of enteric pathogens for two main reasons: 1) to confirm and report pathogens
on the Virginia Reportable Disease List, as required by law, and 2) to investigate AGE outbreaks
within the Commonwealth of Virginia. During 2008-2010, DCLS confirmed over 1,000
bacterial, viral and protozoan pathogens in association with outbreak investigations.
The venues of outbreaks are numerous, ranging from social functions to long-term care
facilities to schools and day care centers, and specimen submission to DCLS is triggered by
reports of clusters of similar illnesses to the Department of Health. Disease clusters are assigned
a formal outbreak number, and a representative number of specimens are submitted for testing to
identify an etiologic agent. The initial goal for identifying a pathogen in a cluster investigation is
to determine if the cases represent an outbreak, which is defined as two or more cases of a
similar illness in unrelated individuals with a common link or exposure (32). Results
communicated to epidemiologists can be further used to aid in making decisions regarding future

11

investigation, additional specimen sampling, food recalls and traceback investigations, isolation
and restrictions of ill persons, and infection control. Results are typically not used for diagnostic
purposes or for decisions related to patient treatment. In addition to directly supporting outbreak
investigations, DCLS also submits representative specimens for selected pathogens to the CDC
for further characterization. These results are used to populate data for surveillance programs
such as CaliciNet, a national norovirus surveillance program, and a variety of other enteric
bacterial surveillance systems for Salmonella, STEC, Shigella and Vibrio.
Current DCLS Enteric Pathogen Detection and Characterization Capabilities. At DCLS,
laboratory analyses in response to infectious gastroenteritis outbreaks encompass a variety of
methods, including microscopy, culture, EIA and molecular protocols. These methods are
performed in separate sections of the laboratory using multiple sample types and a variety of
different procedures. Pathogen identification can take as long as six days depending on the
pathogen type and the initial testing performed. Figure 1 provides a general overview of the
testing capabilities at DCLS, which is reflective of most public health laboratories. The figure
also includes a listing of the primary specimen types received, and the testing typically initiated
in outbreak situations. The decision regarding which tests to perform is determined by the
epidemiological information provided to the laboratory upon submission. In some cases, only
minimal information is known (symptoms, time of onset), so the ability to target testing to a
specific etiologic agent matching the clinical presentation is not always possible. In other cases,
an organism is known due to the fact that the patient was tested elsewhere, and the
epidemiologists require additional testing to pinpoint sources and/or follow-up food service
employees.
Intestinal protozoan testing at DCLS. Protozoan pathogens have historically been identified at
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Figure 1. Overview of typical foodborne outbreak specimen testing algorithm. General
overview of the outbreak testing approach at DCLS, the typical specimen types received, and
examples of testing typically undertaken in outbreak investigations. The decision regarding
which laboratory tests to perform on outbreak-related specimens is determined based on the
epidemiological information provided to the laboratory upon specimen submission.
Abbreviations : LV-PVA, polyvinyl alcohol; NoV, norovirus; EIA, enzyme immunoassay; RV,
rotavirus; RT-PCR, reverse transcriptase polymerase chain reaction; STEC, shiga toxinproducing E. coli.
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Virus
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RV real-time

RV real-time
RT-PCR (reflex if
not tested Day 1)

3 hr -2 days

DCLS using fecal concentration and staining techniques. A molecular assay to differentiate E.
histolytica from E. dispar is available, but has been rarely used. Testing for the identification of
parasites in clinical specimens has been suspended at DCLS and many other state public health
laboratories, resulting in a gap in the ability of laboratories such as DCLS to screen outbreak
specimens for protozoan pathogens. Therefore, specimens submitted in association with
outbreaks investigations for which an enteric parasite might be implicated must be sent to a
private or reference laboratory for testing, greatly delaying the receipt of laboratory results.
Enteric virus testing at DCLS. Enteric virus testing is conducted at DCLS and encompasses
real-time and conventional RT-PCR protocols developed by scientists at the CDC for norovirus
and rotavirus. In a typical outbreak in which parasites are not suspected, the first testing initiated
is typically norovirus real-time RT-PCR, as results are available within just a few hours.
Rotavirus real-time RT-PCR testing may also be initiated on the first day, depending on the
symptoms of the cases in an outbreak. If symptoms do not prompt the immediate inclusion of
rotavirus testing, then testing could be delayed until the next day if all outbreak specimens are
negative for norovirus. If the norovirus assay results are positive, rotavirus testing is not
typically initiated. If the results are all negative, testing to identify enteric bacteria begins.
DCLS also has the capability to further characterize norovirus-positive specimens using
sequencing protocols developed by scientists at the CDC. In addition to the genogroup identified
by real-time RT-PCR, sequencing provides further genotype information. This information is
then entered and tracked using the CaliciNet surveillance program. The typical turnaround time
for outbreak results is 3 hours to 2 days, depending on the timing of rotavirus testing.
Enteric bacterial testing at DCLS. Bacterial pathogens are identified by DCLS using
microscopy, biochemical testing, and EIA techniques. On the first day of outbreak specimen
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submission, plates and broths are prepared and incubated to begin the process of pathogen
isolation. On the second day, bacterial identification begins with enzyme immunoassay testing
for toxins if the specimens are submitted for reference confirmation. Reference specimens
negative for toxins are reflexed for molecular toxin testing. Toxin-positive outbreak specimens
continue to be processed using microbiological techniques for organism identification. On day 3
and beyond, final biochemical and confirmatory testing takes place as appropriate for the
suspected organism. The approximate time to results is 2-6 days.
Additional STEC characterization is typically performed using real-time PCR molecular
methods; however, this testing is mainly used to characterize isolates, and is not performed for
outbreak testing purposes. Specific identification of diarrheagenic E. coli strains other than
STEC O157 is currently not available at DCLS using classical microbiological techniques. A
real-time PCR protocol is maintained for ETEC strain detection, although it is typically reserved
for outbreaks in which primary testing has not yielded an alternate pathogen identification.
Use of Microsphere-Based Multiplex Screening Assays for Pathogen Identification and
Detection. The rapid turn-around time of molecular techniques, combined with increased
sensitivity as compared to classical testing methods, has resulted in an explosion of PCR-based
testing protocols in the literature. Classical methods such as EIA and microscopy are traditional
identification techniques, but are of limited value due to their high detection limits and the
inability to differentiate between closely-related pathogens (e.g., E. histolytica versus E. dispar)
(110, 118). For viruses like norovirus and astrovirus, electron microscopy has been a gold
standard method. However, sensitivity is hampered due to viral morphology and the
accessibility and complexity of this technology (25).
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Because molecular techniques can be designed to detect distinct genomic regions, and
due to their ability to detect small numbers of a microorganism, they may provide greater
sensitivity and specificity versus traditional methods. Another advantage of molecular
techniques is that they lend themselves readily to multiplex applications, allowing a number of
pathogens to be targeted within one reaction tube. Multiplexing has proven useful in identifying
pathogens in clinical specimens, with a variety of protocols described for enteric bacteria,
viruses, and parasites (50, 53, 97, 97). However, multiplex assay design is extremely
challenging due to the potential for primers to interfere with each other. Careful research and
use of design software can facilitate the identification of optimal primer pair combinations.
Detection of PCR-amplified products may be accomplished in a variety of ways, including
conventional gel electrophoresis and staining or real-time fluorescence detection. Visualization
with agarose gel is the most flexible method, as the number of targets that can be visualized at
one time is not limited. Real-time detection platforms, however, are limited in the number of
fluorophores that may be used for detection at one time.
The Luminex XMap® microsphere technology is an open platform that has the capability
for simultaneous detection of up to 100 targets within one reaction. This technology is also
marketed by BioRad as the Bio-Plex™ 200 (BioRad Laboratories, Hercules, CA), and its use is
the focus of this project. The Bio-Plex 200 system consists of a 96-well microtiter plate reader, a
"flow-based" detection system that employs two lasers for detection, and a high throughput
fluids module (7). Integral to the system are the 100 different microspheres (sets), each colorcoded with a unique mix of two fluorophores. Each microsphere is made specific for a genomic
target by chemically oligomerizing amplicon-specific probes to the microspheres, the process of
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which is illustrated in Figure 2. This system can detect up to 100 targets in 96 specimens per
run, thus providing rapid detection without the real-time fluorophore and batch-size restrictions.
Prior to detection with the Bio-Plex, nucleic acids are extracted from clinical specimens
and amplified in multiplex using conventional PCR (Figure 3). One primer of each primer set in
the multiplex reaction mix is biotinylated at the 5’ end. The amplified specimens are then mixed
with a multiplex microsphere ―mix‖ which contains the microsphere sets corresponding to the
targets of the assay, and incubated to allow hybridization of biotinylated amplicon corresponding
with the target microspheres. After incubation, streptavidin-R-phycoerythrin (SAPE) is added to
the sample wells to facilitate detection. The R-phycoerythrin serves as a fluorescent reporter dye
and streptavidin binds the dye to the biotinylated amplicon, if present. The plate is then placed
on the Bio-Plex reader platform and processed for target detection. Using flow-based fluidics,
the Bio-Plex instrument analyzes the microspheres in each sample well individually using lasers
to detect specific bead color for identification purposes and the SAPE:biotin-tagged amplicon
hybridization. Results are provided by the Bio-Plex 200 platform as a value designated the
median fluorescent intensity ( ―FI‖ for the Bio-Plex system), which represents the average
fluorescence of 100 target-specific beads per specimen well.
Utilization of this technology for the multiplex detection of pathogens has been
increasingly described for all pathogen types, in both research and commercial settings, with
pathogen detection assays employing the microsphere-based technology of Luminex and/or the
Bio-Plex 200 detection platform being described for bacteria, fungi, viruses, and parasites (40,
71, 77, 116). A microsphere-based assay for the detection of intestinal protozoa and parasites
was recently described by Taniuchi et al., from which selected pathogen targets are being
evaluated in this project (107) To date, only one Luminex-designed nucleic acid assay is
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Figure 2. Protocol for coupling pathogen-specific DNA probes to microspheres. This figure
provides an overview of the steps required to couple a pathogen-specific probe and a uniquelynumbered microspheres for each target in a Bio-Plex multiplex assay. An image of the
purchased microspheres is shown to the top left. The microspheres initially only possess
carboxyl groups on their surface. DNA probes are synthesized to contain an amino modifier C12
link at the 5’ end. The number of microspheres used to make a batch can vary, but in the studies
described herein, five million beads were typically used. Microspheres are pelleted and the
storage buffer is removed. A pH 4.5 buffer is added to establish the reaction conditions. Next,
the target-specific probe is added followed by addition of EDC {1-Ethyl-3-[3dimethylaminopropyl]carbodiimide hydrochloride} to react with the carboxyl groups on the
microspheres and create a chemical intermediate at each carboxyl site. The intermediate has an
affinity for the amines attached to the probes, thus linking the probes to the microspheres. After
two washes with buffers, the microspheres are counted using a hemacytometer for accurate
addition to the detection plate specimen wells. This process is completed for each target-specific
microsphere to be used in the multiplex assay. Prior to a detection reaction on the Bio-Plex, a
multiplexed bead mixture is made
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Figure 3. Overview of nucleic acid hybridization and detection methodologies using the
Bio-Plex 200. This figure overviews the Bio-Plex 200 detection plate setup and hybridization
steps as described in Materials and Methods. Nucleic acids are extracted from clinical
specimens and amplified with organism-specific primer sets in which one primer is biotinylated.
After amplification, the Bio-Plex plate is prepared. First, organism-specific microspheres are
added to the wells of a 96-well plate (1), followed by addition of the biotinylated amplicon (2).
This mix is heated to eliminate secondary structures, then incubated to allow hybridization of
amplification products to complementary probes. Next, a streptavidin-linked fluorescent reporter
is bound to the biotinylated amplicon (3). If the target DNA is present, the amplified DNA will
hybridize to the probes on the microspheres, creating a microsphere-amplicon-reporter
―sandwich‖ (middle right). The plate is placed on the Bio-Plex analyzer for fluorescence
detection. The Bio-Plex uses two lasers: one to read the spectral address of each bead, thus
identifying the organism target, and the second to measure the presence of the reporter dye, thus
indicating that a target has hybridized. Histograms in the Bio-Plex software are used to measure
bead detection, and final fluorescent intensity results are exported for analysis as qualitative
results.
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available as an FDA-cleared in vitro diagnostic kit -- the xTAG™ RVP (Respiratory Viral Panel)
kit, which targets 12 respiratory virus targets. Two other bead-based assays are available for
research use only: the ResPlex1® assay, which tests for seven respiratory pathogen targets, and
the StaphPlex® which tests for 18 targets to allow Staphylococcus aureus identification and drug
resistance determinations. Luminex Corporation is currently marketing a new xTAG kit
targeting 15 intestinal pathogens. However, it is not yet currently available in the U.S.
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CHAPTER 2 OVERVIEW OF RESEARCH PROJECT

Introduction to the Research Project. Locally and nationally, there is an urgent need for
simple, rapid and cost-effective testing methods for public health laboratories to detect and/or
identify pathogens of national health concern (81). Rapid detection is vital in identifying
foodborne pathogens, allowing public health officials to quickly become aware of problems with
the food supply that otherwise may have gone unnoticed. Once an outbreak is identified, public
health officials can control the occurrence of further infections (32). A wide variety of parasites,
bacteria and viruses may cause foodborne gastrointestinal infections (100). Therefore, to support
the urgency of obtaining outbreak investigation results, simple and rapid testing methods are
desired in order to concurrently screen for as many typical foodborne pathogens as possible. As
discussed in Chapter 1, there are a wide variety of testing methods available for the detection of
foodborne pathogens, ranging from traditional microbiological techniques to multiplex molecular
assays. However, each technique is limited in providing a rapid comprehensive foodborne
pathogen screening capability, either by the number of pathogens that can be detected
concurrently or the time required to obtain a result.
Perhaps the most promising technology to enable comprehensive screening in one testing
format for foodborne pathogens is that of multiplex molecular-based assays, many of which are
described in the literature. However, many of the assays are developed for real-time (RT)-PCR
platforms that may accommodate only a small number of fluorophores, limiting the size of
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multiplex reactions and thus the number of pathogens that may be concurrently detected. The
potential of the Luminex XMap® microsphere technology incorporated into the Bio-Plex 200 to
detect up to 100 molecular targets in one reaction makes the platform an attractive candidate for
the development of multiplex assays capable of detecting more targets than currently allowed on
real-time multiplex platforms, enabling comprehensive screening of foodborne outbreak clinical
specimens on one instrument.
The national emphasis regarding the development of diagnostic techniques for use in
public health laboratories, combined with the availability of the advanced multiplex detection
capability of the Bio-Plex 200, led to the hypothesis that the integration of multiplex Bio-Plex
microsphere protocols with a common extraction method for the simultaneous detection of
protozoan, bacterial, and viral organisms would enable prioritization of public health laboratory
testing efforts and assist in reducing the timeline for identifying the causative agent of a
suspected outbreak.
To address this hypothesis, three specific aims were developed for this research project.
The first specific aim was to assess the performance of a Bio-Plex microsphere assay for the
detection of four different protozoan pathogens in clinical stool specimens. The second specific
aim was to develop and assess the performance of a Bio-Plex microsphere assay for the detection
of enteric bacterial pathogens in clinical stool specimens, with an emphasis on diarrheagenic E.
coli virulence determinants. Finally, the third specific aim was to incorporate a common nucleic
acid extraction method to be used in conjunction with the Bio-Plex assays and two standardized
real-time RT-PCR viral assays utilized for the detection of norovirus and rotavirus agents.
Rationale for Evaluating a Microsphere-Based Multiplex Testing Platform. The detection
of infectious agents associated with enteric outbreaks can be hampered by lack of information,
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improper specimen collection, and non-specific symptoms. Outbreak investigations occurring in
immigrant populations and at institutions such as schools, day care centers, and long-term care
facilities also make information-gathering difficult. In all these cases, the gathering of critical
epidemiological data may be hindered by challenges such as language barriers, age and mental
status, and may ultimately result in misguided testing decisions and delayed pathogen
identification.
Another challenge with respect to outbreak testing is the specimen requirements for
individual testing methods. For example, specimens transported in Cary-Blair medium are
preferred for traditional bacteriological testing, while formalin and low-viscosity polyvinyl
alcohol (LV-PVA) preservation are optimal for traditional parasite microscopy. Depending on
the molecular protocols employed by laboratories, some assays may not be validated for certain
specimen types. For example, specimens preserved in formalin are typically not acceptable
molecular analysis as the formalin may inhibit PCR (94). Should unacceptable specimen types
be submitted, the collection of additional specimens may be required, resulting in testing delays.
If additional specimens cannot be collected, no further testing can be performed. Additionally,
concurrent pathogen testing with multiple methods may require large sample volumes. If sample
volume is low, laboratorians must decide which testing can and should be performed first,
potentially at the expense of testing for a complete panel of pathogens.
Finally, the characteristics of the pathogens also present obstacles. Most public health
laboratories typically characterize outbreaks based on disease onset times and reported
symptoms of ill persons. However, many organisms have similar or overlapping symptoms or
sources. Listed in Table 1 are a number of pathogens associated with significant numbers of
foodborne and waterborne illnesses annually, along with representative incubation times and
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typical symptoms (118). The list is arranged in order of incubation period, from shortest to
longest. These incubation periods are often used by public health authorities to guide laboratory
testing. Of significant note is the overlap in incubation periods and symptoms between many of
the pathogens, which can be misleading in trying to initially determine an outbreak etiologic
agent and may render diagnostic testing decisions difficult. For example, patients may exhibit
similar incubation periods and symptoms when infected with either Salmonella spp. or norovirus,
particularly early in the illness (118). In another example, misinterpretation of non-specific
symptoms was described in one Florida outbreak leading to an initial assessment as norovirus,
but further testing revealed the cause to be Cryptosporidium (68).
Challenges such as those described above potentially cause a delay in identifying the
outbreak pathogen. Using typical laboratory testing protocols, even the preliminary identification
of a causative agent may take up to six days post-submission, as previously shown in Figure 1.
Designing and employing an integrated screening algorithm that incorporates a common
extraction method and multiplex Bio-Plex screening assays to detect enteric pathogens
implicated in AGE outbreaks has the potential to allow laboratorians locally, nationally and
internationally to test specimens and provide preliminary results for multiple pathogen types on
the first day of submission. Therefore, a practical goal for this project was to design a qualitative
screening algorithm in which a variety of specimen types are prepared with a single extraction
method and tested concurrently using the Bio-Plex platform targeting ten protozoan pathogens
and bacterial gene targets in order to decrease the time to preliminary results and to better focus
confirmatory testing. Should this initial screening protocol exhibit acceptable performance and
meet practical goals, it may serve as a testing backbone to which additional molecular targets
may be added to meet future epidemiological testing needs.
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Table 1. Symptoms characteristic of infection by common foodborne pathogens. Outbreaks
involving infectious agents are typically based on time to disease onset and symptoms. The
occurrence of similar or overlapping symptoms or sources have the potential to hinder public
health investigation and laboratory testing decisions.
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Agenta

Symptomsb

Incubation Period

Chemical toxins

1 min-3 hrs

Varied

S. aureus enterotoxins

30 min-6hrs

V, D, N, Cr

B. cereus enterotoxins

1-6 hrs or 6-15 hours

V or D, Cr, V

Salmonella spp., nontyphoidal

6 - 72 hours

N, V, D, Cr

C. perfringens enterotoxins

8-24 hours

N, D, Cr

Noroviruses

10-51 hours

V, D, Cr, Hd, N

Shigella spp.

12 – 50 hours

D (bloody), Cr, F, V

Rotaviruses

24-72 hours

V, D (copious)

E. coli O157:H7

3-9 days

Cr, D (bloody), F (low)

Cryptosporidium spp.

2-28 days

V, D, N, F

Giardia intestinalis

7 - 14 days

D, Cr, N, F, Gas

Salmonella typhi

14 – 40 days

F, N, Cr,

Hepatitis A Virus

15-50 days

Jaundice, N

a
b

Data from reference 118.
V=vomiting, D=diarrhea, N=nausea, F=fever, Cr=cramps, Hd=headache
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Overview of Assays in this Study. Assays targeting enteric protozoa and enteric bacteria were
designed and evaluated in this study. In addition, use of the Bio-Plex extraction method was
evaluated for use with two standardized real-time RT-PCR assays for virus detection. A general
overview of each of the assays that are part of the Bio-Plex screening algorithm is outlined
below, with details of the molecular targets provided in specific assay chapters.
Intestinal protozoan assay. A multiplex assay to detect select intestinal protozoa was designed
by scientists at the University of Virginia (UVA). An initial design employed two multiplex
tests (a two-plex and seven-plex) targeting G. intestinalis, Enterocytozoon bieneusi, Isospora
belli, C. cayetanensis, C. parvum/hominis, Encephalitozoon intestinalis, and E. histolytica.
Preliminary testing showed that the assay had potential for successful screening of specimens
preserved in LV-PVA (data not shown). However, several pathogens targeted by the assay had
no foodborne public health significance in the U.S. Therefore, E. bieneusi, I. belli, and E.
intestinalis were removed from the multiplex, and the primers and probes targeting the remaining
four pathogens were combined into one multiplex PCR detection assay. Details of the primer
and probe sets are provided in Chapter 4. Final assay evaluations were conducted using
unpreserved and LV-PVA specimens.
Enteric bacterial assay. An initial six-plex bacterial assay to detect diarrheagenic E. coli strains
was developed by collaborators at UVA, and included primers and probes specific for EHEC,
ETEC and EPEC genome targets. Preliminary testing using stool-inoculated broth specimens
(hereafter referred to as ―stool broth specimens‖) submitted for STEC reference confirmation
demonstrated the potential of this assay or specimen screening (data not shown). Several
changes were made to the multiplex prior to conducting a formal evaluation. Because the
incidence of EPEC in foodborne outbreaks is very low in the U.S., primers and probes for two
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EPEC molecular targets were removed from the multiplex. Instead, two additions were made,
enabling detection of an E. coli O157-specific gene target (DCLS addition) and a shared target in
enteroinvasive E. coli (EIEC) strains and Shigella spp. (UVA design). Details of the genomic
regions targeted by the primer and probe sets are provided in Chapter 5. Preliminary evaluation
of the revised six-plex assay was conducted with stool broth specimens. Because stool broth
specimens are not typically submitted for outbreak investigations, final validation of this
specimen type was not conducted. Final evaluation of the assay was conducted using stool
specimens diluted in Cary-Blair transport medium.
Enteric viral assay. A Bio-Plex viral assay design targeting norovirus genogroups I and II, and
Group A rotaviruses was initiated at DCLS. Following preliminary testing, the benefit of adding
this assay to complement the other two Bio-Plex assays as part of a multi-pathogen screening
algorithm was re-evaluated. The decision to forego a formal evaluation of this assay was made
for the following reasons: 1) the norovirus genome targets were identical to standardized realtime RT-PCR protocols currently in use at DCLS, 2) the rotavirus Bio-Plex assay did not provide
any additional information than that obtained with standardized real-time RT-PCR protocols
currently in use, and 3) the Bio-Plex protocol required twice as much time to complete as the
real-time RT-PCR protocols, therefore providing no turnaround time benefit.
The use of real-time RT-PCR assays to test viral agents provides a time advantage over
the proposed Bio-Plex assay. However, if outbreak specimens require both Bio-Plex and realtime RT-PCR testing, the existing protocols as designed require two nucleic acid extractions.
Therefore, to make the screening algorithm more efficient, use of a common extraction method is
optimal. To meet this goal, a study was completed in which nucleic acids were extracted from
unpreserved and Cary-Blair specimens using both the Bio-Plex extraction method and the
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extraction method currently in use at DCLS for the standardized viral assay. Nucleic acids were
then tested using real-time RT-PCR assays to detect norovirus or rotavirus, and results were
compared. Achieving comparable results between the two extraction methods would enable
laboratories to utilize the Bio-Plex extraction method simultaneously with the real-time RT-PCR
assays, thus reducing the need for a second extraction when both Bio-Plex testing and viral
testing is required.
Overview of Validation Studies. In order to implement Bio-Plex assays for outbreak specimen
screening, specific performance characteristics must be established for each of the assays.
Regulations governing validation are provided in the Clinical Laboratory Improvement
Amendments (CLIA), section 493.1253, which state that performance characteristics must be
established for both qualitative and quantitative assays that are not FDA-cleared or subject to
clearance, a category within which the described Bio-Plex assays fall (31). The performance
standards to be evaluated include accuracy, precision, analytical sensitivity/specificity, reportable
range of results, and reference intervals, as appropriate for the assay (31). To facilitate these
studies, the Clinical and Laboratory Standards Institute (CLSI) offers guidance on assessing
molecular assay performance characteristics, and a comprehensive review article consolidating
validating recommendations is available in the literature (8, 27, 29). Review of these guidelines
and publications allowed for the selection of several Bio-Plex assay performance characteristics
to be evaluated as part of this project.
Qualitative tests have one of two possible results: detected or not detected (28). The
multiplex assays evaluated for this project have three steps: nucleic acid extraction, nucleic acid
(template) amplification, and analyte (amplicon) detection. The Bio-Plex instrument is used for
the detection step and yields a numerical ―median fluorescent intensity‖ (FI) value that is
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translated into a qualitative result of ―detected‖ or ―not detected‖ by the operator. Specific
guidance for the validation of qualitative multiplex molecular assays is provided in CLSI
documents MM17-A and MM3-A2 and determinations of accuracy, precision, and analytical
specificity are required for qualitative molecular assays (27, 29). Because a numerical value is
used to generate a qualitative result, assessments of analytical sensitivity, or limits of detection
(LoD), are also important as these values potentially impact the positive cutoff point of the assay
(30). Therefore, the validation studies performed as part of this project included the performance
characteristics of analytical sensitivity (limit of detection, LoD), analytical specificity (crossreactivity, interference), precision (repeatability, reproducibility), and accuracy (comparison-ofmethods).
Reference/Testing materials. The primary specimens used for the validation studies were
archived stool specimens, including unpreserved stools and stool specimens diluted in LV-PVA
or Cary-Blair transport medium. Bacterial isolates and commercially-purchased protozoan
cysts/oocysts were used for both analytical specificity and sensitivity testing studies. Cloned
PCR amplification products inserted into vector plasmids were used for selected analytical
sensitivity testing. All clinical specimens were anonymized prior to use in the validation testing
studies.
Determination of positive cutoff value. All analytical test methods required the establishment of
a cutoff value for determining positivity of results. The CLSI guidelines suggest determining the
highest FI value that is likely to be observed for a blank or negative sample and using this value
to help determine the cutoff (27, 29). However, for the purposes of this project, the FI value for
the blank samples was not used as the cutoff for the following reasons: 1) assay cutoff values for
selected assays had previously been established by collaborators developing the initial testing
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protocols, and 2) preliminary testing in our laboratory showed that negative specimens yielded
fluorescent readings lower than the minimum FI regarded to be relevant (<50 FI) by the Luminex
Corporation (J. Eveleigh, personal communication). Alternative guidelines suggest that
choosing a signal-to-noise ratio between 2:1 and 5:1 allows the nucleic acid targets to be
distinguished from background (27). Therefore, the working cutoff for designating positive
results was established at two times greater than the background value when background value
was subtracted. Precedence for using this cutoff is also provided in the scientific literature (39,
40, 116).
Additionally, a final cutoff value for the Bio-Plex assays under evaluation must be chosen
to indicate positivity based on the data gathered during the study. Standardized guidance is not
available in the literature; rather, various approaches to assigning a positive value have been
described. Typical approaches compare sample and negative background well FI values and
calculate cutoffs at either two times background fluorescence, two times background
fluorescence with the background fluorescence subtracted, or fluorescent values up to nine times
background (39, 40, 71, 116). An alternative approach to establishing cutoff values employs the
use of receiver operating characteristic (ROC) plots (71, 107). Data generated for the screening
assays described for this project were calculated using a value of two-times background.
Analytical sensitivity or limit of detection (LoD). The LoD, or analytical sensitivity, of an assay
describes the lowest amount of analyte that can be detected consistently at a specified level of
confidence (8, 27). The LoD can be established using two approaches. First, the LoD can be
calculated using the FI data generated with negative specimens (statistical testing) or second,
established by testing specimens with known amounts or concentrations of target (empirical
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testing) (8). Empirical testing should take place over a series of days to account for procedural
variations and the LoD determined for each target in a multiplex and for each matrix type (8, 29).
For this project, empirical testing was used to determine the assay’s LoD. Each matrix
was spiked with serial dilutions of known concentrations of organism or cloned nucleic acid. It
is recommended that 60 data points be collected in LoD studies (8, 30). However, guidelines
also acknowledge that availability of resources and cost may impact study design (8, 29). Due to
the relatively high cost-per-test, and the intent of these assays to serve as screening assays, not
confirmation assays, it was determined that performing a minimum of three replicate
experiments per organism or nucleic acid was acceptable. In most cases, five dilutions were
tested in each experiment, representing dilutions above, at, and below the anticipated LoD for the
target(s) being tested, yielding an average of 15 data points for each assay target per matrix type.
The limits of detection were established as a range in which the lower limit represented the
lowest dilution yielding one positive result and the upper limit represented the lowest dilution
yielding three positive results.
Once the LoD is established for each assay target, it is recommended that data
verification be conducted by incorporating additional targets or reaction components that could
potentially interfere with the detection of low-concentration targets (29). For example, for the
detection of infectious disease agents, it may be useful to add a high-concentration target to a
low-concentration target (i.e., pathogen), as this could mimic a true clinical specimen and a highconcentration target could potentially interfere with detection of the low-concentration target.
For the purposes of this study, this type of parameter was automatically evaluated in the study
since numerous high-concentration nucleic acid targets in combination with low-concentration
pathogen assay targets was inherent in the stool specimens, as a wide variety of normal flora
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were present in the stool specimens. The question as to whether these assays can detect targeted
pathogens in the presence of other organisms is additionally supported by the fact that in most
public health outbreak investigations, a single etiologic agent is identified and is often recovered
from multiple specimens submitted as part of the outbreak investigation.
Analytical specificity (cross-reactivity/interference). Analytical specificity describes the ability
of an assay to detect only the agent that is targeted (29). Assessing analytical specificity may be
accomplished in multiple ways: 1) using multiplex data to rule out cross-reactivity or
interference of primer and probe sets with non-target nucleic acids, 2) challenging reactions with
organisms not specifically targeted by the assay but that may be considered normal flora or
causative agents of similar symptoms, 3) spiking specimens with substances that might interfere
with the analytical procedure, and/or 4) evaluating sequences for potential cross-reactivity using
internet databases and comparison programs (8, 29).
Most of the primer and probe sequences were adapted from published studies for which
specificity experiments had been previously described. Therefore, data detailing the non-target
organisms against which the primers and probes were tested for cross-reactivity was available.
The analytical specificites of the Bio-Plex assays described in this study were further assessed in
multiple ways. Novel primer and probe sequences designed for use in this study were tested for
potential cross-reactivity by collaborators using the Basic Local Alignment Search Tool
(BLAST) maintained by NIH (data not shown). In addition, each target in the multiplex assay
was assessed for cross-reactivity to non-complementary nucleic acid templates, mainly using
qualitative results obtained during the comparison-of-methods study. Specifically, results for
assay targets that were expected to be negative based on reference testing were quantified and
compared. If no cross-reactivity exists between non-target primers and probes or with known
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non-target organism in the specimen, a negative result should be expected. For example, a
Giardia-positive specimen is expected to yield negative results when tested using the other three
non-Giardia primer and probe sets in the protozoan assay multiplex. If all negative results are
observed, the data suggests no cross-reactivity. If positive results are detected for any of the
targets other than Giardia, the data indicates there is potential cross-reactivity between the nontarget primers and probes and the nucleic acid template. Finally, additional pathogens were
included in order to assess for cross-reactivity to assay primers and probes. For the protozoan
assay, the majority of the LV-PVA validation specimens were determined by reference method
to contain other intestinal parasites not targeted by the current Bio-Plex assay (e.g., Blastocytis
hominis, Chilomastix mesnili, etc.). Therefore, the absence of positive results in the presence of
non-complementary target can be used to rule out cross-reactivity to these organisms. For the
bacterial assay, several sources of non-target pathogens were used to challenge the Bio-Plex
assay, including bacterial isolates representing non-targeted E. coli strains and serotypes and
other enteric bacterial pathogens.
It has been well documented that stool samples contain multiple inhibitors of nucleic acid
amplification reactions, including medications and/or their breakdown products, food
components, bile salts and normal bacterial flora (111). Directly assessing all the potential
interfering substances, known and unknown, in a stool specimen by spiking studies is not
practical and was not part of the current validation studies. However, assay interference was
indirectly assessed since the specimens tested in the current validation studies were
representative of stool specimens typically submitted to DCLS and, therefore, included a range
of different consistencies, normal bacterial flora, storage conditions, and preservation methods,
and presumably contained a variety of medications and other components reflective of patient
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diets, as specimens are submitted from a variety of different patients throughout the
Commonwealth of Virginia. To assess interference by these variables, comparison-of-method
study data was evaluated for negative results obtained for targets expected to positive when
tested with the Bio-Plex system. Specimens yielding false negative results were diluted and
tested to determine potential presence of inhibitors.
Precision (repeatability and reproducibility). Precision describes how well replicates of a given
measurement agree when tested under defined conditions (8, 29). Precision studies typically
incorporate two types of evaluations: repeatability and reproducibility. In repeatability studies
(―within-run‖ studies), specimens of varying concentrations are tested in replicate using the exact
same conditions. For the protozoan and bacterial assays, amplicons from specimens representing
various concentrations of organism, matrices, and assay targets were tested in ten replicates on a
single Bio-Plex run by a single operator.
In reproducibility studies (―between-day studies‖), specimens of varying concentrations are
tested under a variety of conditions. Ideally, variation should include multiple lots of reagents,
multiple operators, various testing times, etc. (29). However, reproducibility studies often
employ single lots of reagents and single operators, as was conducted in the current study (8).
Reproducibility for the protozoan and bacterial assays was determined by amplifying extracted
nucleic acid templates from select specimens and performing the detection step in single wells on
the Bio-Plex system, one time per day over five days. Testing occurred only once per day, as
opposed to multiple runs, to reflect how the assay would actually be used during an outbreak
investigation (8). The reproducibility studies included both replicate detection of the same
amplicon over multiple days and replicate amplification combined with Bio-Plex detection over
multiple days. Thus, statistics describe both the precision of the detection step and overall
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precision of the amplification and detections steps together, taking into account the single
variable of time.
Guidelines recommend that precision studies be conducted with specimens of typical
clinical analyte concentrations and that represent all specimen matrices to be tested (29).
Evaluations of quantitative assays should include specimens not only at the assay cutoff point,
but also at other points in the assay measuring range. Evaluations of qualitative assays should
emphasize specimens at or near the limit of the assay (8, 29). Because this multiplex assay is a
semi-quantitative assay (quantitative results are used to generate a qualitative result), the
precision evaluation is based on both recommendations and employs specimens yielding
fluorescence results both near the assay cutoff of two times background, and results higher in the
measurement range. As recommended, the specimen panels evaluated included the typical
specimen matrix type for each assay (29) For both repeatability and reproducibility studies,
mean and standard deviation (SD) of the FI minus background results were calculated for both
positive and negative multiplex targets. In addition, the coefficient of variation [CV,
(SD/mean)x100] was calculated for positive targets. CV was not calculated for negative targets
as the resulting percentages are statistically impractical.
Guidance publications also provide varying recommendations for precision study sample
size, ranging from 40 replicates for qualitative tests to 120 data points for quantitative tests (8).
However, it is acknowledged that achieving these numbers of replicates may not be feasible due
to limited specimens and resources (28). Minimizing the panel size, number of replicates, and the
scope of the precision study decreases the confidence level of the results and may underestimate
the overall assay imprecision. However, because the assay is intended to be used as a screening
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assay to rule in suspected pathogens, the precision data was adequately descriptive for this
intended use.
The literature contains limited data with respect to the precision of Bio-Plex 200 nucleic
acid assays and there are no standards established to determine the acceptability of precision data
for molecular assays (8). Therefore, the repeatability and reproducibility data generated by this
evaluation were compared to data available in two commercial and scientific studies (75, 77). In
order to assess the precision of organism-positive assay targets, the CV data generated in this
study were compared to positive target CV data published for the only commercially-available,
FDA-cleared, infectious disease microsphere multiplex assay, the xTAG® RVP (Respiratory
Viral Panel) (Luminex Molecular Diagnostics, Inc., Toronto). The RVP data differed from the
current study data in that the RVP study represented a multiple-laboratory evaluation and
measured precision for extraction, amplification and detection steps (75). However, to the
author’s knowledge it is the only commercial document available in the U.S. describing
precision for Luminex-based nucleic acid assays, and therefore was used for comparison
purposes.
Fluorescent intensity values less than 50 are below the detection threshold of the
Luminex technology, and variation is considered difficult to assess (J. Eveleigh, personal
communication). Prior experience with the BioPlex assay has suggested that CV values of
negative specimens are often impractically high and potentially misleading; therefore SD values
were used to describe the variation for target-negative specimens. To assess statistical
acceptability for negative targets, the calculated SD values were compared to those described for
an alternate microsphere-based assay described in the literature (77).
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Because there are no established standards of precision acceptability for Bio-Plex nucleic
acid assays, it is incumbent upon the testing laboratory to determine criteria for acceptability.
Standards of precision for chemistry assays provide some basis for analysis, although even these
assays demonstrate a 15% to 30% variance (8). Because this technology is relatively new, and
well-established precision data is not available, comparisons to that described for the RVP assay
and by McNamara et al. (75, 77) were considered acceptable.
Analytical accuracy (comparison-of-methods). Accuracy describes how closely a result agrees
with an established reference, or for validation studies, how closely a new method correlates with
the reference method (8, 29). Therefore, a comparison-of-methods study may be conducted to
evaluate the accuracy of a new method.
Comparison-of-methods studies were conducted to assess the performance of the BioPlex protozoan and bacterial assays and to determine their potential for use in outbreak
investigations. Previously characterized specimens -- as determined using the reference
methods of microscopy, molecular methods, or enzyme immunoassay -- were tested using the
appropriate Bio-Plex assay and the results compared to establish the level of agreement between
the two methods. Bio-Plex results were designated as either true positive (TP), true negative
(TN), false positive (FP), or false negative (FN) (Figure 4). Additionally, the sensitivity (Se) and
specificity (Sp) for each assay target were calculated as described in Figure 4. Bio-Plex results
that did not correlate with the reference method results were investigated using re-extraction and
re-testing, repeating the reference method testing, and/or using alternative molecular assays, as
available.
The number of specimens recommended for a comparison-of-methods study varies
greatly, ranging from a minimum of 20 specimens to 100 specimens, although typically 40-50
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Figure 4. General algorithm to determine correlation between a new test method and the
corresponding reference method. To determine correlation (sensitivity and specificity)
between a new test method and a reference method, specimens were tested with both methods
and the results compared. A grid is generated for each target in the assay. A specimen that is
positive when tested with both a reference method and a new method is considered to be a true
positive (TP). Similarly, a specimen that tests negative with both methods is considered a true
negative (TN). A specimen giving positive results with the reference method and negative
results with the new method is a false negative (FN), and likewise, a negative reference method
result and a positive result with a new method indicates a false positive (FP). Upon completion
of the study, the sensitivity and specificity are then calculated for each target using the equations
to the right of the grid.
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specimens are tested (8). CLSI guidelines for qualitative test comparison studies recommend
that 50 positive and 50 negative specimens be tested, although smaller sample sizes may be used
with resulting larger confidence intervals (8, 28). The goal for the protozoan and bacterial assays
was to test a minimum of 40 specimens. However, for certain targeted pathogens, the number of
available specimens was limited; in these cases, all available specimens were tested and the
small sample size noted.
The parameters of Se and Sp are important in assessing the appropriateness of assay use
and guides result interpretation. The higher the sensitivity, the more confident a user can be that
a negative result is truly negative, since there will be few false negatives. Conversely, the higher
the specificity, the more confident a user can be that a positive result is truly positive, since there
will be few false positives. As discussed previously, the intended use of these Bio-Plex
multiplex assays is to screen specimens submitted as part of foodborne or waterborne outbreak
investigations. Any positive results would allow for preliminary notification of epidemiologists
and a prioritization of confirmatory testing used to characterize the detected pathogen. In most
outbreak investigations, up to six specimens are typically accepted for testing. At least two
specimens from different patients must be positive with a confirmatory method to assign a
causative agent to an outbreak. If all specimens are negative, testing will continue regardless of
the screening results as illustrated in Figure 1. Therefore, high specificity is the desired outcome
since the decision to continue with testing is based on positive results. A lower sensitivity
(higher number of false negatives) is acceptable for the following reasons: 1) all specimens will
be confirmed regardless of whether positive or negative, 2) no action decisions will be made
based on negative screening results, and 3) multiple outbreak specimens will typically be tested,
inherently increasing the overall screening sensitivity for the outbreak. Based on these factors,
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the minimum acceptable standards were established to be 80% sensitivity and 95% specificity
for the Bio-Plex assays.
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CHAPTER 3 MATERIALS AND METHODS

Materials and Methods – Protozoan Assay.
Specimens. Specimens tested in this study were anonymized to fulfill the requirements of the
University of Virginia IRB for Health Sciences Research exemption (IRB-HSR #14597). Forty
stool specimens preserved with low-viscosity polyvinyl alcohol (LV-PVA) and 30 unpreserved
stool specimens were examined. The 40 LV-PVA specimens included specimens positive for the
assay targets of G. intestinalis (n=8), E. histolytica/dispar (n=3), and both G. intestinalis and E.
histolytica/dispar (n=4), as determined by microscopy. The 30 unpreserved stools included
specimens positive for C. cayetanensis (n=6), C. parvum (n=2), C. hominis (n=1) and G.
intestinalis (n=3), as determined by PCR. LV-PVA specimens were stored at room temperature
or washed and stored at -80ºC prior to testing. Unpreserved specimens were stored at 4ºC or
-80ºC prior to testing. Nucleic acids extracted from the specimens were stored at -80ºC prior to
comparative testing. Specimens containing C. cayetanensis, C. parvum, and C. hominis were
generously provided by Dr. Alexandre J. da Silva of the Centers for Disease Control and
Prevention, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Division of
Parasitic Diseases, Atlanta, GA.
Cyst and oocsyt standards. G. intestinalis cysts and C. parvum oocysts were purchased as
1x106/4mL concentrations from Waterborne, Inc. (New Orleans, LA). Following vortexing
and/or sonication, cysts were ten-fold serially diluted in 1X phosphate-buffered saline. To
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establish assay limits of detection, dilutions of 104-100 cysts (40 μL) were spiked into 200 mg of
parasite-negative LV-PVA or unpreserved stool to yield 104-100 cysts per 200 mg of stool.
Spiked stool specimens were vortexed to evenly distribute organisms and stored at 4°C for a
minimum of 30 minutes prior to extraction, amplification and detection as described below.
Dilution series were tested in triplicate and total numbers of positive and negative qualitative
results for each dilution were summarized. The limits of detection were established as a range in
which the lower limit represented the lowest dilution yielding one positive result and the upper
limit represented the lowest dilution yielding three positive results.
Cloned DNA standards. C. cayetanensis and E. histolytica DNA was PCR amplified and cloned
into the pCR®2.1 TA vector (Invitrogen, Carlsbad, CA) per manufacturer’s TOPO TA cloning
kit instructions. Screen-positive cells were grown overnight and plasmid DNA isolated using the
PureLink™ Quick Plasmid Miniprep Kit per manufacturer’s instructions (Invitrogen). The
concentration of cloned DNA was determined using a NanoDrop 2000 (Thermo Scientific,
Wilmington DE). The cloned nucleic acid stock concentration was used to calculate
approximate genome copies/μL for this study as described by Staroscik (106). To establish assay
limits of detection, ten-fold serial dilutions were prepared in nuclease-free water and spiked in 10
μL volumes into 200 mg of parasite-negative LV-PVA or unpreserved stool aliquots. LV-PVA
specimens were washed twice with 1X PBS prior to spiking with clone. Spiked stool specimens
were vortexed to evenly distribute plasmid DNA and stored at 4°C for a minimum of 30 minutes
prior to extraction, amplification and detection as described below. Dilution series were tested in
triplicate and total numbers of positive and negative qualitative results for each dilution were
summarized. The limits of detection were established as a range in which the lower limit
represented the lowest dilution yielding one positive result and the upper limit represented the
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lowest dilution yielding three positive results. Concentrations expressed as genome copies/μL
were converted to reflect approximate organisms/200 mg stool using the following formula:
(genome copies/200mg stool) / (genome copies/organism). Copy numbers of the assay gene
targets for Cyclospora spp. and E. histolytica are estimated to be 2-20 copies/oocyst and 200
copies/trophozoite, respectively (5, 112).
Extraction of nucleic acids. Nucleic acid was extracted from stool specimens (200 mg) using
the QIAamp DNA Stool Mini Kit (QIAGEN, Hilden, Germany) per manufacturer’s instructions,
with modification. PVA-preserved stools were washed twice using 1 mL of 1X phosphatebuffered saline per wash and centrifuging at 10,000 rpm for 2 minutes. QIAamp Buffer ASL
was added to all specimens, followed by the addition of beads from one UltraClean® Fecal DNA
Isolation Kit Dry Bead Tube (Mo Bio Laboratories, Inc., Carlsbad, CA). Beads were not
included in the extraction of spiked clone standards in order to preserve the integrity of the
cloned DNA. The extraction continued per manufacturer’s instructions to the final elution of
DNA in 200 μL of AE buffer. Extracted DNA was further purified using a Zymo-Spin™ IVHRC filtration column (Zymo Research, Orange, CA) per manufacturer’s instructions.
Primers and probes. Primers and probes were previously described or designed by collaborators
at the University of Virginia (Table 2). Reverse primers were modified at the 5’ end with biotinTEG and probes with the amino modifier C12. Expected amplification products were as follows:
G. intestinalis (62 bp), C. cayetanensis (280 bp), C. parvum/hominis (138 bp), and E. histolytica
(134 bp). Primers and probes were purchased from Integrated DNA Technologies (Coralville,
IA) or Eurofins MWG Operon (Huntsville, AL).
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Table 2. Oligonucleotide primers and probes for a microsphere suspension array assay for
the simultaneous detection of G. intestinalis, C. cayetanensis, C. parvum/hominis and E.
histolytica. Modifications at the 5’ end are biotin-TEG (reverse primers) and amino modifier
C12 (probes).
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Target

Sequence (5’-3’)

Ref.

G. intestinalis
(107, 113)
G62F
GACGGCTCAGGACAACGGTT
G62btn
TTGCCAGCGGTGTCCG
G62P
CCCGCGGCGGTCCCTGCTAG
C. cayetanensis
(24, 85)
Cc280F
GTAGCCTTCCGCGCTTCG
Cc280Rbtn
CGTCTTCAAACCCCCTACTGTCG
Cc280P
GCATTTGCCAAGGATGTTTT
This study a
C. parvum/hominis
(44)
C138F
CGCTTCTCTAGCCTTTCATGA
C138Rbtn
CTTCACGTGTGTTTGCCAAT
C138p
CCAATCACAGAATCATCAGAATCGACTGGTATC
E. histolytica
(98, 107)
Eh134F
AACAGTAATAGTTTCTTTGGTTAGTAAAA
Eh134Rbtn
CTTAGAATGTCATTTCTCAATTCAT
Eh134P
ATTAGTACAAAATGGCCAATTCATTCA
a
Designed by Dr. Mami Taniuchi, Division of Infectious Diseases and International Health,
University of Virginia, Charlottesville, VA (unpublished data)
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Coupling of oligonucleotide probes to microspheres. Oligonucleotide probes were coupled to
microspheres (Bio-Rad Laboratories, Hercules, CA) using the recommended coupling protocol
provided by Luminex Corporation (Austin, TX), with the addition of a 1400 rpm rotation step
during the first incubation (74). Coupled microspheres were enumerated using a hemacytometer
per the Luminex protocol.
Protozoan assay multiplex PCR. Amplification of extracted nucleic acid was performed in 50
μL reaction volumes using Bio-Rad iQ™ Multiplex Powermix (Bio-Rad). Each reaction
contained 25 μL of 2X iQ Multiplex Powermix and 0.3 mmol/L of each primer. Amplification
was performed using the 96-well GeneAmp® PCR System 9700 (Applied Biosystems, Carlsbad,
CA), and cycling conditions consisted of 3 minutes at 95°C followed by 40 cycles of 15 seconds
at 95°C and 60 seconds at 58°C.
Detection of nucleic acid targets using Bio-Plex microsphere assay. Hybridization of
amplicons to coupled microspheres was conducted using the recommended hybridization
protocol provided by Luminex Corporation, with modifications (73). Briefly, detection reactions
were performed in 50 μL volumes in 96-well plates, and consisted of approximately 5000
coupled microspheres for each of the four targets (G. intestinalis, C. cayetanensis, C.
parvum/hominis, E. histolytica), 33 μL of 1.5X TMAC solution, 12 μL of 1X TE buffer, and 5
μL of amplified DNA. Reaction plates were incubated at 95°C for 3 minutes to denature
oligonucleotide secondary structure, then underwent 15 minutes of shaking incubation at 50°C
and 800 rpm. After addition of 25 µL of 10 μg/mL streptavidin-R-phycoerythrin reporter dye,
plates underwent a second shaking incubation at 50°C and 800 rpm for 10 minutes. Detection of
hybridized amplicons was performed using the Bio-Plex® 200 Suspension Array System using a
low RP1 target setting. Specimens were tested in single wells, with negative non-template
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amplification controls placed at the beginning, middle and end of each detection run. The
negative well placed at the end of the run was used as the background well for result calculation.
Data output of the Bio-Plex 200 is median fluorescent intensity (FI). In order to determine
positivity or negativity, the FI of the background well was subtracted from the FI of the
specimen and compared to background. Results greater than or equal to two times the
background were considered to be ―screen positive‖.
Trichrome stain. Trichrome staining was performed using Remel Wheatley Trichrome Stain
(Remel, Lenexa, KS). Slides were placed into Coplin jars containing 70% alcohol plus iodine for
20 minutes, followed by two washes with 70% alcohol for five minutes each. Slides were then
placed into trichrome stain for eight minutes, followed by a rinse with 95% alcohol. Slides were
placed into a second jar of 95% alcohol for five minutes, then carbol-xylene for 10 minutes, and
xylene for 10 minutes. Slides were mounted with coverslips using Permount and were
examined by oil immersion microscopy at 100X.
Singleplex PCR assay for the detection E. histolytica and E. dispar (alternate molecular
method). Amplification of nucleic acid was performed using PSP3 and PSP5 primers specific
for E. histolytica and NSP3 and NPSP5 primers specific for E. dispar (26). Singleplex reactions
were mixed in 50 μL volumes using ABI AmpliTaq Gold® Master Mix (Applied Biosystems,
Carlsbad, CA). Each reaction contained 25 μL of master mix and 0.24 mmol/L of each primer.
Template DNA was diluted 1:10 and 10 µL of template added to the reaction volume.
Amplification was performed using the 96-well GeneAmp® PCR System 9700 (Applied
Biosystems, Carlsbad, CA), and cycling conditions consisted of 5 minutes at 95°C followed by
40 cycles of 15 seconds at 94°C, 15 seconds at 50°C and 90 seconds at 72°C. Amplification was
completed with a final extension step at 72°C for 10 minutes. Amplification products were
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visualized using 2% agarose gel electrophoresis or Agilent DNA1000 Kit and the Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA). Nucleic acid extracted from E. dispar
trophozoite cultures was thoughtfully provided by Dr. Ibne Karim Ali, Division of Infectious
Diseases and International Health, University of Virginia, Charlottesville, VA.
Precision studies. Precision characteristics of the Bio-Plex 200 assay were determined by
testing DNA extracted and amplified from a panel of five specimens that included two LV-PVA
stool specimens positive for G. intestinalis and E. histolytica, respectively, and three unpreserved
stool specimens positive for G. intestinalis, C. cayetanensis, and C. hominis, respectively. The
specimens chosen for this panel demonstrated fluorescence results both near the assay cutoff of
two times background or results higher in the Bio-Plex measuring range. Repeatability (withinrun precision) was determined for select specimens by testing amplicon from a single specimen
in ten separate wells of a Bio-Plex detection plate. Results were calculated by subtracting the
mean of ten background wells from the Bio-Plex FI output for individual sample wells. The
mean and standard deviation (SD) of the FI minus background results for ten individual wells
were calculated for both positive and negative multiplex targets. In addition, the coefficient of
variation [CV; (SD/mean)x100] was calculated for positive targets. CV was not calculated for
negative targets as the resulting percentages are statistically impractical. Reproducibility
(between-day precision) was determined for select specimens by amplifying extracted nucleic
acids from each specimen and detecting in single wells on the Bio-Plex system one time per day
over five days. In order to determine variability in the detection step only, amplicon from the
first day of the study was detected in single wells on the Bio-Plex system one time per day for
four days. The FI minus background values of each target in the multiplex were calculated for
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each specimen by subtracting the FI value of the negative background well at the end of the run
from the FI value of each sample well.
Materials and Methods – Bacterial Assay.
Specimens. Specimens tested in this study were anonymized to fulfill the requirements of the
University of Virginia IRB for Health Sciences Research exemption (IRB-HSR #14597).
Testing of the bacterial Bio-Plex assay was performed using 50 stool broth specimens, which
were primarily MacConkey’s enrichment broths inoculated with a sterile swab dipped into a
small quantity of stool then placed into the broth (―stool broth specimens‖). Specimens were
stored at -80°C prior to testing. The 50 stool broth specimens included positives for the assay
targets of stx1 (n = 31), stx2 (n = 21), and uidA (n = 4). Specimens were previously
characterized by PCR to be positive for one or multiple assay targets. Eight stool broth
specimens evaluated were negative for all targets. Validation studies were completed using
specimens place into Cary-Blair medium (n = 16), and included stools positive for E. coli
O157:H7 (n = 2), E. coli non-O157 (n = 1), E. coli of unknown serotype (n = 3), Shigella spp. (n
= 4), and Salmonella spp. (n = 5). Specimens were stored at -80°C prior to testing. Specimens
were previously characterized to be positive for one or multiple assay targets by PCR. One stool
specimen in Cary-Blair medium included in the study was determined to contain no pathogenic
enteric bacteria by reference methods.
Additional bacterial strains. Additional bacterial isolates used in this study for establishing
performance characteristics included ETEC strains (serotypes O153:H45, Ound:H16, Ound:NM,
O6:H16, O148:NM) and EPEC strains (serotypes O119:H6, O55:NM, Ound:NM, O115:NM,
Orough:H8) graciously provided by Victoria Lappi, Molecular Epidemiology Unit, Public Health
Laboratory - Clinical Labs, Minnesota Department of Health, St. Paul, MN. Two EIEC strains
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(serotypes O124:NM, O29:NM) were obtained from DCLS archives. Additional EPEC strains
(serotypes O111:NM, O55:H6, O111:H2, O128:H1, O86:H34) were thoughtfully provided by
Dr. Nancy Strockbine, National Center for Zoonotic, Vector-Borne, and Enteric Diseases,
Centers for Disease Control and Prevention, Atlanta, GA.
Bacterial standards. Reference strains for establishing analytical sensitivity included ETEC
(ATCC 35401), E. coli O157:H7 (EDL 9333), and Shigella flexneri (ATCC 12022). Several
colonies grown on blood agar plates were inoculated into 0.85% sterile saline to yield a turbidity
reading of 0.1, approximating a bacterial count of 108 CFU/mL. Ten-fold serial dilutions were
performed in 1 mL volumes and 100 μL of the 104-100 dilutions transferred to blood agar plates.
Dilutions were spiked in 10 μL volumes into 200 mg (µL) of Cary-Blair stool negative for
enteric bacteria as follows: ETEC (108-103), O157:H7 (108-104) and S. flexneri (106-102).
Spiked specimens were then extracted, amplified and detected, as described. Inoculated blood
plates were incubated overnight, and colonies counted at approximately 24 hours. Dilution
series were tested in triplicate and total numbers of positive and negative qualitative results for
each dilution were summarized. The limits of detection were established as a range in which the
lower limit represented the lowest dilution yielding one positive result and the upper limit
represented the lowest dilution yielding three positive results.
Extraction of nucleic acids, isolates and stool broth specimens. Nucleic acid was extracted
from isolates or stool broth specimens using a boil preparation method. For isolates, a 1 µL
calibrated loop was used to remove bacterial growth from blood agar plates. The bacteria were
suspended into 300 µL of nuclease-free water. The sample was vortexed and heated at 100°C for
10 minutes. Following centrifugation at 4,500 rpm for two minutes, the supernatant was
removed and used for amplification. For stool broth specimens, 300 µL of specimen was
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vortexed, heated and centrifuged, as described. Supernatant was removed and used for
amplification.
Extraction of nucleic acids, Cary-Blair specimens. Nucleic acids were extracted from 200 mg
of stool diluted in Cary-Blair medium using a QIAamp DNA Stool Mini Kit (QIAGEN, Hilden,
Germany) per manufacturer’s instructions.
Primers and probes. Primers and probes were previously described or designed by collaborators
at the University of Virginia (Table 3). Reverse primers were modified at the 5’ end with biotinTEG, and probes with amino modifier C12. Expected amplification product sizes are as follows:
stx1 (132 bp), stx2 (255 bp), uidA (143 bp), eltA (62 bp), estA (172 bp) and ipaH (64 bp).
Primers and probes were purchased from Eurofins MWG Operon (Huntsville, AL).
Coupling of oligonucleotide probes to microspheres. Oligonucleotide probes were coupled to
BioPlex microspheres (Bio-Rad Laboratories, Hercules, CA) using a standard coupling protocol
provided by Luminex Corporation (Austin, TX), with the addition of rotating step at 1400 rpm
during the first incubation (74). Coupled microspheres were enumerated using a hemacytometer
per the Luminex protocol.
Bacterial assay multiplex PCR. Amplification of extracted nucleic acids was performed in 50
μL reaction volumes using the QIAGEN® Multiplex PCR Kit (QIAGEN, Hilden, Germany).
Each reaction contained 25 μL of 2X Multiplex PCR Master Mix, 5 μL of Q-Solution, and 0.2
mmol/L of each primer. Amplification was performed using the 96-well GeneAmp® PCR
System 9700 (Applied Biosystems, Carlsbad, CA). Cycling conditions consisted of 15 minutes
at 95°C followed by 40 cycles of 30 seconds at 94°C, 30 seconds at 58°C and 60 seconds at
72°C. A final extension step was performed for 10 minutes at 72°C.
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Table 3. Oligonucleotide primers and probes for a microsphere suspension array assay for
the simultaneous detection of stx1, stx2, uidA, eltA, estA and ipaH. Modifications at the 5’
end are biotin-TEG (reverse primers) and amino modifier C12 (probes).
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Target

Sequence (5’-3’)

Ref.

stx1
(53)
EH132F
ACTTCTCGACTGCAAAGACGTATG
EH132Rbtn
ACAAATTATCCCCTGAGCCACTATC
EH132P3
CTCTGCAATAGGTACTCCA
stx2
(90)
EH255F
GGCACTGTCTGAAACTGCTCC
EH255Rbtn
TCGCCAGTTATCTGACATTCTG
EH255P2
GGGGAGAATATCCTTTAATA
This studya
uidA
(119)
uidAF241
CAGTCTGGATCGCGAAAACTG
uidAR383btn
ACCAGACGTTGCCCACATAATT
uidAP266a
ATTGAGCAGCGTTGG
eltA (LT)
(53)
ET62F
TTCCCACCGGATCACCAA
ET62Rbtn
CAACCTTGTGGTGCATGATGA
ET62P
CTTGGAGAGAAGAACCCT
estA (ST)
This studya
ET172F
TTCACCTTTCGCTCAGGATG
ET172Rbtn
AGCACCCGGTACAAGCAG
ET172P
ATTACTGCTGTGAATTGTG
ipaH
EI64F
CCTTTTCCGCGTTCCTTGA
This studya
EI64Rbtn
CGGAATCCGGAGGTATTGC
EI64P
CGCCTTTCCGATACCGTCTCTGCA
a
Designed by Dr. Mami Taniuchi, Division of Infectious Diseases and International Health,
University of Virginia, Charlottesville, VA (unpublished data)
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Detection of nucleic acid targets using Bio-Plex microsphere assay.. Hybridization of
amplification products to coupled microspheres was conducted using a standard hybridization
protocol by Luminex Corporation, with modifications (73). Briefly, detection reactions were
performed in 50 μL volumes in 96-well plates, and consisted of approximately 5000 coupled
microspheres for each of the six targets (stx1, stx2, uidA, LT, ST, ipaH), 33 μL of 1.5X TMAC
solution, 12 μL of 1X TE buffer, and 5 μL of amplified DNA. Reaction plates were incubated at
95°C for 3 minutes to denature oligonucleotide secondary structure, then underwent 15 minutes
of shaking incubation at 50°C and 800 rpm. After addition of 25 µL of 10μg/mL streptavidin-Rphycoerythrin reporter dye, plates underwent a second shaking incubation at 50°C and 800 rpm
for 10 minutes. Detection of hybridized amplification products was performed using the BioPlex® 200 Suspension Array System using a low RP1 target setting. Specimens were tested in
single wells, with negative non-template amplification controls placed at the beginning, middle
and end of each detection run. The negative well placed at the end was used as the background
well for result calculation. Data output of the Bio-Plex 200 is median fluorescent intensity (FI).
In order to determine positivity or negativity, the FI of the background well was subtracted from
the FI of the specimen and compared to background. Results greater than or equal to two times
the background were considered to be ―screen positive‖.
Real-time PCR for the detection of stx1 and stx2. Amplification of stx1 and stx2 targets was
performed using a multiplex shiga toxin real-time PCR reaction containing the previously
described primers and probes STEC-1, STEC-2, STEC I-HP-1, STEC I-HP-2, STEC II-HP-1,
and STEC II-HP-2 (56, 95). Each reaction was prepared as follows using the LightCycler®
DNA Master HybProbe kit (Roche Applied Science, Indianapolis, IN), for a total of 19 µL: 2
mM MgCl2, 2 µL of 10X LightCycler DNA Master HybProbe, 0.5 mmol/L of each primer and
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0.2 mmol/L of each probe. Each reaction capillary contained 18 µL of the shiga toxin PCR
reaction mixture and 2 µL of nucleic acid template. Amplification and detection was performed
on the LightCycler® 2.0 Instrument (Roche Diagnostics Corporation, Indianapolis, IN). Cycling
conditions consisted of 30 seconds at 95°C followed by 50 cycles of 0 seconds at 95°C, 20
seconds at 50°C and 30 seconds at 72°C. Melting conditions consisted of 0 seconds at 95°C, 10
seconds at 40°C and continuous detection from 40°C to 95°C. The reactions were cooled at
40°C for 2 minutes.
Real-time PCR for the detection of uidA. Amplification of the uidA target was performed in
singleplex utilizing the previously described primers and probes O157-PT-2, O157-PT-2, O157HP-1, and O157-HP-2 (10, 53). Each reaction was prepared as follows using the LightCycler®
DNA Master HybProbe kit, for a total of 19 µL: 2 mM MgCl2, 2 µL of 10X LightCycler DNA
Master HybProbe, 0.5 mmol/L of each primer and 0.2 mmol/L of each probe. Each reaction
capillary contained 18 µL of the shiga toxin reaction mixture and 2 µL of nucleic acid template.
Amplification and detection was performed on the LightCycler® 2.0 Instrument. Cycling
conditions consisted of 30 seconds at 95°C followed by 40 cycles of 0 seconds at 95°C, 10
seconds at 65°C and 20 seconds at 72°C. Melting conditions consisted of 0 seconds at 95°C, 10
seconds at 55°C and continuous detection from 55°C to 95°C. The reactions were cooled at
40°C for 2 minutes.
Real-time PCR for the detection of LT and ST. Amplification of LT and ST gene targets of
ETEC was performed utilizing previously described primers and probes (96). To amplify the LT
target, each singleplex reaction was prepared as follows using the LightCycler® DNA Master
HybProbe kit, for a total of 19 µL: 2 mM MgCl2, 2 µL of 10X LightCycler DNA Master
HybProbe, 0.5 mmol/L of each primer and 0.2 mmol/L of each probe. Each reaction capillary
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contained 18 µL of the LT reaction mix and 2 µL of nucleic acid template. To amplify ST
targets, each multiplex reaction was prepared as follows using the LightCycler® DNA Master
HybProbe kit, for a total of 19 µL: 2 mM MgCl2, 2 µL of 10X LightCycler DNA Master
HybProbe, 0.5 mmol/L of each primer and 0.2 mmol/L of each probe. Each reaction capillary
contained 18 µL of the LT reaction mix and 2 µL of nucleic acid template. Amplification and
detection was performed on the LightCycler® 2.0 Instrument. Cycling conditions consisted of
30 seconds at 95°C followed by 50 cycles of 0 seconds at 95°C, 20 seconds at 50°C, and 30
seconds at 72°C. Melting conditions consisted of one cycle of 0 seconds at 95°C, 10 seconds at
40°C, and continuous detection from 40°C to 95°C. The reactions were cooled at 40°C for 2
minutes.
Precision studies. Precision characteristics of the Bio-Plex 200 were determined by testing
template DNA extracted and amplified from a panel of four specimens that included Cary-Blair
clinical specimens positive for O157:H7 (stx1, stx2, uidA) and S. flexneri (ipaH). A Cary-Blair
stool specimen spiked with ETEC (ATCC 35401) was also included (eltA, estA). The fourth
panel specimen was a Cary-Blair specimen characterized to be negative for pathogenic enteric
bacteria. The specimens chosen for this panel represented fluorescence results both near the
assay cutoff of two times background (stx2, uidA, estA) and higher in the Bio-Plex measuring
range (stx1, eltA, ipaH). Amplicon for determining repeatability (within-run precision) was
obtained by amplifying two 50 µL reactions per specimen and combining the products. Ten
separate wells of amplicon from each specimen were then tested on a single Bio-Plex detection
plate. Results were calculated by subtracting the mean of ten background wells from the BioPlex FI output of individual sample wells. Mean and standard deviation (SD) of the FIbackground results for ten individual wells were calculated for both positive and negative
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multiplex targets. In addition, the coefficient of variation [CV, (SD/mean)x100] was calculated
for positive targets; CV was not calculated for negative targets as the resulting percentages are
statistically impractical. Reproducibility (between-day precision) was determined for select
specimens by amplifying extracted nucleic acid template from each specimen in single reactions
and detecting in single wells on the Bio-Plex system one time per day over five days. In order to
determine variability of the detection step only, amplicon from the first day of the study was
detected in single wells on the Bio-Plex system one time per day for four days. The FIbackground values of each target in the multiplex were calculated for each specimen by
subtracting the FI value of the negative background well at the end of the run from the FI value
of each sample well.
Materials and Methods – Viral Assay.
Specimens. Specimens were anonymized to fulfill the requirements of the University of Virginia
IRB for Health Sciences Research exemption (IRB-HSR #14597). Comparison of extraction
methods was performed using unpreserved and Cary-Blair stool specimens. Unpreserved
norovirus specimens were stored at 4°C and unpreserved rotavirus specimens were stored at 80°C prior to testing. Cary-Blair specimens were stored at room temperature prior to testing.
Automated extraction of nucleic acids. Nucleic acid was extracted from unpreserved stool
specimens and stool specimens diluted in Cary-Blair transport medium (300 mg) using the
Ambion® MagMAX™-96 Viral RNA Isolation Kit (Ambion, Inc., Austin, TX) automated on
the KingFisher® Magnetic Particle Processor (Thermo Fisher Scientific, Inc., Vantaa, Finland).
Extractions were performed according to manufacturers’ instructions.
Manual extraction of nucleic acids. Nucleic acids were manually extracted from unpreserved
stool specimens and stool specimens diluted in Cary-Blair transport medium (200 mg) using the
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QIAamp DNA Stool Mini Kit (QIAGEN, Hilden, Germany) per manufacturer’s instructions.
Real-time RT-PCR for the detection of norovirus GI and GII. Amplification of norovirus GI
and GII targets was performed using two singleplex reactions containing previously described
primers and probes (60). Each NoV GI reaction was prepared as follows using the LightCycler®
RNA Amplification Kit HybProbe kit (Roche Applied Science, Indianapolis, IN), for a total of
19.8 µL: 3.0 mM MgCl2, 4.0 µL of LightCycler® RT-PCR Reaction Mix HybProbe, 0.4 µL of
LightCycler® RT-PCR Enzyme Mix, 0.4 mmol/L of each NoV GI primer and 0.2 mmol/L of
each NoV GI probe. NoV GII reactions were prepared as follows, for a total of 19.0 µL per
reaction: 2.0 mM MgCl2, 4.0 µL of LightCycler® RT-PCR Reaction Mix HybProbe, 0.4 µL of
LightCycler® RT-PCR Enzyme Mix, 0.4 mmol/L of each NoV GII primer and 0.4 mmol/L of
NoV GII probe. Reaction capillaries for both GI and GII contained 19 µL of the respective
reaction mixture and 1 µL of nucleic acid template. Amplification and detection was performed
on the LightCycler® 2.0 Instrument (Roche Diagnostics Corporation, Indianapolis, IN). Cycling
conditions began with a 30-minute reverse transcription step at 55°C followed by initial
denaturation for 30 seconds at 95°C and 45 cycles of 0 seconds at 95°C, 60 seconds at 58°C and
13 seconds at 72°C. The reactions were cooled at 40°C for 30 seconds.
Real-time RT-PCR for the detection of rotavirus. Amplification of the rotavirus genome target
was performed in singleplex utilizing previously described primers and probe (59). Each
reaction was prepared as follows using the QuantiTect Probe RT-PCR Kit (QIAGEN, Hilden
Germany) for a total of 24 µL: 12.5 µL of 2x QuantiTect Probe RT-PCR Master Mix, 0.25 µL of
QuantiTect RT Mix, 0.25 mmol/L of each primer and 0.1 mmol/L of the probe. Sample wells
contained 24 µL of reaction mix and 1 µL of RNA template. Prior to addition to the sample
well, RNA template was pre-heated to 95°C for 5 minutes, followed by 5 minutes of cooling on
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wet ice. Amplification and detection was performed on the ABI 7500 FAST Real-Time PCR
System (Applied Biosystems, Foster City, CA). Cycling conditions began with a 30-minute
reverse transcription step at 50°C followed by initial denaturation for 15 minutes at 95°C and 45
cycles of 10 seconds at 94°C, 30 seconds at 55°C and 20 seconds at 72°C.
Statistical Methods. Shapiro-Wilk test for normal distribution and Spearman’s rho test for
correlation were both performed using PASW 18.0 (SPSS Inc., Chicago, IL). Fisher r-to-z
transformation to determine correlation coefficient confidence intervals was performed using a
VassarStats web-based calculator (72).
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CHAPTER 4 EVALUATION OF A PCR-BASED PROTOZOAN BIO-PLEX ASSAY

Overview of Enteric Protozoa and Assay MolecularTargets. Primers and probes targeting
select protozoan pathogens were developed for utilization with the Bio-Plex system by
collaborators at the University of Virginia. Targeting four enteric protozoa of public health
concern in the U.S., the primers and microsphere-coupled probes were combined into one
multiplex assay for this project, enabling detection of Giardia intestinalis, Cryptosporidium
parvum, Cyclospora cayetanensis and Entamoeba histolytica.
Giardia intestinalis. G. intestinalis (previously called G. lamblia or G. duodenales) is a
flagellate organism and is the most prevalent protozoan in the U.S. (91). Its pathogenesis is
attributed to the damage it inflicts on the intestinal mucosa and the resulting immune response
(55). Clinical presentation may be asymptomatic, acute and self-limiting after 7-10 days, or
chronic (>14 days) (55). Chronic diarrhea due to Giardia presents with the distinguishing
symptoms of greasy and foul smelling stools that may alternate with constipation or normal
stools. Chronic disease presentation may also result in malabsorption and/or lactase deficiency
(55).
The genetic target of the primers and probe in this assay is a 62 base-pair region of the
small subunit ribosomal RNA gene (SSU rRNA) (113). This region is attractive as a molecular
target for two reasons. First, rRNA sequences are typically conserved, accompanied by regions
of variability that provide pathogen specificity for molecular assays (102). Second, the rRNA
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genes are organized as a cistron that has been reported to be present in repeats numbering from
60 – 132 copies per organism, increasing the potential for detection and overall assay sensitivity
(46, 102). The primers and probe were originally designed to be used in a singleplex real-time
PCR assay and subsequently were adapted for use in the current BioPlex assay (107, 113).
Cryptosporidium spp. Cryptosporidium spp. are intracellular parasites of the phylum
Apicomplexa, the sporozoites of which infect intestinal epithelial cells (23). General symptoms
of Cryptosporidium infection include non-bloody, watery diarrhea which may be accompanied
by cramping, nausea and vomiting, which is a result of abnormal absorption and altered secretion
by intestinal epithelial cells (23, 91). As is the case for Giardia, clinical presentation of
Cryptosporidium in immunocompetent patients may be asymptomatic, acute, or persistent. In
general, symptoms last approximately two weeks (23).
The primers and probe for this assay were previously described for a real-time PCR
platform and were designed to amplify and detect a 138 base-pair region that falls within a 450
base-pair sequence described by Laxer et al. (44, 67). No specific gene has been attributed to
this region, and the cited Genbank accession identifies the sequence as ―Cryptosporidium
parvum genomic sequence‖. This region appears to have been chosen for organism specificity
and not due to an associated virulence determinant target (44),(67).
Cyclospora cayetanensis. C. cayetanensis is a relatively recently-identified intracellular
pathogen, also of the phylum Apicomplexa and is currently known to infect only humans (86, 87,
91). The pathogen infects the intestinal epithelium of the small intestine, causing inflammation
and villous atrophy. Typical symptoms of infection include diarrhea, nausea, flatulence, lowgrade fever, fatigue and weight loss, and may last from a few days to over a month (18, 86).
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The genetic target of this primer and probe set is the SSU rRNA gene region. As is
typical of rRNA, this region is present in multiple copies, with the total number of copies
dependent on the sporulation state of the extracted organisms. Assuming the Cyclospora
population in stool represents all life cycle stages (sexual and asexual), it is estimated that the
copy number is 2-20 per organism (112). The expected amplicon size is 280 base pairs. The
primers were previously described for a conventional multiplex PCR assay for the differentiation
of Cyclospora spp. and Eimeria spp. (85). The probe was designed by Dr. Mami Taniuchi of the
University of Virginia (M. Taniuchi, unpublished data).
Entamoeba histolytica. E. histolytica is characterized by an amoeboid trophozoite stage and an
infectious cyst stage (104). Infection may present as asymptomatic or amoebic colitis, and in
some cases progress to amoebic liver abscess. Infection in the human host takes place at the
colonic epithelium, and is characterized by mucosal thickening and ulceration due to cytolytic
activity. The organism can also invade the mucosa, eventually traveling to the liver, causing
amoebic liver abscesses (104). Typical colitis cases present with bloody diarrhea and abdominal
pain for several weeks, although symptoms may vary in severity between patients (104).
The primers and probe used to detect this pathogen target a 134 base-pair region of the
SSU rRNA gene. These were originally designed for use in a singleplex real-time molecular
beacon PCR assay for the detection of E. histolytica, and were adapted directly to the Bio-Plex
system (98, 107). The rRNA genes have been shown to reside on an extrachromosomal circular
episome, with an estimated 200 gene copies per organism (6).
Results.
Validation of LV-PVA and unpreserved specimens - precision studies. Repeatability (withinrun precision) was determined for a panel of select specimens by testing amplicons from a single
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specimen in ten separate wells of a Bio-Plex detection plate, as described in Materials and
Methods. To assess repeatability, precision for positive-target specimens was expressed as the
CV, which ranged from 5.89% to 30.36% for the five specimens tested in the study (Table 4).
Each specimen in the panel also yielded negative results for three additional assay targets.
Within-run precision for negative targets was expressed as SD, and ranged from 3.35 – 15.53
(Table 5).
Reproducibility (between-day) precision of the amplification and detection steps
combined was determined by amplifying and detecting extracted nucleic acid from select
specimens each day for five days, as described in Materials and Methods. Precision was
calculated in the same manner as repeatability, with positive-target specimens yielding a CV
range of 12.50% to 59.54% (Table 6), and SD values for negative assay targets ranging from
1.72 to 11.51 (Table 7). Precision for the detection step alone was determined by amplifying
extracted nucleic acid from each specimen once and detecting each day for four days, as
described in Materials and Methods. Evaluation of precision for the detection step alone resulted
in a CV value range of 6.20% to 28.71% (Table 8) for positive-target specimens, while negative
targets exhibited an SD value range of 3.09-8.96 (Table 9).
Validation of LV-PVA and unpreserved specimens - analytical sensitivity (limits of detection).
The analytical sensitivity or limits of detection of the described multiplex assay was evaluated
using cultivated G. intestinalis cysts and C. parvum oocysts. Because quantifiable C.
cayetanensis and E. histolytica organisms were not available, cloned nucleic acid standards were
evaluated as a measure of analytical sensitivity for these targets. Table 10 summarizes the limit
of detection ranges established for each assay target in both unpreserved and LV-PVA specimen
types. Analytical sensitivity of the assays ranged from 101 – 102 cysts/200 mg stool for
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Table 4. Bio-Plex 200 detection repeatability results for positive targets in LV-PVA and
unpreserved stool specimens. Specimen type and positive assay target is indicated for each
specimen. Extracted nucleic acid from each specimen was amplified and then detected in ten
replicate wells, as described in Materials and Methods. Mean, SD and CV were calculated using
result values for each well obtained by subtracting the mean fluorescence of ten background
wells from the Bio-Plex FI output of individual sample wells.
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Mean
(FI)
(n = 10 wells)

SD
(FI)

CVa
(%)

LV-PVA
G. intestinalis

46.30

14.06

30.36

Unpreserved
C. cayetanensis

81.15

9.85

12.14

Unpreserved
G. intestinalis

181.65

12.09

6.66

Unpreserved
C. hominis

2619.90

154.39

5.89

LV-PVA
E. histolytica

147.55

13.79

9.34

Specimen/
Target Organism

a

CV: coefficient of variation; (SD / mean) x 100
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Table 5. Bio-Plex 200 detection repeatability results for negative targets in LV-PVA and
unpreserved stool specimens. Specimen type and positive assay target is indicated for each
specimen used in the study. Mean and SD were calculated using result values for each well
obtained by subtracting the average of ten background wells from the Bio-Plex FI value. Ranges
provided for mean and SD reflect the range of statistics calculated for all specimens of the
indicated type (LV-PVA or unpreserved) that were negative for the target listed to the left of the
table. The total number of specimens in the panel that were negative for the select target is
indicated.
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Specimen/Target Organism

Total specimens
negative for target

Mean (FI)
(n = 10
wells/specimen)

SD
(FI)

LV-PVA
G. intestinalis
C. cayetanensis
C. parvum/hominis
E. histolytica

1
2
2
1

-3.25
-2.75 - -2.70
-5.70 – 6.10
-5.90

5.61
4.05 - 4.84
3.71 – 4.58
3.35

Unpreserved
G. intestinalis
C. cayetanensis
C. parvum/hominis
E. histolytica

2
2
2
2

-2.10 – 4.80
-2.05 – 16.30
-1.70 – 9.95
-3.95 – 15.30

4.18 – 6.42
5.38 – 15.53
3.61 – 7.70
5.94 – 14.77
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Table 6. Amplification and Bio-Plex 200 detection reproducibility results for positive
targets in LV-PVA and unpreserved stool specimens. Specimen type and positive assay
target is indicated for each specimen used in the study. Extracted nucleic acid from each
specimen was amplified and detected each day for five days, as described in Materials and
Methods. Mean, SD and CV were calculated by using results representing the specimen FI
minus the background well FI for each positive target.
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Mean (FI)
(n = 5)

SD
(FI)

CVa
(%)

LV-PVA
G. intestinalis

87.50

32.76

37.44

Unpreserved
C. cayetanensis

99.00

58.94

59.54

Unpreserved
G. intestinalis

245.60

30.71

12.50

Unpreserved
C. hominis

2050.90

258.13

12.59

LV-PVA
E. histolytica

255.80

50.00

19.55

Specimen/
Target Organism

a

CV: coefficient of variation; (SD / mean) x 100
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Table 7. Amplification and Bio-Plex 200 detection reproducibility results for negative
targets in LV-PVA and unpreserved stool specimens. Specimen type and positive assay
target is indicated for each specimen used in the study. Nucleic acid extracted from each
specimen was amplified and detected each day for five days, as described in Materials and
Methods. Mean and SD were calculated using result values for each well obtained by
subtracting the mean of one background well from the Bio-Plex FI output of individual sample
wells. Ranges for mean and SD reflect the range of statistics calculated for all specimens of the
indicated specimen type (LV-PVA or unpreserved) that were negative for the target listed to the
left of the table. The total number of specimens in the panel that were negative for the select
target is indicated.

75

Specimen/Target Organism

Total specimens
negative for target

Mean (FI)
(n = 5/specimen)

SD
(FI)

LV-PVA
G. intestinalis
C. cayetanensis
C. parvum/hominis
E. histolytica

1
2
2
1

13.90
6.10 – 7.10
-1.30 – 1.40
-1.70

8.00
6.11 – 7.50
9.51 – 11.51
6.82

Unpreserved
G. intestinalis
C. cayetanensis
C. parvum/hominis
E. histolytica

2
2
2
2

-4.90 – 0.80
0.20 – 6.80
-4.10 – -1.40
-6.20 – 4.00

1.72 – 7.21
5.89 – 10.04
8.15 – 10.57
2.58 – 6.28
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Table 8. Bio-Plex 200 detection reproducibility results for positive targets in LV-PVA and
unpreserved stool specimens. Specimen type and positive assay target is indicated for each
specimen used in the study. Extracted nucleic acid from each specimen was amplified once and
detected each day for four days, as described in Materials and Methods. Mean, SD and CV were
calculated using result values for each replicate well obtained by subtracting the fluorescence of
one background well from the Bio-Plex FI output of individual sample wells.

77

Mean (FI)
(n = 4)

SD
(FI)

CVa
(%)

LV-PVA
G. intestinalis

64.00

18.38

28.71

Unpreserved
C. cayetanensis

62.00

6.75

10.88

Unpreserved
G. intestinalis

257.25

19.26

7.49

Unpreserved
C. hominis

2358.88

148.98

6.32

LV-PVA
E. histolytica

211.50

13.12

6.20

Specimen/
Target Organism

a

CV: coefficient of variation; (SD / mean) x 100
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Table 9. Bio-Plex 200 detection reproducibility results for negative targets in LV-PVA and
unpreserved stool specimens. Specimen type and assay target is indicated. Nucleic acid
extracted from each specimen was amplified once and detected each day for four days, as
described in Materials and Methods. Mean and SD were calculated using result representing the
specimen FI for minus the background well FI for each positive target. Ranges values for each
well obtained by subtracting the fluorescent of one background well from the Bio-Plex FI output
of individual sample well. Mean and SD ranges reflect the range of statistics calculated for all
specimens of the indicated type (LV-PVA or unpreserved) that were negative for the target listed
to the left of the table. The total number of specimens in the panel that were negative for the
select target is stated.
.
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Specimen/Target Organism

Total specimens
negative for target

Mean (FI)
(n = 4/specimen)

SD
(FI)

LV-PVA
G. intestinalis
C. cayetanensis
C. parvum/hominis
E. histolytica

1
2
2
1

15.38
5.75 – 7.50
-1.88 – 3.25
3.38

6.74
6.33 - 7.99
5.66 – 6.99
3.09

Unpreserved
G. intestinalis
C. cayetanensis
C. parvum/hominis
E. histolytica

2
2
2
2

1.13 – 4.50
-0.75 – -1.75
-3.13 – 3.63
-3.38 – 1.13

8.04 – 8.96
7.64 – 7.66
4.53 – 4.77
4.84 – 5.99
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G. intestinalis in unpreserved stools to the maximum estimated range of 3.5x102-3.5x104
oocysts/200 mg stool for C. cayetanensis clone in LV-PVA stools.
Validation of LV-PVA and unpreserved specimens - analytical specificity (cross-reactivity).
Many of the LV-PVA specimens tested in this study contained organisms not targeted by the
Bio-Plex protozoan assay, including Blastocystis hominis, Entamoeba coli, Entamoeba
hartmanni, Dientamoeba fragilis, Chilomastix mesnili and/or Endolimax nana. No crossreactivity was observed between these organisms and any of primer and probe sets in the
multiplex assay (data not shown). In addition, the specimens positive for G. intestinalis,
Cryptopsoridium spp., C. cayetanensis, and E. histolytica tested in the study exhibited no crossreactivity to non-complementary primers and probes in the multiplex assay.
Validation of LV-PVA and unpreserved specimens - comparison-of-methods.

Seventy (70)

specimens were tested using the multiplex microsphere assay and results compared to those
obtained with the reference methods of either microscopy or PCR. Positive specimens, as
characterized by reference methods, included: G. intestinalis (n=13), E. histolytica/dispar (n=4),
G. intestinalis and E. histolytica/dispar (n=3), C. cayetanensis (n=6), C. parvum (n=2), and C.
hominis (n=1). The calculated sensitivity and specificity for each target and corresponding
confidence intervals are shown in Table 11. The sensitivity for G. intestinalis, C. cayetanensis,
C. parvum/hominis, and E. histolytica was 81.25%, 83.33%, 100.00% and 42.86%, respectively.
Specificity of all targets was at or near 100%.
Discussion. In this study, a multiplex PCR-based Bio-Plex assay targeting intestinal protozoan
pathogens was evaluated for precision (repeatability and reproducibility), analytical sensitivity
(limits of detection), analytical specificity (cross-reactivity), and performance as compared to
reference methods. Results were evaluated for acceptability as a screening method to provide
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Table 10. Analytical sensitivity (limits of detection) of the Bio-Plex 200 intestinal protozoan
assay. Quantified cysts, oocysts, or cloned amplicon were diluted and spiked into 200 mg
stool, as described. Spiked stools were extracted, template amplified, and detected as described.
Dilutions were performed in triplicate. Positivity was determined as described for detection of
targets in Materials and Methods. The limit of detection range represents the concentration of
organism or cloned amplicon in the lowest dilutions yielding a minimum of 1 positive result.
Analytical sensitivity was determined for each assay target using both unpreserved and LV-PVA
specimens.
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Limit of Detection
Organism

Unpreserved

LV-PVA

G. intestinalis

101 – 102
(cysts/200 mg stool)

102 – 104
(cysts/200 mg stool)

C. parvum

102 - 104
(cysts/200 mg stool)

103 - 104
(cysts/200 mg stool)

C. cayetanensis
7x102-7x103
(genome copies/200 mg stool)

7x103-7x104
(genome copies/200 mg stool)

3.5x101-3.5x103
(oocysts/200 mg stool, estimated)

3.5x102-3.5x104
(oocysts/200 mg stool, estimated.)

E. histolytica
4x103
(genome copies/200 mg stool)

4x102-4x103
(genome copies/200 mg stool)

2x102
(organisms/200 mg stool,
estimated)

2x101-2x102
(organisms/200 mg stool,
estimated)
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Table 11. Comparison of multiplex microsphere assay results to reference method results,
by assay target. Qualitative results of multiplex PCR testing using the Bio-Plex platform to
detect protozoan pathogens in LV-PVA and unpreserved stool specimens were compared to
those obtained with the reference methods of microscopy and/or PCR. Sensitivity was calculated
using the formula: [TP/(TP+FN)]x100. Specificity was calculated using the formula:
TP/(TP+FN)]x100. Confidence intervals were calculated using Wilson’s score confidence
interval method (28).
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TP
(n)

FN
(n)

G. intestinalis

13

3

C. cayetanensis

5

C. parvum/hominis

E. histolytica

Se
(%)

CISe, 95

TN
(n)

FP
(n)

Sp
(%)

CISp, 95

81.25

L: 56.99
U: 93.41

54

0

100.00

L: 93.36
U: 100.00

1

83.33

L: 43.5
U: 97.00

64

0

100.00

L: 94.34
U: 100.00

3

0

100.00

L: 43.85
U: 100.00

67

0

100.00

L: 94.58
U: 100.00

3

4

42.86

L: 15.82
U: 74.96

62

1

98.00

L: 91.54
U: 99.72

Abbreviations:
TP, True positive; Bio-Plex 200 positive for an organism identified as positive by reference
method;
TN, True negative; Bio-Plex 200 negative for an organism identified as negative by reference
method;
FP, False positive; Bio-Plex 200 positive for an organism identified as negative by reference
method;
FN, False negative; Bio-Plex 200 negative for an organism identified as positive by reference
method;
Se, sensitivity; Sp, specificity; CI. confidence interval; L, lower limit; U, upper limit
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preliminary outbreak etiologic agent information to epidemiologists and to focus confirmatory
testing decisions in the laboratory.
Precision of the protozoan assay was evaluated by testing a panel of specimens
representing stool specimens typically received by public health laboratories in the course of an
outbreak investigation. As previously discussed in Chapter 2, the literature contains limited data
with respect to the precision of Bio-Plex 200 nucleic acid assays and there are no standards
established to specifically determine the acceptability of precision data for molecular assays (8).
Therefore, the repeatability and reproducibility data generated by this study were compared to
data available in the commercial and scientific literature. In order to assess the precision of
organism-positive targets, the CV values calculated in both the repeatability and reproducibility
studies were compared to CV values published for the only FDA-cleared infectious disease
microsphere multiplex assay on the market, the xTAG® RVP (Respiratory Virus Panel).
Coefficient of variation values for the RVP assay were established in a reproducibility study to
range from 2.40% to 87.20% (75). This wide range in precision represented testing conducted at
multiple laboratories for a variety of targets using single-infection specimens containing a range
of virus concentrations (75). As shown in Table 4, the CV value range of 5.89% to 30.36%
achieved with the protozoan assay in the repeatability study for all positive-target specimens
were comparable to the precision ranges reported for the RVP assay. Similarly, as shown in
Tables 6 and 8, the reproducibility study CV values ranging from 12.50% to 59.54% for the
amplification and detection steps combined, and 6.20% to 28.71% for the detection step alone,
were comparable to those published for the RVP assay. Of note is the marked reduction in the
detection step CV values (Table 8) as compared to the CV values for the combined amplification
and detection steps (Table 6), suggesting that the amplification step is an important source of
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variability in this assay. Although the RVP assay and intestinal protozoan assay precision
studies differed in several respects, this comparison suggests that multiplex microsphere-based
nucleic acid assays may exhibit a wide range of variability, particularly at the low end of the FI
measuring range for positive specimens, and facilitates the conclusion that the Bio-Plex
protozoan assay exhibits comparable repeatability and reproducibility for pathogen-positive LVPVA and unpreserved specimens.
As discussed in Chapter 2, variation of fluorescent intensity values less than 50 are
difficult to assess (J. Eveleigh, personal communication). Therefore, standard deviation (SD)
was used to assess the variation for target-negative specimens. The SD was compared to similar
calculated values described in the literature for a microsphere-based Plasmodium spp assay (77).
For both Plasmodium-negative specimens and negative targets of the malaria assay, SD values
ranged from 18.1 to 39.0 based on mean FI values of 81.3 to 121.2 (77). These values were
calculated using FI values detected on the Bio-Plex with a high RP1 target setting, which
typically results in higher FI values as compared to using the low RP1 target setting. Because
the protozoan PCR assay is detected on the Bio-Plex using a low RP1 target setting, the mean FI
and SD values for negative specimens in the study described here are lower than those described
for the Plasmodium assay. However, a relative comparison of the two assays remains
informative. As shown in Table 5, the SD range of 3.35-15.53 FI obtained for negative targets in
the repeatability study similarly represent the range of variability described for the multiplex
microsphere-based assay described by McNamara et al. (77). In addition, the SD value ranges of
2.58 – 11.51 FI and 3.09 – 8.96 FI achieved in the reproducibility study of negative targets for
both the amplification/detection and detection-only steps, respectively, are comparable to
published data (Tables 7 and 9). This comparison therefore allows us to conclude that the Bio-
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Plex protozoan assay exhibits comparable precision for pathogen-negative LV-PVA and
unpreserved specimens.
Analytical sensitivity data for microscopic techniques used for the detection and
identification of intestinal protozoa is not readily available in the published literature; therefore,
comparisons to limits of detection established in this study were not possible. However, it is
acknowledged that molecular amplification techniques for the detection of protozoa are typically
more sensitive than microscopy (43, 70, 99, 105). Comparing limits of detection for each primer
and probe set with published data is informative in understanding how well established primers
and probes can be adapted to the Bio-Plex platform. Therefore, the analytical sensitivity (limits
of detection) of the Bio-Plex assay primers and probes when used to detect pathogens in
unpreserved stools were compared to the published data available for the original testing
platforms from which most of the Bio-Plex primers and probes were adapted.
Analytical sensitivity of the Giardia primers and probe are previously described for a
multiplex real-time PCR format and were estimated to be 10 trophozoites/200 mg stool (50). In
addition, Taniuchi et al. (107) recently published a limit of detection of 103 Giardia cysts/200
mg stool for the Bio-Plex platform. Interestingly, Taniuchi et al. observed a greater limit of
detection of 103 cysts/200 mg stool when the primers and probe were evaluated using real-time
PCR, as described by Haque et al. (107). Therefore, the analytical sensitivity of the Giardia
primers and probe achieved in this study for unpreserved stool specimens was comparable to that
described for the real-time multiplex assay and more sensitive than described for the BioPlex by
Taniuchi et al. (Table 10) (50, 107). Differences in Bio-Plex platform analytical sensitivity in
this study as compared to Taniuichi et al. may be due to the use of different extraction and/or
amplification methods. In contrast, the C. parvum target was not as sensitive as that described
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by Fontain et al. (44), yielding detection limits 10-fold to 1000-fold higher than the 5
oocysts/PCR reaction described for a singleplex real-time PCR assay (Table 10). Sensitivity of
the Bio-Plex assay could be reduced due to the fact that the assay is a multiplex detection assay
or due to differences in method biochemistries. The C. cayetanensis target limit of detection of
3.5x101-3.5x103 oocysts/200 mg stool from this study was comparable only at the lower limit to
the sensitivity of 10 oocysts described by Orlandi et al. when the primers were used for multiplex
conventional PCR testing (85).
Finally, the E. histolytica target exhibited an estimated limit of detection 10 to 100-fold
higher than the limit of 1 trophozoite/200 mg stool previously described for a multiplex real-time
PCR assay (50). These primers and probe were also tested on the Bio-Plex platform and in a
real-time PCR assay developed by project collaborators, and determined to have a limit of
detection of 10 trophozoites/200 mg stool in both cases (107). The comparison of assays in this
case is not a direct one, as cloned DNA was used to establish the limits of detection of the
primers and probe utilized in this study and trophozoites were used in the other two studies (50,
107). Differences in Bio-Plex platform sensitivity may be due to the use of different extraction
and/or amplification methods as well as the approach used to establish limit of detection. The
limits of detection established using cloned DNA is an estimate, as mathematical formulas are
used to calculate both the genome copy values and the organism equivalents. It is also important
to note that the limit of detection range for the E. histolytica target is a better estimate of
trophozoite concentration in stool than that of cyst concentration. This is due to the fact that the
conversion factor used to estimate the number of genome copies (Materials and Methods)
present in the cloned standards was originally established for trophozoites, and it has been
postulated that copy numbers in cysts may be lower (82).
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Comparative data describing limits of detection for the protozoan assay targets in LVPVA specimens is not readily available. When compared to the limits of detection obtained in
this study for unpreserved specimens, the limits of detection for the G. intestinalis, C.
parvum/hominis, and C. cayetanensis targets in PVA specimens were approximately 1-2 logs
higher. These increased limits of detection are possibly due to the addition of washing steps
prior to extraction of Giardia and Cryptosporidium or due to variation in pipetting clone
dilutions of Cyclospora. Interestingly, the analytical sensitivity range of the E. histolytica target
in LV-PVA was lower than that achieved for unpreserved specimens. Again, a plausible source
of this discrepancy is pipetting variation when spiking the cloned plasmid. The difference in
matrix consistency of the unpreserved and LV-PVA specimens may be considered an alternate
source of variation, but is unlikely as the same clone plasmid was used for Cyclospora and a
similar difference in limit of detection ranges was not observed.
Another practical analysis compares the limits of detection to excreted concentrations of
organism available in the literature in order to determine if the assay is sensitive enough to detect
organism in clinical specimens. While excretion patterns of protozoa are highly variable, the
data are useful in estimating actual performance of the assay on clinical specimens collected as
part of an outbreak investigation. For example, a study of asymptomatic pediatric patients
infected with Giardia reported a variety of cyst excretion patterns, with titers ranging from 102000 cysts per milligram of unpreserved stool (34). Converting these titers to 2x103 to 4x105
cysts/200 mg stool enables comparison with the Bio-Plex G. intestinalis limits of detection for
both unpreserved and LV-PVA specimens. Comparing the approximate G. intestinalis target
sensitivity range of 101 to 104 cysts/200 mg stool established in this study for both specimen
types suggests that the assay is sensitive enough to detect pathogen in clinical specimens if the
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patient is excreting at the time of collection (Table 10). A study in which three methods were
used to recover oocysts from unpreserved patient specimens was evaluated and provides a
similar means of comparison for the Cyclospora target (66). Recovery from suspensions
representing 5 mg of stool ranged from one to 7720 oocysts, which can be converted to the
average estimate of 4.0x101 to 3.1x105 oocysts/200 mg stool. Comparison of the Bio-Plex
Cyclsopora limits of detection (Table 10) suggests that this multiplex assay is also capable of
detecting physiological concentrations of organism in both unpreserved and LV-PVA stools.
Similar comparisons cannot be conducted for the Bio-Plex protozoan assay C. parvum and E.
histolytica targets, as no excretion data is available for either organism.
Specificity of the intestinal protozoa assay primers and probe was evaluated by challenge
with non-targeted intestinal parasites in LV-PVA . The assay was challenged with the following
organisms: Blastocystis hominis, Entamoeba coli, Entamoeba hartmanni, Endolimax nana,
Dientamoeba fragilis, and Chilomastix mesnili. No cross-reactivity was observed with these
organisms, as exhibited by the lack of positive results for any assay targets. In addition, the
primers and probes were evaluated for cross-reactivity with other assay targets and similarly no
non-specific amplification was observed. Previously-published studies have also demonstrated
that the primer and probe sequences do not cross-react with a variety of non-target sequences in
other pathogens (44, 113). However, unexpected cross-reactivity of the E. histolytica primers
and probe to E. dispar was identified in one LV-PVA specimen (data not shown). Additional
testing using an alternate conventional PCR assay that discriminates between E. histolytica and
E. dispar confirmed cross-reactivity to E. dispar. Sequencing of the amplification product
identified five mismatched base pairs when compared to the E. histolytica probe sequence. The
sequence analysis utilizing the nucleotide Basic Alignment Search Tool (BLAST; National
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Center for Biotechnology Information, Bethesda, MD) ranked the top three alignments to E.
histolytica 18S rRNA gene (Genbank AB426549) and two E. dispar 18S rRNA genes (Genbank
AB282661 and Z49256), with the amplicon sequence aligning most closely to E. dispar.
Additional testing with DNA extracted from cultures of E. dispar trophozoites followed by PCR
and Bio-Plex detection also yielded positive results, further supporting the cross reactivity
finding (data not shown). It is postulated that despite the observed mismatches between the
probe and specimen amplicon, the relatively low stringency of the hybridization conditions in the
Bio-Plex assay enables binding of the E. histolytica-specific probe to E. dispar amplicon
sequences. These findings support those of Taniuchi et al. (107), indicating that the primers and
probe lack species-specificity on the Bio-Plex platform and therefore may not differentiate
between pathogenic and non-pathogenic Entamoeba in all specimens.
Finally, overall Bio-Plex assay performance was assessed by comparing the results
obtained from testing previously characterized specimens representative of those typically
submitted for outbreak investigations with results obtained by performing microscopy and/or
PCR. The analytical sensitivity for G. intestinalis, C. cayetanensis, C. parvum/hominis and E.
histolytica was 81.25%, 83.33%, 100.00%, and 42.86%, respectively. A screening assay with
high sensitivity is typically desirable as it gives the operator confidence that negative results are
true negatives and further testing is not required. However, in most public health laboratories,
multiple specimens are submitted in outbreak situations, allowing for increased sampling and
increased overall sensitivity. In addition, the proposed overall testing algorithm will require
follow-up of testing results with confirmatory methods, particularly in situations in which all
specimens submitted yield negative results. Together these approaches allow for some tolerance
of lower sensitivity values, as discussed in Chapter 2. Therefore, for the intended use of the Bio-
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Plex protozoan as a screening assay, the sensitivity of the Giardia, Cyclospora, and
Cryptosporidium targets is acceptable, as the values exceeded the minimum acceptable
sensitivity of 80% (Chapter 2). In contrast, the sensitivity of the E. histolytica target is markedly
low as compared to microscopy, and discrepants could not be resolved upon further
troubleshooting with microscopy and an alternate PCR method that discriminates between E.
histolytica and E. dispar.
In order to determine if the presence of inhibitors were the cause of eight false-negative
results for the G. intestinalis, C. cayetanensis, and E. histolytica targets, discrepant specimens
were tested using 1:10 and 1:50 dilution of template nucleic acids. Negative results indicated
inhibitors were not present (data not shown). Assay limitations that may have contributed to
decreased sensitivity include prolonged storage of template DNA used for the study, inability to
re-confirm the original reference method results, the presence of amplification products below
assay limits of detection and the small number of specimens available for testing. It is
acknowledged that the sensitivity of morphologic identification of E. histolytica may be as low
as 60% target, resulting in false-positive results (105). It is possible that misidentification of
morphologic features on microscopy may have occurred for several specimens in this study,
contributing to the decreased sensitivity of the E. histolytica target.
Rather than ruling out disease, as with traditional diagnostic screening assays, this multiplex
assay is intended to be used to screen outbreak specimens to rule in a possible etiologic agent in
order to focus further confirmatory testing. Based on this intended use, a high specificity is the
priority, as this provides confidence in positive results due to a low incidence of false positive
results. The specificity of the four multiplex targets was 98-100%, exceeding the minimum
acceptable specificity of 95% established in Chapter 2. The excellent specificity of the assay
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facilitates preliminary identification of the etiologic agent leading to the development of
effective, data driven public health management practices by epidemiologists.
The evaluations described here have assessed the performance of a microsphere-based
multiplex assay for the simultaneous detection of G. intestinalis, C. cayetanensis, C.
parvum/hominis, and E. histolytica in a public health laboratory setting. This assay exhibits
acceptable precision for all targets, as compared to data available in the commercial and
scientific literature for microsphere-based assays. With the exception of G. intestinalis, all
targets exhibited higher limits of detection in unpreserved specimens as compared to the realtime and conventional PCR assays for which they were originally designed. These data suggest
that the chemistry of Bio-Plex reactions may not facilitate direct adaptation of primers and
probes successfully used in other amplification based methods, and instead additional
optimization may be required. A practical comparison of the limits of detection with Giardia
and Cyclospora concentrations described for clinical specimens suggests, however, that the
protozoan screening assay is capable of detecting the intended targets in typical outbreak
specimens. The data also show that analytical sensitivity is somewhat reduced in LV-PVA
specimens; therefore, it is recommended that unpreserved specimens be the preferred specimen
type for testing. The protozoan assay showed acceptable sensitivity as compared to reference
methods for G. intestinalis, C. cayetanensis, and Cryptosporidium spp. targets based on its
intended use as an outbreak screening method. The three targets also exhibited excellent
specificity. Because the sensitivity of the assay is less than 100% for several targets, it is
recommend that an outbreak investigation algorithm include further testing using alternate
protocols when all specimens submitted for an outbreak are negative for assay pathogen targets.
In addition, confirmatory testing to verify screening results is recommended. Finally, the
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multiplex exhibited no cross-reactivity to a variety of non-target intestinal parasites, with the
exception of E. dispar. The capability of the E. histolytica primers and probe to cross-react with
E. dispar sequences requires that the primers and probe be re-designed and optimized to achieve
improved species specificity. In summary, the data demonstrate that the Bio-Plex multiplex
protozoan assay has potential as a screening assay in outbreak investigations, with one target
modification, in order to provide preliminary pathogen information to epidemiologists and to
better focus confirmatory laboratory testing. In addition, the assay may serve as the backbone to
which additional pathogen targets may be added, maximizing the flexibility of the Bio-Plex 200
platform.
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CHAPTER 5 EVALUATION OF A PCR-BASED BACTERIAL BIO-PLEX ASSAY

Overview of Enteric Bacterial Pathogens and Assay Molecular Targets. The six-plex
bacterial assay developed for and evaluated in this aim of the project targets multiple
diarrheagenic E. coli strains and Shigella spp. The primers and probes include previously
published sequences and new unpublished sequences, adapted to or designed for the Bio-Plex
platform by collaborators at the University of Virginia and at DCLS. Genetic targets included in
the Bio-Plex bacterial assay enable the detection of shiga toxin-producing E. coli (STEC),
enterotoxigenic E. coli (ETEC), and enteroinvasive E. coli (EIEC), and Shigella spp.
STEC. Shiga toxin producing E. coli comprise a group of E. coli strains that include multiple
serotypes, including the most well-characterized foodborne pathogen, E. coli O157:H7. Initial
symptoms of infection by STEC include watery diarrhea and abdominal pain for 1-2 days,
followed by an increase in symptom severity that may include bloody diarrhea for several days
(57).

Fever is not a prominent symptom. Perhaps of most concern with these strains is the

potential for the infection to move beyond hemorrhagic colitis to hemolytic uremic syndrome or
thromocytopenic purpura, both of which are life-threatening (57).
STEC strains are characterized by their ability to produce one or both of two shiga-like
toxins, the genes of which are designated stx1 and stx2. These toxins were first described in
Shigella dysenteriae and are composed of one active (A) subunit that interrupts ribosomal RNA
to ultimately halt protein synthesis in the infected cell and five binding (B) subunits (61). There
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is approximately 55% identity between the stx1 and stx2 genes, with the stx1 sequences’ being
well-conserved, while the stx2 sequence exhibits multiple variants. Both stx1 and stx2 are
encoded on lambdoid lysogenic bacteriophages, while the stx2e variant is chromosomallyencoded (79, 109). Bacteria may have single or multiple phage copies (109).
The primers and probe to detect stx1 were adapted directly from a multiplex real-time
PCR assay described by Hidaka et al. (53). The targeted genome sequence is a 132-base-pair
region of the gene encoding the A subunit of the stx1 toxin. The primers for stx2 detection were
adapted from a multiplex conventional PCR assay and yield a 255 base-pair amplification
product representing the gene encoding the A subunit of the stx2 toxin gene (90). The primers
are designed to detect all stx2 variants. The stx2-specific probe was designed by Dr. Taniuchi at
the University of Virginia (M. Taniuchi, unpublished data).
E. coli O157. Because infections caused by E. coli O157:H7 may result in a more severe clinical
presentation than those caused by other STEC strains and the fact that E. coli O157:H7 strains
are more frequently associated with significant foodborne outbreaks, it is desirable to be able to
specifically detect O157 serotypes that may be associated with an outbreak (57). Specific
detection of O157 strains is possible due to the description of a single base pair mutation in the
β-glucuronidase gene (uidA) that is conserved in O157 strains versus other STEC serotypes (10,
42). The current assay incorporates primers and a probe described by Yoshitomi et al. that were
originally designed for use in a singleplex real-time PCR assay and exhibited optimal Bio-Plex
fluorescent data for positive specimens as compared to other primer and probe designs (data not
shown) (119). The probe sequence is specific for the O157 base pair mutation.
ETEC. This group of organisms is the primary cause of ―traveler’s diarrhea‖ (1). In addition,
ETEC strains have been implicated in a variety of outbreaks on cruise ships and within the U.S.,
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many cases of which were due to consumption of contaminated food or water (4, 33). The
primary symptom of ETEC infection is diarrhea, with varying reports of abdominal cramps,
fever, nausea and vomiting. When vomiting is present, diarrhea has generally been reported to
occur at least 2.5 times the incidence of vomiting. Duration of symptoms is widely variable
among reported patients, with a median duration of >72 hours described for multiple U.S.
outbreaks caused by ETEC strains (4, 33).
ETEC strains cause the symptoms of disease through the production of one or both of
two toxins that lead to excess intestinal secretion (61). One toxin is termed ―heat labile toxin‖
(LT), and its structure and function are closely related to the cholera toxin of Vibrio cholerae
(79). There are two serogroups described for LT: LT-I and LT-II. LT-I is produced by ETEC
strains that are pathogenic for both humans and animals. In contrast, strains expressing LT-II are
found primarily in animals, and have not been associated with human disease (79). The gene for
the LT-I toxin is identified as elt, and resides extrachromosomally on a plasmid (79). The
second toxin that may be produced is a ―heat stable toxin‖ (ST). As is the case for LT, there are
several variants of the ST. The toxin variants are small single-peptide toxins of which the STa
(ST-1) variant is primarily associated with human disease (61). The estA gene that encodes this
toxin is located primarily on a plasmid, although the genes have also been found on transposons
(79).
The primer and probe set employed in the multiplex for the LT gene was described for
use in a multiplex real-time PCR assay, targeting a 62 base-pair region of the A subunit gene
(eltA) (53). The primer and probe set to detect the estA gene (ST) was designed by Dr. Mami
Taniuchi of the UVA and produces a 172 base-pair amplification product (M. Taniuchi,
unpublished data).
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EIEC/Shigella. Enteroinvasive E. coli (EIEC) and Shigella spp. are highly similar in terms of
biochemical identification, genetics and pathogenesis. Separate taxonomies are maintained,
however, due to the clinical symptoms of Shigella (61). Clinical presentation of Shigella
infection is that of dysentery: diarrhea with blood and/or mucus, fever, and abdominal cramps
(61). In contrast, infection with EIEC manifests similarly to other E. coli infections, including
watery diarrhea, abdominal cramps, fever and malaise. Progression to dysentery can occur, but
is not common (57). Pathogenesis of both organisms is characterized by invasion of intestinal
epithelial cells, intracellular replication, invasive movement into adjacent cells, and induction of
apoptosis (61).
The genetic region targeted by the Bio-Plex assay for both of these strains is the ipaH
gene, a multi-copy gene on the large invasion plasmid and chromosomes of both Shigella and
EIEC strains (9, 52, 89). Investigation of primarily S. flexneri strains has shown that ipaH gene
products are secreted via the organism’s invasion plasmid-encoded Type III secretion apparatus
(36). Recently the structure and activity of ipaH gene products in Shigella were elucidated,
identifying this family of proteins as a new class of E3 ubiquitin ligases that may be involved in
dampening host innate immune responses (103, 121). The primers and probe set employed in
this assay was designed by Dr. Mami Taniuchi of UVA, and target a 64-base pair sequence of
the ipaH gene (M. Taniuchi, unpublished data).
Results.
Preliminary assessment of the multiplex bacterial assay using stool broth specimens. A
preliminary evaluation of the bacterial assay 6-plex was performed by testing 50 characterized
stool broth specimens using the multiplex Bio-Plex bacterial assay and the qualitative results
were compared to those obtained using molecular and shiga toxin enzyme immunoassay
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reference methods. The calculated sensitivity and specificity for each target and corresponding
intervals are shown in Table 12. The sensitivities for stx1, stx2, and uidA were 100%, 95% and
100%, respectively. Specificity of all targets was 100%, with the exception of 95% specificity of
the stx1 target.
Validation of Cary-Blair specimens - precision studies. Repeatability (within-run precision)
was performed by amplifying nucleic acid from a select panel of specimens using the bacterial
assay and detecting in ten replicate wells on the Bio-Plex, as described in the Materials and
Methods. The statistics of mean, standard deviation (SD) and coefficient of variation (CV) were
calculated, as described. To assess repeatability, the precision for positive-target specimens was
expressed as the CV, which ranged from 6.50% to 26.83% for the three specimens tested in the
study (Table 13). Each specimen in this panel also yielded negative results for additional assay
targets (e.g., O157:H7-positive specimen had negative results for eltA, estA and ipaH). In
addition, the panel included one Cary-Blair specimen known to be negative for enteric bacteria,
and therefore yielded negative results for all assay targets. Within-run precision for negative
targets was expressed as SD, and ranged from 4.32 – 9.30 (Table 14).
In order to evaluate between-day variation (reproducibility) of the amplification and BioPlex steps together, nucleic acid template from the specimen panel used in the repeatability study
was amplified and detected for five days using the Bio-Plex bacterial assay, as described in
Materials and Methods. The mean, SD and CV were calculated as described. The between-day
CV values of the amplification and detection steps combined for positive assay targets ranged
from 13.54% to 41.26% (Table15), and SD values (FI) for negative assay targets ranged from
3.14 – 12.76 (Table 16). Evaluation of the precision of the detection step alone resulted in
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Table 12. Preliminary assessment of a multiplex Bio-Plex 200 bacterial assay using stool
broth specimens. Qualitative results of multiplex testing using the Bio-Plex platform to detect
enteric bacterial pathogens in 50 characterized stool broth specimens were compared to those
obtained with reference methods. Sensitivity was calculated using the formula:
[TP/(TP+FN)]x100. Specificity was calculated using the formula: TP/(TP+FN)]x100.
Confidence intervals were calculated using Wilson’s score confidence interval method (28).
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Target

TP
(n)

FN
(n)

Se
(%)

CISe, 95

TN
(n)

FP
(n)

stx1

31

0

stx2

20

uidA

Sp
(%)

CISp, 95

100.00

L: 88.98
U: 100.00

18

1

95.00 L: 75.36
U: 99.07

1

95.00

L: 77.33
U: 99.16

29

0

100.00 L: 88.31
U: 100.00

4

0

100.00

L: 51.02
U: 100.01

46

0

100.00 L: 92.29
U: 100.00

eltA (LT)

0

0

N/A

N/A

50

0

100.00 L: 92.87
U: 100.00

estA (ST)

0

0

N/A

N/A

50

0

100.00 L: 92.87
U: 100.00

ipaH

0

0

N/A

N/A

50

0

100.00 L: 92.87
U: 100.00

Abbreviations:
TP, True positive, Bio-Plex 200 positive for an organism identified as positive by reference
method;
TN, True negative, Bio-Plex 200 negative for an organism identified as negative by reference
method;
FP, False positive, Bio-Plex 200 positive for an organism identified as negative by reference
method;
FN, False negative, Bio-Plex 200 negative for an organism identified as positive by reference
method;
Se, sensitivity; Sp, specificity; CI. confidence interval; L, lower limit; U, upper limit
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Table 13. Bio-Plex 200 detection repeatability results for positive targets in Cary-Blair
stool specimens. The known pathogen and bacterial assay positive gene target(s) are indicated
for each specimen used in the study. Extracted nucleic acid from each specimen was amplified
and then detected in ten replicate wells, as described in Materials and Methods. Mean, SD and
CV were calculated using result values for each well obtained by subtracting the mean
fluorescence of ten background wells from the Bio-Plex FI output of individual sample wells.
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Mean
(FI)
(n = 10)

SD
(FI)

CVa
(%)

O157:H7
stx1
stx2
uidA

605.50
67.00
74.75

39.33
9.78
20.06

6.50
14.60
26.83

ETEC (ATCC 35401)
eltA (LT)
estA (ST)

1140.20
333.30

112.76
44.63

9.89
13.39

S. flexneri
ipaH

786.25

81.51

10.37

Pathogen/
Gene Target(s)

a

CV: coefficient of variation; (SD / mean) x 100
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Table 14. Bio-Plex 200 detection repeatability results for negative targets in Cary-Blair
stool specimens. The bacterial assay gene target and total number of specimens negative for the
target are indicated. Extracted nucleic acid from each specimen was amplified and then detected
in ten replicate wells, as described in Materials and Methods. Mean and SD were calculated
using result values for each well obtained by subtracting the mean fluorescence of ten
background wells from the Bio-Plex FI output of individual sample wells. Mean and SD ranges
reflect the range of statistics calculated for all panel specimens negative for the respective assay
target. The total number of specimens in the panel that were negative for the select target is
provided.
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Gene Target

stx1
stx2
uidA
eltA (LT)
estA (ST)
ipaH

Number of specimens

Mean (FI)
(n = 10 wells/specimen)

SD
(FI)

3
3
3
3
3
3

-1.00 – 3.05
0.15 – 2.85
-10.00 – -0.40
-3.50 – 2.45
-3.40 – 0.35
-2.70 – 1.70

5.47 – 5.84
5.14 – 5.27
4.76 – 5.52
5.33 – 6.51
4.32 – 9.30
4.45 – 6.35
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Table 15. Amplification and Bio-Plex 200 detection reproducibility results for positive
targets in Cary-Blair stool specimens. The known pathogen and bacterial assay-positive gene
target(s) are indicated for each specimen used in the study. Extracted nucleic acid from each
specimen was amplified and detected each day for five days, as described in Materials and
Methods. Mean, SD and CV were calculated by using results representing the specimen FI
minus the background well FI for each positive target.
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Mean (FI)
(n = 5)

SD
(FI)

CVa
(%)

E. coli O157:H7
stx1
stx2
uidA

965.80
104.10
87.50

309.26
31.91
34.20

32.02
30.66
39.09

ETEC (ATCC 35401)
eltA (LT)
estA (ST)

993.63
163.00

134.56
67.25

13.54
41.26

Shigella flexneri
ipaH

454.10

142.09

31.29

Pathogen/
Gene Target(s)

a

CV: coefficient of variation; (SD / mean) x 100
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Table 16. Amplification and Bio-Plex 200 detection reproducibility results for negative
targets in Cary-Blair stool specimens. The bacterial assay gene target and total number of
specimens negative for the target are indicated. Nucleic acid extracted from each specimen was
amplified and detected each day for five days, as described in Materials and Methods. Mean and
SD were calculated using result values for each well obtained by subtracting the mean of one
background well from the Bio-Plex FI output of individual sample wells. Mean and SD ranges
reflect the range of statistics calculated for all panel specimens negative for the respective assay
target. The total number of specimens in the panel that were negative for the select target is
indicated.
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Gene Target

stx1
stx2
uidA
eltA (LT)
estA (ST)
ipaH

Number of
specimens

Mean (FI)
(n = 5/specimen)

SD
(FI)

3
3
3
3
3
3

2.90 – 9.00
-6.25 – -3.70
-6.30 – 3.13
-3.60 – -1.00
-3.20 – 1.50
-7.63 – -4.00

9.97 – 12.76
4.70 – 10.29
5.23 – 9.56
3.54 – 6.87
3.14 – 7.01
3.67 – 7.87
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a CV value range of 7.28% to 28.23% (Table 17) for positive-target specimens, while negative
targets exhibited an SD value range of 1.65 – 14.26 (Table 18).
Validation of Cary-Blair specimens – analytical sensitivity (limits of detection). The analytical
sensitivity, or limits of detection (LoD), of each target in the bacterial assay was evaluated using
E. coli O157:H7, ETEC (ATCC 35401) and S. flexneri (ATCC 12022) isolates spiked into CaryBlair stool aliquots characterized to be negative for pathogenic enteric bacteria, as described.
Dilution series were extracted and tested in triplicate and colony counts on blood agar plates
were conducted to determine organism concentrations. Table 19 summarizes the limits of
detection established for each assay target in Cary-Blair stool specimens. Analytical sensitivity
of the assay ranged from approximately 2.7x101 CFU/200 mg stool to 2.4x106 CFU/200 mg
stool. Based on a spiking volume of 10 µL, the LoDs can be converted to a range of 2.7x103 to
2.4x108 CFU/mL (Table 19).
Validation of Cary-Blair specimens – analytical specificity. The organisms present in the CaryBlair specimens tested in this study exhibited no cross-reactivity to non-complementary primers
and probes in the multiplex assay (data not shown). Organisms tested included E. coli O157:H7
(n = 2), E. coli non-O157 (stx1-positive; n = 1), E. coli of unknown serotype (stx1-positive, n =
3), Shigella spp. (n = 4) and Salmonella spp. (n = 5). In addition, the assay was challenged with
bacterial isolates including ETEC (n = 5; serotypes O153:H45, Ound:H16, Ound:NM, O6:H16,
and O148:NM), EPEC (n = 10; serotypes O119:H6, O55:NM, Ound:NM, O115:NM,
Orough:H8, O111:NM, O55:H6, O111:H2, O128:H1, and O86:H34), and EIEC (n = 2; serotypes
O124:NM and O29:NM) strains. No cross-reactivity was observed with non-complementary
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Table 17. Bio-Plex 200 detection reproducibility results for positive targets in Cary-Blair
stool specimens. The known pathogen and bacterial assay positive gene target(s) are indicated
for each specimen used in the study. Extracted nucleic acid from each specimen was amplified
once and detected each day for four days, as described in Materials and Methods. Mean, SD and
CV were calculated using result values for each replicate well obtained by subtracting the
fluorescence of one background well from the Bio-Plex FI output of individual sample wells.
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Mean (FI)
(n = 4)

SD
(FI)

CVa
(%)

E. coli O157:H7
stx1
stx2
uidA

818.25
91.50
53.13

105.02
25.83
4.17

12.83
28.23
7.85

ETEC (ATCC 35401)
eltA (LT)
estA (ST)

1084.38
63.13

78.98
11.51

7.28
18.23

Shigella flexneri
ipaH

635.13

74.33

11.70

Pathogen/
Gene Target(s)

a

CV: coefficient of variation; (SD / mean) x 100
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Table 18. Bio-Plex 200 detection reproducibility results for negative targets in Cary-Blair
stool specimens. The bacterial assay gene target and total number of specimens negative for the
target are indicated. Nucleic acid extracted from each specimen was amplified once and detected
each day for four days, as described in Materials and Methods. Mean and SD were calculated
using result values for each well obtained by subtracting the fluorescence of one background
well from the Bio-Plex FI output of individual sample wells. Mean and SD ranges reflect the
range of statistics calculated for all panel specimens negative for the respective assay target.
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Gene Target

stx1
stx2
uidA
eltA (LT)
estA (ST)
ipaH

Number of
specimens

Mean (FI)
(n =4/specimen)

SD
(FI)

3
3
3
3
3
3

-2.75 – 2.38
-2.13 - 5.75
-5.88 – 2.38
-1.38 – 4.75
-4.63 - -1.88
-2.25 – 8.38

2.87 – 5.85
10.05 - 14.26
4.17 – 10.78
2.78 – 5.19
1.65 – 5.11
2.87 – 11.14
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Table 19. Analytical sensitivity (limits of detection) of the Bio-Plex 200 enteric bacterial
assay. Quantified bacterial isolates were diluted and spiked into 200 mg Cary-Blair stool
aliquots, as described. Spiked stools were extracted, template amplified, and detected as
described. Dilutions were performed in triplicate. Positivity was determined as described for
detection of targets in the Materials and Methods section. The limit of detection range represents
the lowest concentrations yielding a minimum of 1 positive result. Limit of detection ranges are
also converted to CFU/g stool and CFU/mL for analytical comparison..
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LoD, CaryBlair stool
(CFU/
200 mg stool)

LoD, CaryBlair stool

stx1

stx2

uidA

eltA (LT)

estA (ST)

ipaH

1.0x103-2.4x104

3.5x101-3.5x103

1.0x105-2.4x106

1.5x102-2.5x103

1.5x104-2.5x104

2.7x101-2.7x102

5.0x103-1.2x105

1.7x102-1.7x104

5.0x105-1.2x107

7.5x102-1.2x104

7.5x104-1.2x105

1.3x102-1.3x103

1.0x105-2.4x106

3.5x103-3.5x105

1.0x107-2.4x108

1.5x104-2.5x105

1.5x106-2.5x106

2.7x103-2.7x104

(CFU/g stool)

LoD, CaryBlair stool
(CFU/mL)
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assay targets, with the exception of a repeated positive result exhibited by one EPEC strain of
serotype O86:H34 when detected with the uidA target.
Validation of Cary-Blair specimens – comparison-of-methods study. Sixteen (16) previouslycharacterized Cary-Blair stool specimens were tested using the multiplex microsphere assay and
results compared to those obtained with molecular and biochemical reference methods. Positive
specimens included: E. coli O157:H7 (n = 2), E. coli non-O157:H7 (n = 1), E. coli of unknown
serotype (n = 3), Shigella spp. (n =4), and Salmonella spp. (n = 5). One specimen was negative
for pathogenic enteric bacteria. The calculated sensitivity and specificity for each target and
corresponding confidence intervals are shown in Table 20. The sensitivity for the stx1, stx2,
uidA and ipaH targets as compared to reference methods was calculated to be 100.00% for all
four targets. No positive specimen data was available to estimate sensitivity of the eltA and estA
targets. Specificity of all targets as compared to reference methods was calculated to be 100%.
Discussion. A comparison-of-methods study was conducted to assess the potential utility of the
six-plex enteric bacterial Bio-Plex assay on DCLS platforms. This initial study was completed
by testing stool broth specimens typically submitted to state public health laboratories for
confirmation of the presence of shiga toxin-producing organisms and characterized to be positive
for stx1, stx2, and/or uidA targets. Studies initially focused on these specimen types because a
large number of specimens were readily available and the original intent was to validate broth
stool matrices for use in outbreak investigations. Results achieved on the Bio-Plex were
compared to those obtained with biochemical and molecular reference methods used to
characterize the specimens upon submission to DCLS, and sensitivity and specificity were
calculated as described. As shown in Table 12, sensitivity for the stx1, stx2, and uidA targets
was excellent, exceeding the minimum acceptable sensitivity of 80% established for this assay.

118

Table 20. Comparison of Bio-Plex 200 bacterial assay results to reference method results,
by assay target. Qualitative results of multiplex testing using the Bio-Plex platform to detect
bacterial pathogens in Cary-Blair stool specimens were compared to those obtained with
molecular and/or biochemical reference methods. Sensitivity was calculated using the formula:
[TP/(TP+FN)]x100. Specificity was calculated using the formula: [TN/(TN+FP)]x100.
Corresponding 95% confidence intervals were calculated using Wilson’s score confidence
interval method. (28)
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Target

TP
(n)

FN
(n)

Se
(%)

CISe, 95

TN
(n)

FP
(n)

stx1

6

0

stx2

2

uidA

Sp
(%)

CISp, 95

100.00

L: 60.97
U: 100.00

10

0

100.00 L: 72.25
U: 100.00

0

100.00

L: 34.24
U: 100.01

14

0

100.00 L: 78.47
U: 100.00

2

0

100.00

L: 34.24
U: 100.01

14

0

100.00 L: 78.47
U: 100.00

eltA (LT)

0

0

N/A

N/A

16

0

100.00 L: 80.64
U: 100.00

estA (ST)

0

0

N/A

N/A

16

0

100.00 L: 80.64
U: 100.00

ipaH

4

0

100.00

L: 51.02
U: 100.01

12

0

100.00 L: 75.76
U: 100.00

Abbreviations:
TP, True positive; Bio-Plex 200 positive for an organism identified as positive by reference
method;
TN, True negative; Bio-Plex 200 negative for an organism identified as negative by reference
method;
FP, False positive; Bio-Plex 200 positive for an organism identified as negative by reference
method;
FN, False negative; Bio-Plex 200 negative for an organism identified as positive by reference
method;
Se, sensitivity; Sp, specificity; CI. confidence interval; L, lower limit; U, upper limit
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Specificity for all targets was also excellent, meeting or exceeding the minimum acceptable
specificity of 95% established for this assay.
Several limitations exist for this comparison-of-methods study. First, no stool broth
specimens were available containing either ETEC or EIEC/Shigella spp., resulting in no
sensitivity data for the eltA, estA and ipaH targets. Second, only four uidA-positive specimens
were available, thus lowering the statistical confidence of the sensitivity data for this target. A
limitation in assay performance was also identified, particularly for the stx2 target. One
specimen was negative for the stx2 target when tested on the Bio-Plex, though it was previously
determined to be positive by both the LightCycler reference method and the Bio-Plex a year
before (data not shown). This broth specimen was highly pigmented and the boiled preparation
yielded equally pigmented supernatant containing template nucleic acid. Testing on both the
Bio-Plex and LightCycler as described using 1:10 and 1:50 nucleic acid template dilutions
revealed that amplification of the specimen was being inhibited, most likely by the substance
causing the pigmentation (data not shown). Such pigmentation is rare in stool broth specimens;
therefore, it is recommended that a simple procedure for diluting pigmented stool broth
specimens be added to future testing protocols, rather than pursuing a more complicated solution
of incorporating an inhibition control.
Following completion of the comparison-of-methods study, further validation was not
pursued with stool broth specimens. As mentioned previously, this specimen type is submitted
to state reference laboratories in order to enable the isolation and confirmation of shiga toxinproducing E. coli bacteria. Since stool-containing broth specimens are not a primary specimen
type collected for testing in outbreak investigations, the need for validation of this specimen type
with the bacterial assay was not pursued. Instead, validation studies were conducted on the
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primary outbreak specimen type submitted during outbreak investigations, which are stools
diluted in Cary-Blair medium (referred to here as ―Cary-Blair stools‖ or ―Cary-Blair
specimens‖).
Following initial testing of stool broth specimens, the multiplex assay was evaluated
using Cary-Blair specimens for the characteristics of precision (repeatability and
reproducibility), analytical sensitivity (limits of detection), analytical specificity (crossreactivity), and performance as compared to reference methods. Validation study results were
then evaluated for assay acceptability as a screening method to provide preliminary outbreak
etiologic agent information to epidemiologists and to focus confirmatory testing in the
laboratory.
As described, precision studies were conducted with a panel of four Cary-Blair
specimens representing the type of specimen typically received in the course of an outbreak
investigation. As was done in the enteric protozoan study, the CV data generated in the
repeatability and reproducibility studies for positive assay targets were compared to positive
target CVs published for the xTAG® RVP commercial assay. Coefficient of variation values for
the RVP assay were established in a multi-laboratory reproducibility study to range from 2.40%
to 87.20% for a range of virus single-infection virus concentrations (75). As shown in Table 13,
the within-run (repeatability) CV value range of 6.50% to 26.83% achieved for positive targets
with the bacterial assay was comparable to the values reported for the RVP assay. Of some
concern was the larger CV exhibited for the uidA target as compared to the other two targets near
the assay cutoff value (stx2, estA). The higher variance suggests that low-concentration
specimens positive for uidA may exhibit a higher incidence of false negative results due to lack
of sensitivity. Interestingly, singleplex real-time detection of uidA using other established assays
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at DCLS have also historically exhibited notable variation in uidA detection, suggesting that
optimizing the chemistry of detecting the single base pair mutation in O157 strains is inherently
difficult and the source of variability.
Similarly, as shown in Tables 15 and 17, the reproducibility study CV value range of
13.54% to 41.26% for the amplification and detection steps combined, and 7.28% to 28.23% for
the detection step alone, were comparable to the values published for the RVP assay. It is worth
mentioning that on several days of the reproducibility studies the uidA-positive specimen yielded
negative qualitative results for that target. Based on this performance in both the repeatability
and reproducibility studies, it should be noted that low-concentration uidA targets may not be
detected consistently. As was the case for the protozoan assay, the enteric bacterial assay
exhibited a notable reduction in the detection-only CV values as compared to those seen for the
combined amplification and detection steps, suggesting that amplification is an important source
of variability. Therefore, the comparison of Bio-Plex bacterial assay precision values for
positive targets with those of the RVP assay suggests that multiplex microsphere-based nucleic
acid assays may exhibit a wide range of variability, particularly at the low end of the FI
measuring range for positive specimens, and facilitates the conclusion that the Bio-Plex bacterial
assay exhibits comparable precision for Cary-Blair stool specimens.
As performed with the protozoan assay, SD values were used in this study to describe the
variation for target-negative specimens and were compared to those described for a microspherebased assay to detect Plasmodium spp. (77). In the malaria assay, SD values ranged from 18.1 to
39.0 for both negative specimens and negative targets, based on mean FI values ranging from
81.3 to 121.2. These values were calculated using FI values detected on the Bio-Plex with a high
RP1 target setting, which typically results in higher FI values as compared to using the low RP1
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target setting. Because the bacterial assay is detected on the Bio-Plex using a low RP1 target
setting, the mean FI and SD values for negative specimens in the study described here are lower
than those described for the Plasmodium assay. However, a relative comparison of the two
assays remains informative. Although not a direct comparison, the SD range of 4.32-9.30 FI
achieved in the repeatability study appears to similarly represent the range of variability
described for this type of assay (Table 14). In addition, the between-day SD ranges of 3.14 –
12.76 for the combined amplification and detection steps (Table 16) and 1.65 – 14.26 (Table 18)
for the detection step only are comparable to published data. Based on these evaluations, the
Bio-Plex bacterial assay exhibits comparable precision for pathogen-negative Cary-Blair
specimens.
Several primers and probes used in the bacterial multiplex assay were adapted from
previously-published real-time or conventional PCR protocols. Therefore, a limited comparison
of Bio-Plex assay’s analytical sensitivity (limits of detection) to that of previously-described
assays was conducted to evaluate how well the described primers and probes were adapted to the
Bio-Plex platform. The stx1 and eltA (LT) primers and probes were adapted from a multiplex
real-time PCR assay for which the limits of detection were established by diluting organism
spiked into enrichment broths, as opposed to the stool aliquots used in this Bio-Plex study (53).
The Bio-Plex limits of detection are comparable to or lower than the published values of 2.02.7x106 CFU/mL for stx1 and 1.3-1.6x106 CFU/mL for eltA (Table 19). Reasons for the lower
limit of detection of the bacterial assay may be affinity of the probe for the Bio-Plex chemistry,
differences in experimental design, or different gene copy numbers in the isolates used.
The stx2 primers were also adapted, in this case from a published conventional assay
(90). The probe was designed in this study for the Bio-Plex assay. Again, comparison of
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detection limits is not exact, as the published sensitivity for the primers was established using
spiked fecal cultures, not stool, and the probe is a new design. The Bio-Plex limit of detection as
determined for a 200 mg stool reaction was slightly lower than the 1x103 CFU/reaction achieved
for the conventional assay and may be due to the Bio-Plex chemistry and probe design. In the
case of the uidA target, both primers and probe from the literature were used in the Bio-Plex
assay (119). Comparison of sensitivity data is difficult, however, as the published limit of
detection of 1-1000 CFU/g was estimated by spiking food supplemented by enrichment, not a
stool matrix. However, the analytical sensitivity of this target as compared to others in the BioPlex multiplex indicates that adaptation to the Bio-Plex format reduced the sensitivity of the
primer and probe set (Table 19). No comparative data is available for the estA (ST) and ipaH
targets, as they were designed for this study.
A practical comparison of the Bio-Plex assay limits of detection to known excreted
concentrations of organism is also useful in determining if the Bio-Plex bacterial assay is
sensitive enough to detect organism concentrations typically seen in clinical specimens. As was
the case for enteric protozoa, examples of bacterial shedding concentrations are available in the
literature. It is important to note that data discussed below for ETEC and S. flexneri are from
volunteer challenge studies, so the organism concentrations determined to be excreted may not
be an exact representation of natural infection. In a study of pediatric patients infected with E.
coli O157, long-term shedders excreted over 106 CFU/g stool, while convalescent shedders were
determined to excrete 105-106 CFU/g stool (63). It was noted, however, that convalescent
shedders may excrete lower levels of organism that may not have been detected due to the LoD
of the assay used in the Karch et al. study (63). A comparison of the detection limits, as
converted to CFU/g stool, for the Bio-Plex stx1 and stx2 targets to the study data suggests that
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the bacterial assay is capable of detecting physiologic concentrations of organism in clinical
specimens (Table 19). Detection of uidA may be limited as suggested by the estimated limit of
detection and precision data described previously.
An example of ETEC excretion levels is provided in a heat-labile toxin vaccine study,
during which volunteers were challenged with 6x108 CFU of organism (76). The median peak
excretion was quantified to be 1x108 CFU/g stool, with the implication that excretion levels may
be lower. Comparison of the estimated limit of detection ranges for Bio-Plex eltA and estA
targets with these data suggests that the bacterial assay is capable of detecting clinically relevant
concentrations of organism (Table 19). In an antibiotic efficacy study, volunteers were
challenged with 1500 CFU of S. flexneri, and peak shedding in those taking placebo was
quantified to be 1x103-3x106 CFU/g stool (108). Comparison of the estimated Bio-Plex ipaH
limit of detection with these data indicates the bacterial assay is capable of detecting
concentrations of organism that may be expected in clinical specimens (Table 19).
A potential limitation in estA (ST) target detection was identified when testing several
ETEC isolates previously characterized by the Minnesota Department of Health to contain the
estA1 allele. Confirmation testing upon receiving isolates of serotype Ound:H16 and O148:NM
with the Bio-Plex bacterial assay yielded negative results for ST. Subsequent testing using an
alternate DCLS ETEC real-time protocol, as described in Materials and Methods, yielded
positive ST results (data not shown). Bio-Plex primers and probe sequences were compared with
those published for the complete coding sequence for the estA1 allele of the heat-stable toxin I
gene from E. coli strain 18D (Genbank accession M58746) (data not shown). Multiple base pair
mismatches were identified between the Bio-Plex primers and probe and the published gene
sequences, suggesting that detection of this ST allele is hindered in the Bio-Plex assay. Re-
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design of the primers and probe or addition of an allele-specific primers and/or probe may be
desired.
The Bio-Plex bacterial assay exhibited no cross-reactivity between microsphere targets.
In addition, when challenged with ETEC, EIEC, and most EPEC strains, none of the multiplex
microspheres yielded positive results. These data complement previously-published studies
demonstrating that the primers and/or probe sequences for stx1, six2 and eltA (LT) do not crossreact with non-target sequences in other pathogens (53, 90). Of note is repeated cross-reactivity
of the uidA probe with one EPEC strain (serotype O86:H34) tested in the study. Similar crossreactivity with several EPEC strains was also seen with experimental uidA probes designed at
DCLS (data not shown). As discussed previously, detection of the O157-specific uidA sequence
is based on a one base-pair mutation as compared to non-O157 strains in the β-glucuronidase
gene. Designing reaction conditions to ensure specific hybridization can be a challenge. As
described by Yoshitomi et al. (119), even under real-time singleplex conditions very stringent
cycling temperature and probe and magnesium concentrations must be established to reduce
cross-reactivity to non-O157 strains. Due to the possibility of cross-reactivity with EPEC
strains, it is recommended that result interpretation of the uidA target be accomplished only when
stx1 and/or stx2 targets are positive.
Finally, overall performance of the bacterial Bio-Plex assay was assessed by comparing
results obtained from testing well-characterized Cary-Blair specimens representative of those
typically submitted during outbreak investigations with results obtained by performing the
reference methods of biochemical, enzyme immunoassay and/or molecular testing. Based on
Bio-Plex and reference method result comparisons, Bio-Plex results were designated as either
true positive (TP), true negative (TN), false positive (FP), or false negative (FN), and the
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analytical sensitivity and specificity for each assay target were calculated (Table 20). Bio-Plex
results that did not correlate with the reference method upon initial testing (FP, FN) were
investigated using re-extraction and re-testing with both the Bio-Plex and molecular reference
methods, as available. As shown in Table 20, sensitivity for the stx1, stx2, uidA, and ipaH
targets is excellent, exceeding the minimum acceptable sensitivity of 80% established for this
assay (Chapter 2). Specificity for all targets is also excellent, exceeding the minimum acceptable
specificity of 95% established for this assay (Chapter 2).
Several limitations exist for the comparison-of-methods study. First, no Cary-Blair stool
specimens containing ETEC organisms were available, resulting in no comparative data for the
eltA and estA targets. However, successful detection of ETEC strains in Cary-Blair specimens
can be anticipated based on the ability to detect low concentrations of organism in the course of
the analytical sensitivity (LoD) study (Table 19). Second, the comparison-of-methods study
sample size was limited by availability and was thus very small (n = 16). Therefore, the
sensitivity confidence limit ranges for stx1, stx2, uidA and ipaH are fairly wide, illustrating the
low statistical confidence provided by the sensitivity calculations. Additional data can be
gathered in the course of future outbreak investigations to bolster the statistical confidence.
Confidence limit ranges for the calculated specificity of all targets are smaller than those for the
sensitivity calculations, providing a higher level of confidence in these data.
An evaluation has been conducted to assess the performance of a microsphere-based
multiplex assay for the simultaneous detection of six STEC, ETEC, and EIEC/Shigella spp.
molecular targets in Cary-Blair stool specimens in a public health laboratory setting. This assay
exhibits acceptable precision for all targets, as compared to data available in the commercial and
scientific literature (75, 77). A potential limitation is that variability of the uidA target in

128

specimens with organism concentrations near the assay cutoff may lead to inconsistent target
detection. The stx1, stx2, and eltA (LT) targets exhibited similar or lower limits of detection
when compared to the previously-published assays from which the primers and/or probes were
adapted. In addition, a comparison of the Bio-Plex analytical sensitivity results (CFU/g stool)
with those described for clinical and challenge studies suggests that the Bio-Plex assay targets of
stx1, stx2, eltA, estA, and ipaH are capable of detecting physiologic concentrations of organism
in clinical specimens. Performance of the uidA target in limit of detection studies was not
optimal, again suggesting that detection of the uidA gene target in Cary-Blair specimens may be
problematic. Optimization of the uidA primers and probe reaction conditions has been described
to be critical to successful O157 strain detection (119). However, conditions for the other primer
and probe sets in the multiplex must also be considered, therefore limiting optimization. As
discussed earlier in this chapter, testing of alternate primer and probe designs yielded less
successful performance, suggesting that the current primers and probe are at this time the best
option as long as the operator is aware of the performance limitations. In the case of the estA
(ST) target, however, re-design of the primers and probe or addition of an allele-specific primer
and probe set may be desired in the future.
The assay targets exhibited no cross-reactivity when challenged with a variety of E. coli,
Shigella spp. and Salmonella spp. One notable exception was repeated cross-reactivity of the
uidA target to a select EPEC strain. Because cross-reactivity to EPEC strains may occur, it is
recommended that uidA results be considered for interpretation only when stx1 and/or stx2
targets are also positive. Finally, comparison of Bio-Plex qualitative results for Cary-Blair
specimens with those of reference methods yielded sensitivity and specificity values that
exceeded expectations, although confidence of sensitivity data is lowered due to the small
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sample size. Despite the small study sample sizes and potential limitations, the Bio-Plex
bacterial assay exhibits performance characteristics sufficient for use as a screening assay to
provide preliminary etiologic agent information and focus laboratory confirmatory testing in
outbreak investigations.
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CHAPTER 6 EVALUATION OF A MANUAL METHOD FOR THE EXTRACTION OF
VIRAL NUCLEIC ACIDS

Overview of Norovirus and Rotavirus Pathogens and Molecular Assays for Detection of
Gene Targets. Noroviruses are the leading cause of acute gastroenteritis in the U.S., and are the
leading non-bacterial cause of foodborne illness (22, 100). Rotaviruses are more typically
associated with gastroenteritis in pediatric patients, although they have also been implicated in
foodborne illnesses (11). An overview of the viruses, their clinical signs and symptoms and
testing methods utilized by public health laboratories to detect these viruses is provided below.
Norovirus genogroups I and II. Noroviruses (NoVs) are small round-structured non-enveloped
RNA viruses belonging to the family Caliciviridae (51). They are currently classified into five
genogroups, with GI and GII primarily associated with human infection (3). Genogroups are
further subdivided into genotypes based on sequence variations in the capsid genes of the viruses
(3, 120). Definitive characterization of NoVs is conducted under the auspices of the CDC’s
CaliciNet Network, a national NoV electronic surveillance network intended to track NoV
strains and outbreak trends through the use of a comprehensive genome sequence database (22).
Based on data analyzed through CaliciNet, variants of NoV genotype GII.4 have been the
predominant cause of NoV infections in the U.S. since 2001 (22).
Infection with NoV causes acute gastroenteritis, typically after a 12-48 hour incubation
period. Symptoms include diarrhea, vomiting, nausea, and/or abdominal cramps. Infrequently
patients may experience low-grade fever and/or body aches (22). Infections are usually self131

limiting in immunocompetent people. Prolonged symptoms, including dehydration, can occur in
the young, elderly, and hospitalized (22).
Detection and characterization of NoVs are primarily performed using molecular
methods, as no culture techniques are available. Only one FDA-approved immunoassay recently
became available in the U.S., but is not recommended as a replacement for molecular methods in
public health outbreak investigations because negative samples must still be confirmed by a
second technique (22). The NoV genome is a single-stranded, positive sense RNA of
approximately 7.7kb in length (51). The genome contains three open reading frames (ORFs), of
which ORF1 encodes non-structural proteins, ORF2 encodes the major capsid protein VP1, and
ORF3 encodes the minor structural protein VP2 (51). Detection of NoV GI and GII is currently
performed at state laboratories in collaboration with the CDC using a real-time RT-PCR assay
targeting the relatively conserved junction between the ORF1 and ORF2 (60). In addition,
conventional RT-PCR methods are performed to target the capsid regions encoded on ORF2 and
amplification products sequenced to identify the genotype of the viruses detected in clinical
specimens (114).
Group A rotaviruses. Rotaviruses (RVs) are non-enveloped RNA viruses that belong to the
family Reoviridae, named for their wheel-like shape when visualized using electron microscopy
(2). Like NoVs, these viruses are classified based on the characterization of serotypes and/or
genotypes of specific viral proteins. Major RV groupings are designated A to G, and are based
on antigenicity of epitopes in the most abundant virus structural protein, VP6 (47). Group A
rotaviruses are the primary rotavirus type that causes disease in the U.S., and are further
characterized based on the serological reactivity of two outer capsid proteins, VP7 and VP4. The
VP4 protein determines the P type, and VP7 the G type of the virus (37). Fourteen G types are
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known, with G1-G4 being the most common, and it has been shown that serotype directly
correlates with genotype. Twenty P types have been identified, with ten known to occur in
human RV infections. For the P types, serotype does not correlate directly with genotype (37).
The incubation period for RV infection is usually 24-48 hours. Typical symptoms in
both adults and children are fever and vomiting for several days, followed by often profuse
diarrhea. However, time to onset of illness and symptoms in adults may be widely variable (2).
As is the case for norovirus, dehydration is a concern, particularly in children and the elderly.
The rotavirus genome is made up of 11 segments that are double-stranded. Segments
range in size from 660 to 3,300 base pairs (37). Historically at DCLS, as well as other state
public health laboratories, a conventional RT-PCR assay targeting the VP6 gene has been used
for viral detection (49, 92). Recently, a real-time RT-PCR assay was implemented targeting a
structural protein, NSP3, that exhibits a more conserved sequence than that of VP6 (59).
Integration of Enteric Virus Detection into a Foodborne Outbreak Screening Algorithm.
The original intent during the initial stages of this project was to design a multiplex Bio-Plex
enteric viral assay, similar to those designed for protozoa and bacteria. Bio-Plex assay design
was to complement the other two assays and create a multiple pathogen approach in which three
Bio-Plex assays could be utilized to concurrently screen clinical specimens for protozoa, bacteria
and viruses of public health significance in foodborne outbreaks. In support of this goal, BioPlex primers and probes targeting NoV GI, NoV GII and RV were designed based on sequences
previously described for real-time and conventional RT-PCR methods [J. Vinjé, unpublished
data; (49, 60, 64)]. While the NoV GII and RV designs adapted readily to the Bio-Plex platform,
issues such as lack of sensitivity and cross-reactivity with the NoV GII target were encountered
with the NoV GI designs (data not shown). Exhaustive efforts to modify primers, probes and
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reaction conditions finally resulted in a set of NoV GI-specific probes that showed promise in
multiplex, but still required extensive testing to confirm acceptable performance (data not
shown).
As assay development and evaluation progressed, the vision of the integrated screening
algorithm was reassessed and it was concluded that continuing to develop a Bio-Plex the virus
assay provided no benefit to the overall testing algorithm. In fact, multiple real-time RT-PCR
assays for the detection of NoV and RV are readily available at most state public health
laboratories and these methods yield confirmatory results faster than the Bio-Plex screening
assay. As previously discussed in Chapter 2, additional practical reasons for not pursuing the
assay further included the fact that the Bio-Plex norovirus gene targets were the same as those
detected using current standardized real-time assays and the Bio-Plex rotavirus gene targets,
though different than standardized protocols, provided no additional information than that gained
from the current method. Therefore, unlike the parasite and bacterial assays that would be filling
a testing void and reducing turnaround time for screening results, a Bio-Plex virus assay would
only provide a redundant testing system that would be more costly in terms of supplies and
manpower than current confirmatory testing methods.
However, integrating the real-time RT-PCR virus testing procedure into an outbreak
screening algorithm which also includes the Bio-Plex protozoan and bacterial assays was
required. Harmonization called for the ability to test a single stool specimen with all the assays.
Therefore, it was determined that the extraction step needed to be changed to enable an efficient
testing algorithm, since the extraction method for the real-time protocols was different than that
used for the Bio-Plex assays and a common extraction method was required. The current
extraction method utilized for the real-time RT-PCR norovirus and rotavirus methods is the
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Ambion® MagMAX™-96 Viral RNA Isolation Kit combined with the automated KingFisher®
Magnetic Particle Processor, whereas the manual QIAamp DNA Stool Mini Kit method is used
in conjunction with the Bio-Plex assays. Successful extraction of norovirus nucleic acids has
been previously described using the Qiagen QIAamp DNA Stool Mini Kit (97). Establishing the
Bio-Plex extraction method as the common protocol would allow nucleic acids to be used for
testing with not only the Bio-Plex assays, but also the real-time RT-PCR viral assays. Therefore,
a parallel study was conducted to compare the results obtained for specimens extracted with both
methods and then tested using the NoV and RV real-time RT-PCR assays.
Results.
Comparison of extraction methods. Unpreserved stool specimens and stools in Cary-Blair
transport medium known to be positive for NoV or RV were extracted as described using both
the Ambion® MagMAX™-96 Viral RNA Isolation Kit combined with the automated
KingFisher® Magnetic Particle Processor and the manual QIAamp DNA Stool Mini Kit
extraction method, as described (Table 21). Extracted nucleic acids were tested using the
standardized real-time RT-PCR assays currently employed at DCLS for NoV or RV, as
appropriate. The real-time RT-PCR crossing point values (Ct) obtained upon testing are
summarized in Table 22. Pooled study results representing Ct values for Kingfisher-extracted
and Qiagen-extracted specimens were tested separately for a normal distribution using the
Shapiro-Wilk test (78). Because the p-values for both the Kingfisher and Qiagen data sets were
less than 0.05 (α), it can be concluded that the data are not from a normally distributed
population (Kingfisher: W = 0.938, p = 0.015, n = 47; Qiagen: W = 0.922, p = 0.004, n = 47).
Therefore, correlation between pooled Kingfisher and Qiagen results was performed using the
Spearman’s rho (rank) correlation, which is appropriate for data that is not normally
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Table 21. Summary of the NoV and RV specimens tested in a nucleic acid extraction
comparison study. Pathogen, specimen type and total number are summarized for the
specimens utilized to compare the automated Kingfisher and manual Qiagen extraction methods.
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Virus

Specimen Type

Number (n)

NoV GI

Unpreserved
Cary-Blair

6
6

NoV GII

Unpreserved
Cary-Blair

14
7

RV

Unpreserved
Cary-Blair

7
7
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Table 22. Real-time RT-PCR crossing point (Ct) values obtained for specimens positive for
NoV GI, NoV GII and RV, using Kingfisher and Qiagen extraction methods. Select
specimens positive for NoV and RV were extracted with both the Kingfisher automated
extraction method and the manual Qiagen extraction method and tested using real-time RT-PCR
assays. (A) The Ct values obtained are for unpreserved and Cary-Blair specimens positive for
NoV GI are summarized. (B) The Ct values obtained are for unpreserved and Cary-Blair
specimens positive for NoV GI are summarized. (C) The Ct values obtained are for unpreserved
and Cary-Blair specimens positive for NoV GI are summarized. Abbreviations: KF, Kingfisher;
Q, Qiagen
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(A)
Unpreserved Specimens
Specimen
Identification

KF
(Ct)

Q
(Ct)

V-S-001

28.19

27.72

V-S-009

36.92

V-S-118

Cary-Blair Specimens
Specimen
Identification

KF
(Ct)

Q
(Ct)

V-CB-145

28.70

28.68

32.90

V-CB-146

37.31

35.74

25.31

23.90

V-CB-147

25.59

22.24

V-S-120

23.76

21.88

V-CB-148

35.87

33.60

V-S-143

34.60

31.46

V-CB-149

36.49

34.57

V-S-144

36.68

23.22

V-CB-150

35.42

33.86

(B)
Unpreserved Specimens
Specimen
Identification

KF
(Ct)

Q
(Ct)

V-S-011

22.61

25.71

V-S-013

19.85

V-S-015

Cary-Blair Specimens
Specimen
Identification

KF
(Ct)

Q
(Ct)

V-CB-151

29.49

27.79

17.81

V-CB-152

19.93

17.89

25.13

28.47

V-CB-153

20.91

21.39

V-S-017

28.82

27.73

V-CB-154

16.51

16.58

V-S-021

27.45

26.86

V-CB-157

35.59

33.28

V-S-033

16.73

16.42

V-CB-158

33.9

32.76

V-S-037

20.71

17.52

V-CB-159

28.25

28.05

V-S-038

17.15

16.04

V-S-047

17.87

17.14

V-S-055

23.07

22.065

V-S-056

33.39

37.15

V-S-059

31.65

28.8

V-S-063

23.07

18.74

V-S-066

36.37

32.76

139

(C)
Unpreserved Specimens
Specimen
Identification

KF
(Ct)

Q
(Ct)

V-S-537

26.14

34.25

V-S-558

14.05

V-S-559

Cary-Blair Specimens
Specimen
Identification

KF
(Ct)

Q
(Ct)

V-CB-568

16.46

21.16

17.01

V-CB-569

16.73

21.08

16.29

23.44

V-CB-570

28.66

32.63

V-S-562

14.27

16.20

V-CB-571

32.28

32.05

V-S-564

17.12

20.13

V-CB-572

31.30

35.39

V-S-565

17.35

18.43

V-CB-574

14.92

19.32

V-S-566

27.05

31.53

V-CB-575

19.17

20.36
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distributed (35). The correlation coefficient was calculated to be 0.886, indicating a statistically
significant correlation between the Kingfisher and Qiagen results (p = 0.000, α=0.01).
Correlation analysis data output and the corresponding scatterplot are illustrated in Figure 5.
Confidence intervals for the correlation coefficient were calculated at the 95% level to be 0.80 –
0.93 using the Fisher z transformation as described by Dawson and Trapp (35, 72). The standard
deviation of the differences between the Kingfisher and Qiagen Ct values for each specimen was
also calculated (S.D. = 3.05), and the 1 S.D. and 2 S.D. ranges are illustrated in Figure 5.
In addition to the statistical analyses, the difference in Ct values of Kingfisher-extracted
versus Qiagen-extracted stool specimens (ΔCt) amplified by RT-PCR were calculated and
graphed (Figure 6). Delta Ct values greater than 0 (bar above the x-axis) indicate that the Ct
value of the Qiagen-extracted specimen is lower. Conversely, delta Ct values less than 0 (bar
below the x-axis) indicate that the Ct value of the Kingfisher-extracted specimen is lower.
Twenty-seven (27) of 33 norovirus specimens exhibited lower Ct values when extracted with the
Qiagen method, and 14 of 14 rotavirus specimens exhibited lower Ct values when extracted with
the Kingfisher method.
Discussion. A three-plex viral assay targeting NoV GI, NoV GII and group A RV genome
targets was initially designed and evaluated at DCLS. However, when considering the most
efficient testing algorithm for screening of outbreak specimens, it was determined that
development of a viral Bio-Plex assay was not optimal. Due to the time required to perform the
newly developed BioPlex viral assay, it was determined that its use did not improve the timeline
for detection of viral agents in association with viral outbreaks. Instead, the focus of integrating
an enteric virus testing assay into a multi-agent screening algorithm moved toward establishing a
common extraction method. As discussed previously, the Kingfisher extraction method
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Figure 5. Spearman rho correlation data output and corresponding scatterplot, comparing
Kingfisher and Qiagen extraction methods. Real-time RT-PCR crossing points (Ct) obtained
by testing unpreserved and Cary-Blair specimens positive for NoV or RV and extracted with
both Kingfisher and Qiagen methods were pooled and assessed for normal distribution.
Correlation of Kingfisher and Qiagen results was calculated using the Spearman rho correlation,
and 95% confidence intervals determined using the Fisher z transformation. Descriptive
statistics as determined by analysis using PASW 18.0 are presented in addition to the scatterplot
illustrating comparative results. Maroon lines at Ct = 40 indicate positive cutoff value for realtime RT-PCR assays. Dashed blue line: One standard deviation of the difference between
Kingfisher and Qiagen Ct values (ΔCt; Kingfisher minus Qiagen). Solid blue line: Two
standard deviations of the difference between Kingfisher and Qiagen Ct values (ΔCt; Kingfisher
minus Qiagen).

142

Descriptive Statistic

Output

n

47

Mean, Kingfisher

25.4289

Mean, Qiagen

25.6106

Standard deviation, Kingfisher

7.26226

Standard deviation, Qiagen

6.63405

Spearman’s rho

0.886

Significance (2-tailed, α = 0.01)

0.000

CI95

0.80 – 0.93

Comparison of Real-Time NoV and RV RT-PCR Results of
Specimens Extracted with Kingfisher and Qiagen Methods
(All specimens, unpreserved/Cary-Blair; Ct)
45
40

Qiagen

35

1 S.D.

30

2 S.D.

25
2 S.D.
20

1 S.D.

15
10
10

15

20

25

30

KingFisher
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35

40
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Figure 6. Comparison of real-time RT-PCR crossing points (Ct) for NoV and RV
specimens extracted with Kingfisher and Qiagen methods. Crossing points achieved by
testing Kingfisher- and Qiagen-extracted NoV and RV positive specimens followed by real-time
RT-PCR assays were subtracted to yield a delta Ct (ΔCt; Kingfisher minus Qiagen). Bars above
the x-axis indicate a lower Ct achieved for a Qiagen-extracted specimen as compared to
Kingfisher; bars below the x-axis indicate a lower Ct achieved for a Kingfisher-extracted
specimen as compared to Qiagen. A) Unpreserved specimens positive for NoV GI and GII. B)
Cary-Blair specimens positive for NoV GI and GII. C) Unpreserved and Cary-Blair specimens
positive for RV.
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currently used at DCLS for virus molecular assay testing is different from the Qiagen extraction
method used with the protozoan and bacterial Bio-Plex screening assay. Therefore, in order to
perform virus testing in conjunction with the Bio-Plex parasite and enteric bacterial screening
assays, two extraction methods would be required. The capability of using only one extraction
method for both the virus real-time assays and the parasite and bacterial Bio-Plex screening
assays was desired. Thus, a comparison was conducted using the current DCLS real-time RTPCR NoV and RV assays to test positive stool specimens extracted with both the Kingfisher
automated method and the Qiagen manual method, as described. The Kingfisher extraction
method is currently used to obtain RNA from virus containing stool specimens followed by realtime RT-PCR assay detection. If the Qiagen method yielded comparable results, nucleic acids
extracted for Bio-Plex testing could also be used for real-time RT-PCR virus testing, thus
reducing the need for a second extraction.
A total of 47 unpreserved and Cary-Blair specimens known to be positive for NoV or RV
were extracted with both the Kingfisher and Qiagen methods, tested using real-time RT-PCR
protocols, and crossing point (Ct) data pooled and analyzed for statistical correlation (r) (35).
Correlation between the Kingfisher and Qiagen Ct results were found to be statistically
significant and the 95% confidence interval was small (Figure 5). An important practical note is
the fact that no specimen Ct values exceeded the positive cutoff values of either assay with either
extraction method, providing anecdotal confidence that both extraction methods would yield
comparable results. Evaluation of the delta Ct data presented in Figure 6 suggests that the
Qiagen extraction method is more efficient for NoV nucleic acid extraction, while the Kingfisher
method appears more efficient for RV nucleic acid extraction. However, as noted previously, all
specimens yielded positive results in this study as expected regardless of the extraction method.
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Preliminary design and testing have led to the development and adaptation of primers and
probes targeting NoV GI, NoV GII and RV genome sequences for detection on the Bio-Plex
platform. Initial studies suggest that the NoV GII and RV assays may work well in multiplex
without the specificity issues encountered during development. Upon conducting a benefit
analysis of the three Bio-Plex assays under development, the viral assays were determined to
provide redundant qualitative results when compared to current testing capabilities and did not
provide any turn-around time advantage at this time.
Although a complete validation of the viral BioPlex assay was not conducted, the primers
and probes described are available for future assay development, if desired. The RV primer and
probe set has been updated to detect VP6 sequences of recent strains, as recommended by Kerin
et al., and could be used on the Bio-Plex or adapted to other detection platforms (64). Sequencespecific probes have been designed to specifically detect predominantly circulating NoV GI
genotypes and thus could serve as a model for genotype screening.
A comparison study has been conducted in order to assess the performance of the Qiagen
manual extraction method to the Kingfisher automated extraction method. Comparison of realtime RT-PCR assay results for unpreserved and Cary-Blair specimens positive for NoV GI, NoV
GII or RV following RNA extraction with both methods indicates that the positive correlation is
statistically significant. Based on this study, it is recommended that specimens to be tested with
both Bio-Plex and real-time RT-PCR viral assays be extracted with the Qiagen manual method,
eliminating the need for two extractions.
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CHAPTER 7 CONCLUSIONS AND OVERALL OBSERVATIONS

Implementation of a Bio-Plex Assay Outbreak Screening Algorithm. Development and
implementation of rapid and easy-to-use testing methods to concurrently screen clinical
specimens for a variety of foodborne pathogens enables public health laboratories to provide
timely preliminary etiologic agent information to epidemiologists or outbreak investigators and
to focus subsequent confirmatory testing. Toward this aim, two multiplex assays targeting
enteric protozoa and enteric bacteria were developed for the Bio-Plex 200 platform and
performance characteristics were established. In addition, detection of viral nucleic acids
extracted with two different extraction protocols was compared using a real-time RT-PCR assay
currently in use for the detection of viral pathogens. With several limitations, the Bio-Plex
assays and manual extraction of viral nucleic acids are suitable for integration into a screening
algorithm for use in foodborne outbreak investigations in a public health laboratory setting.
Proposed outbreak screening algorithm. The typical outbreak investigation protocol employed
by DCLS is illustrated in Figure 1 (Chapter 1), which summarizes a sometimes lengthy process
that incorporates biochemical, enzyme immunoassay and molecular methods, as well as a
reliance on reference laboratory testing for detection of intestinal protozoa. Based on the overall
vision of this project, and the results of our subsequent studies, we propose the algorithm shown
in Figure 7 for screening clinical specimens submitted during foodborne outbreak investigations.
The proposed algorithm integrates the enteric protozoan and bacterial multiplex Bio-Plex
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Figure 7. Proposed foodborne outbreak investigation testing algorithm with Bio-Plex
screening. The proposed algorithm integrates the enteric protozoan and bacterial multiplex BioPlex screening assays and real-time RT-PCR viral assays with one nucleic acid extraction
method. Examples of possible symptoms and other epidemiologic data that may be provided for
use in directing the decision as to whether to use each assay are provided. Confirmatory testing
following initial screening with the Bio-Plex assays is recommended below the algorithm, as
well as estimated time to achieve preliminary and confirmatory results.
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Extraction
(Qiagen DNA Mini Stool Kit)

UNKNOWN HISTORY

Assay

Travel outside U.S.

Suspected
virus
Acute onset
Vomiting/diarrhea
combined
Long-term care
facility

Cary-Blair

History

Suspected
bacterium
Bloody stools
Diarrhea 2.5x>
vomiting

Suspected
protozoan
Long-term symptoms
Flatulence
Travel outside U.S.
Suspect water source

Protozoan

Bacterial

Viral

(Bio-Plex)

(Bio-Plex)

(Real-time RT-PCR)

OVERLAPPING SYMPTOMS

Confirmation:
Some/all
positive

Microscopy, EIA
Molecular ID
Reference lab

Biochemical ID
Molecular ID

>2 positive
confirms

All negative

Microscopy, EIA
Molecular ID
Reference lab

Biochemical ID
Molecular ID

Outbreak neg
for NV, RV

-----screen with alternate assays if not already performed-----

Time, preliminary:
Time, confirm:

4-6 hrs
3-6 days

5-6 hrs
2-6 days

* Virus real-time RT-PCR assay is confirmatory
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N/A*
3 hr-2 days

screening assays and real-time RT-PCR viral assays with one extraction method. These assays,
by design, can be used alone or in combination as the situation dictates. Examples of symptoms
and other epidemiologic data that may be used to decide which assays to use are illustrated in
Figure 7. Because the assays are separate, yet linked with a common extraction method,
laboratories can decide to utilize one assay in outbreaks which have detailed epidemiologic data,
or all assays in outbreaks for which no case history is provided or symptoms are confusing.
Confirmatory testing that is required following initial screening with the Bio-Plex assays is
included in the algorithm. The estimated times to achieve preliminary and confirmatory results
are also provided.
Patient and/or outbreak history provided by epidemiologists may be useful in identifying which
screening (protozoan, bacterial) and/or confirmatory (viral) assay(s) to be performed. In some
outbreaks, as in a recent Giardia outbreak in Virginia, the identification of the etiologic agent
may already be reported for some patients that were diagnosed at local physician offices and/or
by laboratory testing conducted at private or commercial laboratories. A decision flow chart is
provided in Figure 8 that illustrates how the screening algorithm may be specifically employed in
outbreak situations in which information is already known about the etiologic agent. In other
outbreaks, public health officials may only provide limited reported symptoms and/or incubation
times to help guide testing decision. However, as illustrated in Table 1 (Chapter 2), symptoms
for infections may overlap greatly. Figure 9 provides a decision flow chart that may be used to
assist in determining assay(s) to perform when information regarding symptoms of outbreak
cases is available. In these situations, active involvement of the laboratory’s management or
scientific team in making testing decisions will be required. However, the proposed decision
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Figure 8. Proposed decision chart for outbreaks in which the etiologic agent is known. The
proposed decision chart is provided to guide testing decisions for foodborne outbreaks in which
an etiologic agent has been previously identified by another laboratory. In these outbreaks, a
laboratory may choose to perform only a single assay targeting the previously identified
pathogen. The pathogen targets of each of the assays are listed at the top of the decision chart to
easily identify the correct assay. If the pathogen information provided by public health officials
is not detected by the protozoan, bacterial or viral assays, alternative testing may be required.
For the protozoan and bacterial assays, preliminary positive screening results should be
communicated to public health officials, prior to obtaining final confirmatory test results. All
negative Bio-Plex assay results will require confirmation using standard methodologies
employed by the laboratory except for the viral real-time RT-PCR assay results, which are
confirmatory.
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Foodborne Outbreak Screening Decision Chart Pathogen Identification Provided
G. intestinalis
C. cayetanensis
C. parvum or hominis
E. histolytica

Bio-Plex
protozoan
assay
(+ or -)

EHEC (STEC)
ETEC
EIEC
Shigella spp.

Norovirus
Rotavirus

Bio-Plex
bacterial
assay

Real-time
RT-PCR

(+ or -)

Notify PH officials

Notify PH officials

Perform confirmatory
testing

Perform confirmatory
testing

(+ or -)

Notify PH officials
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Other identified
pathogen

Consult with
management or
scientific team

Figure 9. Proposed decision chart for outbreaks in which symptoms are known. The
proposed decision chart is provided to assist in guiding testing decisions for foodborne outbreaks
in which detailed or sufficient information concerning symptoms and/or incubation periods are
provided by public health officials. The chart is based on the symptoms of diarrhea and/or
vomiting, and incorporates key incubation periods. Additional symptoms may be experienced by
patients, including fever, cramps and/or nausea, depending on the infection, and these data may
be further considered in triage decisions at the discretion of laboratory management or scientific
staff. For the protozoan and bacterial assays, preliminary positive results should be
communicated to public health officials, followed by confirmatory testing. All negative BioPlex assay results will require confirmation using standard methodologies employed by the
laboratory except for the viral real-time RT-PCR assay results, which are confirmatory.
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Foodborne Outbreak Screening Decision Chart Symptoms Provided by Public Health (PH) Officials
Primary Symptom:
Diarrhea

Bloody

Bio-Plex
bacterial
assay

(+ or -)

Non-bloody

Watery >48 hrs

Watery ≤ 48 hrs
Symptoms ≤ 48 hrs

Suspect
E. histolytica

(-)

Bio-Plex
protozoan &
bacterial assays

Bio-Plex
protozoan
assay

(+ or -)

Primary Symptoms:
Diarrhea + Vomiting

Flatulence
Steatorrhea
Cramping

Bio-Plex
protozoan
assay

Viral realtime RT-PCR
(-)

(+ or -)
(+ or -)

Notify PH
officials

(+ or -)

(+ or -)

Notify PH officials

Notify PH officials

Perform confirmatory
testing

Perform confirmatory
testing
155

≥15 hrs
incubation

<15 hrs
incubation

Bio-Plex
bacterial
assay amplification

Possible toxin;
consult with
management
or science
team

Bio-Plex
bacterial
assay detection

flow chart facilitates screening for the widest variety of pathogens with the least number of
screening assays to conserve resources. Finally, in some cases, clinical specimens may be
submitted to a public health laboratory for outbreak investigation with sparse or no
epidemiologic data available at that time. In these situations, laboratorians have the flexibility to
test with all three assays using a single eluted nucleic acid sample from each specimen, as
illustrated by the decision chart provided in Figure 10. Examples of non-symptom
epidemiologic data, such as travel or location, may be available and may be used to decide which
screening assays to perform.
Assuming that all three assays are to be performed concurrently to test specimens
submitted in support of an outbreak investigation, it is recommended that conventional
amplification (Bio-Plex) and real-time RT-PCR (virus) reactions be set up in a specific order so
as to minimize the time to results. The bacterial assay requires the longest amplification period
at 2.5 hours, and therefore should be set up first. The protozoan assay should follow, with an
amplification of 1.5 hours. Finally, the viral assay may be set up as both amplification and realtime detection only require 1.5 hours. While amplification of the Bio-Plex reactions is
occurring, preparations may be performed for the detection steps on the Bio-Plex platform. Once
amplification is complete, wells can be prepared on the Bio-Plex detection plate for both the
protozoan and bacterial assays. The laboratorian could opt to set up separate detection runs for
each assay; however, this would delay preliminary results if only one heated shaker is available
as plate setup cannot be accomplished concurrently. Starting with the extraction, estimated time
to preliminary Bio-Plex results is 4-6 hours (Figure 7). Time to confirmatory virus results is
approximately 3 hours for NV or NV plus RV, and 48 hours if the RV assay is tested as a reflex
assay.
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Figure 10. Proposed decision chart for outbreaks in which epidemiologic information is
limited or unknown. The proposed decision chart is provided to assist in guiding testing
decisions for foodborne outbreaks in which the epidemiologic data provided public health
officials is limited or unknown. Non-symptom information such as travel, suspected sources,
and/or location, if available, may be used in determining which of the assays to perform. In
situations in which no epidemiologic data is available, laboratories may choose to perform all
three assays following preparation of nucleic acids with the common extraction method. Based
on the time required for nucleic acid amplification and detection for each assay, the most
efficient set-up order is noted. For the protozoan and bacterial assays, preliminary positive
results should be communicated to public health officials, followed by confirmatory testing. All
negative Bio-Plex assay results will require confirmation using standard methodologies
employed by the laboratory except for the viral real-time RT-PCR assay results, which are
confirmatory.
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Foodborne Outbreak Screening Decision Chart Limited or Unknown Epidemiologic Data

Set-up order:
First
Bio-Plex bacterial
assay
(+ or -)

Second

Third

Bio-Plex protozoan
assay

Viral real-time RT-PCR
assays

(+ or -)

Notify PH officials

Notify PH officials

Perform confirmatory
testing

Perform confirmatory
testing
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(+ or -)

Notify PH officials

Because the Bio-Plex assays are to be used for screening and providing preliminary
results to public health officials, follow-up confirmatory testing is recommended (Figure 7).
Should some or all of the specimens submitted in support of an outbreak yield positive results for
a protozoan target, specimens would be confirmed using microscopy, EIA, and/or molecular
methods, if available, or sent to a reference laboratory for confirmation. Additional testing may
then be suspended. Positive bacterial assay results may be confirmed with biochemical and/or
alternate molecular techniques in order to focus testing on the final identification of the detected
organism, as appropriate. Should all specimens be negative for all Bio-Plex assay targets, testing
with confirmatory techniques and/or by a reference laboratory would still be required. The time
to obtain confirmatory results for protozoan and bacterial testing varies from 2-6 days.
Advantages of the screening algorithm. The recommended foodborne outbreak screening
algorithm illustrated in Figure 7 provides several advantages. First, addition of the protozoan
and bacterial assays, albeit in a screening capacity, may fill a testing void for a public health
laboratory. In the case of DCLS no testing is currently available for the identification of
parasites or EIEC. In addition, a real-time PCR assay has been validated for the detection of
ETEC, but it is rarely employed. Therefore, the algorithm provides new testing capabilities, and
testing with the bacterial multiplex will enable more routine screening for both ETEC and EIEC
strains, perhaps revealing a higher prevalence of these strains than is currently understood.
Recent reports of at least three outbreaks in the state of New York associated with a restaurant
and catered events and affecting over 28 people suggests that the routine addition of ETEC
testing in outbreak investigations should be considered (H. Hanson, personal communication).
Second, the algorithm reduces the time required to inform public health officials of the possible
outbreak etiologic agent, which is a high priority. Third, detection of positive screening targets
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allows laboratorians to quickly and efficiently focus confirmatory testing, potentially reducing
the unnecessary wasting of resources expended on pathogen identification. A fourth advantage
is that of flexibility. The two validated Bio-Plex assays were designed separately, allowing
laboratorians to screen with only the assay(s) if desired based on outbreak information.
Additional flexibility is provided by the ability of these screening assays to utilize the same
extracted nucleic acids for both the Bio-Plex and virus real-time RT-PCR portions, thus
eliminating the need to conduct multiple different extractions. Long-term flexibility is afforded
by the potential to add primer and probe sets to each multiplex assay to expand the number of
pathogens targeted for screening. Finally, since the unpreserved, LV-PVA and Cary-Blair stool
specimens tested in the described studies were representative of those specimens typically
submitted in an outbreak investigation, and were of the types validated for other confirmatory
molecular assays, new specimen preservation methods need not be added to collection protocols.
Disadvantages of the screening algorithm. The recommended screening algorithm and the
assays that are incorporated into that algorithm have several disadvantages. The first
disadvantage is that of time; the Bio-Plex assays may take up to six hours to complete.
Therefore, it is important that specimen processing and testing begin immediately upon specimen
arrival in order to gain the maximum benefit of obtaining first-day preliminary results. A second
disadvantage is that of programming limitations in the current Bio-Plex software. The version
currently in use does not allow for concurrent detection of multiple microsphere mixes (i.e.,
assays) within the same run on the same plate. Therefore, when a detection plate is set up to
include more than one assay, the operator must program the Bio-Plex to detect one multiplex
microsphere mix, then quickly re-program to detect a second. A new BioPlex software version
eliminates this limitation, and should be considered for future implementation. A third
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disadvantage is the low sensitivity of the E. histolytica primers, indicating the potential to miss
pathogen detection. Despite high specificity for this target, positive results are not readily
available for epidemiological use due to potential cross-reactivity with E. dispar, thus requiring
confirmation with a discriminatory assay. However, the target will remain as part of the
validated format at this time. Another disadvantage is that of the potential inability of the
bacterial assay to detect estA1 alleles of the heat stable toxin in ETEC strains. This lack of
specificity may result in missed preliminary detection of an outbreak etiologic agent.
Other Considerations for Bio-Plex Protocol Implementation. Although establishing the
performance characteristics described in previous chapters is a major element in employing new
molecular assays, other practical considerations for deciding to implement Bio-Plex assays
include ease of use, personnel qualifications and training, equipment and supply requirements,
and cost.
Ease of use of the Bio-Plex assays and system. For a laboratorian trained in molecular
techniques, using the Bio-Plex assays to test outbreak specimens is relatively easy. At a
minimum, the Bio-Plex assay is no more difficult than performing real-time PCR molecular tests
that are routinely performed in a public health molecular laboratory. Chemical solutions
required for microsphere-probe coupling and Bio-Plex detection plate setup are easily mixed
using readily-available standard protocols and coupling of the target-specific probes to the BioPlex microspheres is a straightforward series of adding solutions, centrifuging, and removing
supernatant. The manual extraction employs a commercial spin column method that is easy to
follow, though it is a bit time-consuming. Setup of the multiplex PCR amplification reactions is
equivalent in technique to those used for real-time and conventional molecular PCR methods,
and is made easier with the use of commercial master mix kits. Working with the Bio-Plex
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microspheres and setting up the detection plate may be initially challenging, as the operator must
become comfortable with working swiftly and efficiently so the microspheres do not settle or
clump. The most difficult portion of the setup is removing the adhesive film plate cover, which
is done twice. Peeling the film off the plate requires firm handling in order to not tear the film
and to not cross-contaminate wells. The Bio-Plex system facilitates flexible batch sizes, ranging
from 1 well to 96 wells, and use of multi-channel pipettes eases setting up larger batch sizes.
Programming of the Bio-Plex is well-described in the software manual, allowing assay
parameters to be saved for repeated use and providing flexibility in programming the output
order of results without regard for how the wells are set up on the plate. Results may be exported
as a spreadsheet for analysis; graph functions are also available, but were not utilized in this
project.
Personnel qualifications and training. The Bio-Plex assay and detection plate setup require the
same qualifications and training needed to perform other molecular-based assays. Training for
an experienced molecular scientist would be minimal, and could realistically be completed
following one or two learning and familiarization runs, an observed run, an unobserved run, and
a final certification run. Training for an operator with little-to-no experience in molecular testing
would, by necessity, be more extensive.
Equipment and supply requirements. In addition to the Bio-Plex system, very little extra
equipment is needed to support testing. A heated 96-well plate shaker, sonicator, centrifuges and
vortexers are typically standard equipment in a molecular laboratory or can readily be purchased.
Facilities for sample extractions, amplification setups and storage are also required. Facility and
engineering controls are required for the detection solutions, as they contain chemicals that are
respiratory, skin and eye irritants. Solutions should be handled in a fume hood or dead air
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cabinet (<1mL only), and although not designated to be carcinogenic, caution should be
exercised in allowing pregnant personnel to handle the solutions. There is a significant up-front
supply requirement to begin Bio-Plex testing, particularly if microspheres will be coupled inhouse. Items to purchase include microspheres, primers, probes, chemicals for coupling and
detection solutions, detection plates and covers, Bio-Plex validation and calibration kits and
system sheath fluid. Once purchased, the supplies can last several months to a year, particularly
if testing is not done daily or in high volume. Other support items such as microcentrifuge tubes,
pipettes, pipette tips, deionized water, isopropyl alcohol, plate racks, personal protective
equipment, etc. are standard in a molecular laboratory.
Sustainment costs of Bio-Plex assays. Costs for long-term sustainment of the extraction and
amplification steps of Bio-Plex assays are similar to those for real-time molecular assays. The
pricing for the QIAamp DNA Stool Mini Kit extraction method validated in the described studies
lies within the typical range of costs for commercial extraction kits. The costs per test of both
master mix kits used for the protozoan and bacterial assays are a bit higher than for other PCR
master mix kits, but are less expensive than RT-PCR kits. Pricing for Bio-Plex primers has
proven to be less expensive than that for real-time primers and probes, mainly because the BioPlex oligonucleotides do not require as high a level of purification following synthesis.
Added costs include the probes, which are inexpensive compared to real-time probes, and
the coupling reagents. Most reagents can be purchased relatively inexpensively in bulk. The
additional costs of Bio-Plex detection are overcome by the platform’s ability to accommodate
large multiplex reactions, which is a limitation for real-time platforms. However, if only a twoor three-plex is desired and high throughput is not a goal, the Bio-Plex platform may not be a
cost-effective option.
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Future Considerations. This paper describes two Bio-Plex assays that have been validated for
use as screening tools in foodborne outbreak investigations and a proposed testing algorithm that
also maximizes use of extracted nucleic acids for other testing platforms. However, some
improvements may be considered to address assay limitations, expand testing capability, and
take advantage of instrumentation system upgrades. Due to the low sensitivity of the E.
histolytica target as compared to reference methods and the potential to cross-react with E.
dispar gene sequences, it is recommended that a re-designed primer and probe set be
incorporated. An alternative approach would be to remove the E. histolytica target from the
multiplex completely, due to low prevalence of the pathogen in foodborne outbreaks in the U.S.
In either case, re-validation would be required. A similar re-design recommendation is made for
the estA target of the bacterial assay. It is also recommended that performance characteristics of
the bacterial assay be established using unpreserved stool specimens, as this specimen type may
also be submitted during outbreak investigations in lieu of Cary-Blair specimens. Validating the
assay for unpreserved stool specimens provides an additional flexible testing option. As
mentioned previously, a new software upgrade is available for the Bio-Plex platform that
incorporates concurrent detection of up to twelve multiplex assays on one detection plate.
Implementing this software will make the detection step more efficient and require less operator
intervention. Finally, additional pathogen targets may be considered for addition to the existing
assays or additional multiplex assays implemented for concurrent detection with the protozoan
and bacterial assays on the Bio-Plex platform in order to build a more comprehensive screening
protocol for foodborne outbreak investigations.
Conclusions. In the studies described here, two multiplex nucleic acid assays for the detection
of enteric protozoa and bacteria were designed for the Bio-Plex 200 platform and performance
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characteristics evaluated. Both the Bio-Plex protozoan and bacterial assays exhibited precision
similar to that described for other microsphere-based nucleic acid methods. Analytical
sensitivity of the assay targets was established and comparison to the previously published
assays from which most primers and probes were adapted showed that some targets exhibited
improved limits of detection on the Bio-Plex platform while others did not. A comparison to
organism excretion concentrations in the literature suggests, however, that most assay targets are
capable of detecting organism concentrations typically encountered in clinical specimens.
Sensitivity and specificity of most targets as compared to reference methods ranged from 81.25%
to 100%, which is acceptable for the screening assays. Sensitivity for the E. histolytica target in
the enteric protozoan assay was 42.86%, another indicator that re-design of this target should be
considered. Both the protozoan and bacterial assays exhibited no cross-reactivity to a variety of
non-target parasites and bacteria, with the exception of E. dispar (E. histolytica target in the
protozoan assay) and EPEC strains (uidA target in the bacterial assay). Additionally, no crossreactivity between assay targets was noted. Interpretation of results for the uidA target only
when shiga toxin targets are positive overcomes the cross-reactivity of the uidA target with
certain EPEC strains. The development of a Bio-Plex multiplex assay to detect viral targets,
while promising, was not required due to redundancy with other rapid testing protocols. Realtime detection of NV and RV nucleic acids extracted from clinical specimens with the QIAamp
DNA Stool Mini Kit was found to be statistically comparable to detection of nucleic acids
extracted with the current viral RNA extraction method on the Kingfisher platform. Therefore,
should Bio-Plex testing be desired in addition to viral testing, only one extraction method would
be required. In summary, integration of the Bio-Plex and real-time assays with a common
extraction method provides a simple, rapid and flexible foodborne outbreak screening algorithm
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that can be optimized and tailored based on epidemiological history and preliminary etiologic
agent data provided on the day of specimen submission, and may be used to focus subsequent
confirmatory laboratory testing.
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